Immune status and tumour localization in the development and prognosis of genital (pre)malignancies in women by Hinten, F.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/173471
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
IMMUNE STATUS AND 
TUMOUR LOCALIZATION IN 
THE DEVELOPMENT AND 
PROGNOSIS OF GENITAL 
(PRE)MALIGNANCIES 
IN WOMEN
Floor Hinten
iMMUne StAtUS AnD tUMoUr loCAliZAtion in tHe DeVeloPMent AnD ProGnoSiS 
oF GenitAl (Pre)MAliGnAnCieS in WoMen
Thesis, Radboud university medical center, Nijmegen, the Netherlands
The financial support of this thesis was kindly provided by Chipsoft, DDL Diagnostic Laboratory, 
Nierstichting Nederland, Pfizer B.V., Radboud university medical center, Rovers Medical Devices, 
Will Pharma
For reasons of consistency, terminology may be changed throughout this thesis when compared 
to the original publications.
iSBn: 978-94-028-0673-1
Design and lay-out:
Mikka Art, Den Bosch
Print
Ipskamp Printing, Enschede
©Floor Hinten, 2017
All rights are preserved. No part of this book may be reproduced in any form or by any means 
without permission of the author.
IMMUNE STATUS AND 
TUMOUR LOCALIZATION IN 
THE DEVELOPMENT AND 
PROGNOSIS OF GENITAL 
(PRE)MALIGNANCIES 
IN WOMEN
ProeFSCHriFt
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken, 
volgens besluit van het college van decanen 
in het openbaar te verdedigen op woensdag 5 juli 2017 
om 10.30 uur precies
door
Floor Hinten
geboren op 8 november 1985
te Tilburg
ProMotoren  Prof. dr. L.F.A.G. Massuger
   Prof. dr. L.B. Hilbrands
CoProMotoren  Dr. J.A. de Hullu
   Dr. W.J.G. Melchers
MAnUSCriPtCoMMiSSie Prof. dr. P.C.M van de Kerkhof
   Prof. dr. J.B. Prins
   Prof. dr. G.G. Kenter (VUmc)
PArAniMFen  Dr. K. Lammers
   Drs. L. Maas


CONTENTS
Chapter 1 General introduction 8
Chapter 2 Clitoral involvement of squamous cell carcinoma of the vulva: 
localization with the worst prognosis
European Journal of Surgical Oncology 2015; 41(4): 592-8
22
Chapter 3 Vulvar cancer: two pathways with different localization and prognosis
Submitted.
38
Chapter 4 HPV-related (pre)malignancies of the female genital tract in renal 
transplant patients
Critical Reviews in Oncology and Hematology 2012; 84(2): 161-180
60
Chapter 5 Reactivation of latent HPV infections after renal transplantation 
American Journal of Transplantation 2016 Dec 23. [Epub ahead of print].
98
Chapter 6 Barriers and facilitators in regular gynaecological screening of 
female renal transplant recipients
Submitted.
140
Chapter 7 Improvement of gynaecological screening of female renal 
transplant recipients by self-sampling for HPV detection
Journal of Lower Genital Tract Disease 2017 Jan;21(1):33-36.
162
Chapter 8 General discussion 174
Chapter 9 Summary / Samenvatting 192
Appendix Curriculum Vitae
Publicatielijst
Dankwoord
209
211
213

GENERAL INTRODUCTION
1

General introduction 11
1GENERAL INTRODUCTION
Genital (pre)malignancies in women comprise all (pre)malignancies found in the female genital tract: 
ovary, tuba, uterus, cervix, vagina and vulva. This thesis mainly focuses on the lower genital tract, 
namely cervix and vulva. Cervical cancer is a major health problem, with more than 500.000 new 
cases occurring each year worldwide, especially in developing countries. In 2012 about 265.000 
deaths from cervical cancer were reported, making it the fourth leading cause of cancer death in 
women in the world (1). Virtually all cervical cancers are caused by high-risk (hr) Human Papillo- 
mavirus (HPV) infection, which implies that cervical cancer does not and will not develop in the absence 
of persistent HPV DNA (2). The primary site for cervical cancers is the cervical transformation zone 
(border between the glandular and squamous epithelium). The transformation zone is assumed to 
be more susceptible to oncogenic influences, like hrHPV infection, due to the high cell-turnover (3). 
Cervical intraepithelial neoplasia (CIN) is the non-invasive precursor lesion of cervical cancer. The 
CIN lesions are classified as CIN 1, CIN 2 and CIN 3 based on the presence of mitotic activity and 
nuclear atypia within respectively the basal third, two thirds and whole thickness of the epithelium 
(4). Since the introduction of cytological screening for cervical cancer in many developed countries, 
the incidence and mortality rate of cervical cancer in these countries have markedly diminished 
(5), despite differences in terms of invitation methodology, target population (start between 18-30 
years until 59-70 years), screening intervals (once a year until once every 5 years), organization and 
quality assurance methodology. In the Netherlands, all women between 30-60 years of age receive 
an invitation from the regional screening organization or from their general practitioner for cervical 
screening once every five years. The participation rate of the screening programme is about 65% 
(6). About half of all women with newly diagnosed invasive cervical cancer never participated in 
any screening programme (7-9). As previously stated, HPV causes almost all cervical cancers and is 
therefore the main factor in the oncogenesis of cervical cancer. The sensitivity of hrHPV detection 
is higher than for cytology (~90% versus ~60%), but the specificity is slightly lower (70-90% versus 
90-100%) (10-16). Recently, it has been decided to introduce the hrHPV test as primary screening 
tool in the Netherlands in 2016-2017 (17). 
Vulvar cancer is a rare disease, representing approximately 3-5% of malignancies of the female 
genital tract (18). There are two different etiologic pathways for the development of vulvar squamous 
cell carcinoma (SCC) (19, 20). In the first, most common pathway, the most precursor lesion is 
differentiated vulvar intraepithelial neoplasia (dVIN), which often occurs in the background of lichen 
sclerosus. This pathway is rarely associated with a hrHPV infection. The second pathway is related 
to a hrHPV infection and covers about 20-30% of all vulvar SCCs (19, 21, 22). The precursor lesion 
in this pathway is usual vulvar intraepithelial neoplasia (uVIN). Differentiated VIN is suggested to be 
highly proliferative, increasing the likelihood of progression to vulvar SCC compared to uVIN (23, 
24). Most vulvar SCCs are dVIN-related, while most isolated premalignant lesions are of the usual 
type (20, 25). In general, the possibility of uVIN progressing into vulvar SCC is low in comparison 
with dVIN (26), namely 9-16% in untreated patients and 3% in treated patients, compared to about 
30% in patients with dVIN (27). There is no regular screening tool for VIN; symptoms are frequently 
12  Chapter 1
1 absent or variable and suspicious vulvar lesions are not always histopathologically examined. The absence of symptoms might cause this disease to be underreported. 
HUMAn PAPilloMAVirUS
A common nominator in the genital (pre)malignancies is HPV; cervical cancer for approximately 
100% and vulvar cancer for 20-30% HPV-related. HPV is a double stranded DNA virus that can infect 
basal epithelial cells of all human squamous epithelia. The HPV genome encodes for 9 viral proteins; 
viral proteins E6 and E7 are known cancer promoting genes. The E6 protein inactivates p53 (a 
tumour suppressor protein), which results in chromosomal instability and diminished apoptosis. 
The E7 protein suppresses the retinoblastoma protein (pRB)-pathway which leads to enhanced cell 
proliferation (28, 29) (Figure 1). 
Figure 1. Human papillomavirus with the role of several proteins elucidated.
E3 protein is one of the membrane proteins; no specific role specified (not shown in figure).
HPV can be classified into two groups: cutaneous and mucosal HPV subtypes. Cutaneous subtypes 
are predominantly found in cutaneous verrucae and mucosal subtypes predominate in anogenital 
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1lesions (30, 31). Mucosal HPV subtypes can be divided in high-risk (subtype 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82) and low-risk (subtype 6, 11, 40, 42, 43, 44, 54, 61, 
70, 72, 81, and CP6108) subtypes (10, 32-36). 
Worldwide, the overall cervical HPV prevalence is around 10% (37). The prevalence of any cervical 
HPV infection ranges between 2 and 44%, with a peak in women aged 18-29 years old (38) and, in 
most regions, a subsequent peak in women aged 45 years or older (37). HPV is sexually transmitted 
and up to 80% of sexually active women will be genitally infected by one or more HPV subtypes 
during their life (39, 40). The majority of HPV infections are transient; these infections will be 
cleared by the immunesystem without causing any abnormality (41, 42). However, a part of the 
HPV infections will not be cleared and persist. HPV persistence is commonly defined as having 
two or more positive tests (43, 44), time to clearance (45-47) or proportion of HPV-positive visits 
(48, 49). Persistent HPV infections are strongly associated with the development of CIN 2-3 and 
are considered to drive progression of CIN into invasive cervical cancer (50). Laboratory evidence 
shows that persistent HPV oncogene expression is critical for the maintenance and progression of 
CIN (51). The mean duration of a cervical HPV infection in the general population is thought to vary 
between 8 and 13 months (52). In immunocomprised patients an increased prevalence of genital 
HPV is observed. The largest immunocomprised patient groups are HIV-infected patients and organ 
transplant recipients. In this thesis we focus on the renal transplant recipients (RTRs), because 
little research has been performed compared to HIV-infected patients and renal transplantation 
comprises a large part of all solid organ transplantations.
renAl trAnSPlAntAtion
Renal transplantation is the preferred treatment for most patients with end stage renal disease. Yearly 
more than 1000 renal transplantations are performed in the Netherlands. Organ transplantation 
requires the lifelong administration of intense immunosuppressive therapy. Immediate post-
transplantation, high doses of multi-agent immunosuppressive therapy are needed to prevent 
acute allograft rejection by host immune mechanisms. The current immunosuppressive regimes 
have led to a 1-year graft survival of more than 90% and the incidence of acute rejection has fallen 
to 10-15% (53). Due to the immunosuppression after organ transplantation these patients are 
more susceptible not only for infectious diseases but also for particularly virus-associated cancers. 
Immunosuppressive agents may indirectly contribute to the development of cancer, as an impaired 
surveillance ability of T-cells may disrupt anti-tumour immune surveillance and may potentiate 
oncogenic stimuli as chemical carcinogens, ultraviolet (UV) light and also viruses (54-56). Viruses that 
are associated with the development of cancer in RTRs are the Epstein-Barr virus which can induce 
PTLD and the hepatitis B/hepatitis C virus which are linked to the development of hepatocellular 
carcinoma (57-62). The incidence of virus-associated cancer is estimated to be between 4 and 18%, 
which means a 100-fold increase compared with immunocompetent people (63). HPV causes not 
only anogenital (pre)malignancies in females, but also anogenital (pre)malignancies in males and 
head and neck tumours, and is one of the viruses RTRs are more susceptible to and are more prone 
for progression to (pre)malignant lesions.
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1 HPV inFeCtion in FeMAle renAl trAnSPlAnt reCiPientSRTRs have a higher risk of HPV infections compared to immunocompetent women. The incidence of 
HPV infections, both low and high risk types, in RTRs varies between 22 and 63%. Furthermore, RTRs 
are more often infected with multiple HPV infections compared to the general population (64-70). 
A recent study among 35 RTRs found that 62.8% of the RTRs were positive for HPV-DNA in cervical 
scrapes and that 59% of the HPV-positive RTRs exhibited a hrHPV genotype (69). It is hypothesized 
that transplant recipients may not only have a higher risk to acquire an HPV infection, but that the 
infections may also have a higher potential to develop into (pre)malignancies in a relative short 
period of time (71, 72). The role of HPV in the oncogenesis of cervical cancer suggested that the 
immunosuppressed state of RTRs poses them at risk to HPV infection with subsequent cancer 
development. From 1975 on, several studies reported increased incidence and prevalence rates 
of CIN lesions in RTRs compared to the general population (64, 73). In 1986, Penn et al. already 
showed that 11% of women with post-transplant malignancies had cervical cancer (74). In the 
following years, several other studies showed an increased incidence of cervical cancer after renal 
transplantation with standardized incidence rates (SIRs) described between 2.3 and 8.6 (56, 75-77). 
More recently, a study from our centre showed data that support the findings of earlier studies, 
namely a 2- to 6-fold increased risk of developing CIN (78).
Vulvar (pre)malignancies in RTRs are less frequently described in the current literature. Several 
studies show that 100% of the vulvar lesions among RTRs are HPV-positive, compared to 
approximately 25-30% of the vulvar carcinomas in the general population (22, 65, 79). Vulvar cancer 
has a relatively high prevalence in RTRs compared to the general population and belongs to the 
predominant malignancies in RTRs (63, 77, 80). Several studies found a 50-fold increased risk to 
develop vulvar cancer in female RTRs compared to the general population (78, 81, 82). 
This introduction describes the most common lower genital (pre)malignancies in females, the role 
of HPV in the oncogenesis of these (pre)malignancies in general and the implications of an HPV 
infection in an immunocomprised patient group like the female RTRs. The main objective of this 
thesis is to get insight in the tumour localization of vulvar cancer and especially the role of HPV in 
the oncogenesis in vulvar cancer. Furthermore, the behaviour of genital HPV infection in female 
RTRs and its implications on post transplantation follow up is assessed. 
AiMS AnD oUtlineS oF tHiS tHeSiS: 
This thesis firstly addresses vulvar cancer and especially the role of the tumour localization. The 
main objective of the next chapter is the influence of tumour localization on the prognosis of vulvar 
cancer (Chapter 2). The localization of all vulvar cancers was assessed retrospectively and related 
to the disease free survival. The localization of the vulvar tumour is also of great importance in the 
following chapter (Chapter 3). The relation between HPV and vulvar cancer is well established 
over the years, but the exact oncogenesis remains unknown. Other anogenital (pre)malignancies, 
namely cervical- and anal (pre)malignancies, are located at a transformation zone. However, no 
transformation zone has ever been described in the vulvar area. Micro-traumata caused by sexual 
intercourse might function as a porte d’entree for HPV and the perineum could be prone for 
these micro-traumata. This chapter might provide more insight in the predilection site of HPV-
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1related vulvar cancer and clarify the oncogenesis of vulvar cancer further. Next to the localization of the tumour, the differences in patient- and tumour characteristics, p16 expression and overall-, 
disease free- and disease specific survival between HPV-related and non HPV-related vulvar cancer 
patients are assessed. The next part of this thesis focuses mainly on HPV infections and genital (pre)
malignancies in female RTRs. Chapter 4 provides an extensive overview of HPV-related anogenital 
(pre)malignancies in female RTRs and the consequences for treatment in case of an anogenital 
malignancy. The literature on HPV infections in female RTRs consists primarily of retrospective 
studies, which show an increased risk of developing HPV-related genital (pre)malignancies. The 
renal transplantation and related immunosuppressant regime are considered as main risk factor 
for obtaining an HPV infection. However, no research has been executed on the prevalence of HPV 
infections in patients before and after transplantation. The exact behaviour of an HPV infection 
in female RTRs before and after renal transplantation is unclear. Chapter 5 shows the HPV 
prevalence of female RTRs closest to the transplantation in a six month period before and furthest 
from transplantation in a three to 12 month period after renal transplantation. Furthermore, sexual 
behaviour of the female RTRs and cytological abnormalities are described. The increased risk of 
developing genital (pre)malignancies after renal transplantation has prompted several European 
and American guideline committees to recommend annual cervical cancer screening in female 
RTRs (83-85). Meeuwis et al. (78) and Courtney et al. (86) showed that a considerable proportion of 
the female RTRs does not follow this advice. The reasons for not participating in the gynaecological 
screening are unclear. Of the Dutch female RTRs, 63.4% (128/202) underwent at least one cervical 
smear after their renal transplantation and 36.6% (74/202) were screened once every five years 
according to the national screening programme (78). In the general population the barriers for 
participating in cervical screening programme lay mainly in the organisational domain, for example 
planning an appointment (87). So, to improve the participation rate of female RTRs it is essential to 
first investigate the barriers and facilitators in gynaecological screening of female RTRs. Chapter 6 
shows the results of focus group interviews with female RTRs and nephrologists from which 
barriers and facilitators for gynaecological screening were identified. Ultimately, the aim of this 
study is to present suggestions for increasing the participation rate.  In the general population, a 
self-sampling method was introduced to reach women not participating in the national screening 
programme. Self-sampling is a cervico-vaginal specimen collection method that is highly accepted 
by women and the sensitivity of self-sampling is sufficient to be used as an appropriate alternative 
for physician sampling for HPV testing in low-resource settings or to increase screening rates (88-
91). The next chapter (Chapter 7) focuses on self-sampling in gynaecological screening of female 
RTRs. This article assesses the clinical applicability and acceptability of HPV testing on self-sampling 
material in female RTRs.
In Chapter 8 the data are put into perspective and the implications for the female RTRs are discussed. 
Future perspectives on optimizing post transplantation care in female RTRs, especially in the area of 
gynaecological screening, will be given. Next to these perspectives on post transplantation care, the 
future in diagnosing and treating vulvar cancer will be discussed. A summary follows this general 
discussion.
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CLITORAL INVOLVEMENT OF SqUAMOUS CELL 
CARCINOMA OF THE VULVA: LOCALIZATION 
WITH THE WORST PROGNOSIS
AbSTRACT
Objective: The overall 5-year survival of patients with vulvar squamous cell carcinoma (SCC) is 70%. 
The clinical impression is that localization of SCC on the clitoris may lead to worse prognosis. 
The aim of this study is to assess the disease specific survival (DSS) in patients with clitoral SCC 
compared to patients with SCC without clitoral involvement.
Methods: All consecutive patients with primary vulvar SCC treated with surgery at the Department 
of Gynaecologic Oncology at the Radboud university medical center (Radboudumc) between March 
1988 and January 2012, were analyzed. The clinical and histopathological characteristics and DSS 
rates of patients with (N=72) and without clitoral SCC (N= 275) were compared. Furthermore, 
patients with clitoral involvement were compared to patients with perineal SCCs (N= 52) and other 
central SCCs without clitoral and/or perineal involvement (N= 117). 
Results: Patients with clitoral SCC more often had larger and deeper invaded tumours, lymphovascular 
space involvement (LVSI), positive surgical margins and a higher percentage of positive lymph 
nodes. Kaplan-Meier survival analyses showed worse DSS in patients with a clitoral SCC compared 
to patients without clitoral involvement. Multivariable analysis showed that not clitoral involvement, 
but invasion depth, differentiation grade and lymph node status are independent prognostic 
factors.
Conclusions: Patients with clitoral SCC have worse survival compared to patients without clitoral 
involvement. This is probably caused by unfavourable histopathological characteristics of the 
tumour rather than the localization itself. Prospective studies are needed to further assess the 
influence of localization of the vulvar SCC on prognosis. 
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INTRODUCTION
Vulvar cancer is rare with a worldwide incidence of 2-3 per 100,000 women, increasing with age (1-3). 
It represents 1% of all malignancies in women and about 3-5% of all gynaecological malignancies (4). 
Approximately 80% of vulvar malignancies are squamous cell carcinomas (SCC). Two different types 
of SCC are described, namely a type caused by an infection with high risk Human Papillomavirus 
(HPV) via usual vulvar intraepithelial neoplasia (uVIN) that primarily affects younger women and 
the second type SCC is the most common type, which often occurs in a background of lichen 
sclerosus (LS) and/or differentiated VIN (dVIN), especially in elderly women (5). Taking a biopsy for 
histopathological examination is the gold standard for diagnosing vulvar SCC.
Nowadays, the triple incision technique, consisting of wide local excision (WLE) with uni- or bilateral 
inguinofemoral lymphadenectomy (IFL) via separate incisions, is the standard treatment for vulvar 
SCC with > 1 mm invasion (6). Early stage vulvar SCC patients can be treated by WLE and a sentinel 
lymph node (SLN) procedure, preferentially within the protection of a clinical trial such as the 
GROINSS VII study (7). 
Several studies show that age, tumour size, invasion depth, extranodal growth, and differentiation 
grade are independent prognostic factors in vulvar SCC (8-11); lymph node status being the most 
important prognostic factor (11-14). The overall 5-year survival rate is 70% and in patients with 
negative inguinofemoral lymph nodes (stage I and II) this reaches 90%, but diminishes in case 
of positive inguinofemoral lymph nodes (15, 16). In several other malignancies, an association 
between the anatomic localization and the prognosis has been described. For example, patients 
with cutaneous melanomas have a worse prognosis when the lesions are located on the head, 
neck and/or trunk compared to lesions on the extremities (17). It has been hypothesized that 
the location of the primary tumour in vulvar SCC may also influence prognosis. Magrina et al. (18) 
showed that invasion of the urethra had a significant disadvantageous impact on the 5-year survival. 
Boyce et al. (19) and Andreasson et al. (20) showed the unfavourable impact of clitoral involvement 
on the prognosis, while Masak et al. (21) on the other hand determined that clitoral involvement 
did not predict poor prognosis. Although the literature does not provide unambiguous evidence, 
we hypothesize that primary tumour localization on the clitoris correlates with an unfavourable 
prognosis in patients with vulvar SCC, based on our clinical experience. Therefore, the aim of this 
study is to assess the disease specific survival (DSS) of clitoral SCC compared to SCC of the vulva 
without clitoral involvement.
MATERIALS AND METHODS
Patients and data
Data of 385 consecutive patients with primary vulvar SCC who were primarily surgically treated at the 
Department of Gynaecological Oncology at the Radboud university medical center (Radboudumc) 
between March 1988 and January 2012 (follow up until 1st of August 2012), were selected from the 
local patient registry of vulvar SCC patients. Data were collected after consultation of medical files 
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and pathological reports. A total number of 38 patients were excluded from the analysis; these 
patients did not receive surgical treatment (N=30) and/or received incomplete surgical treatment 
(N=2) and/or the exact localization of the tumour was unclear (N= 6). The variables extracted 
from the database included patient characteristics (age at diagnosis and time of follow up) and 
histopathological characteristics (tumour size, focality, depth of invasion, surgical margin status 
(positive, ≤8mm or > 8mm). Furthermore, lymphovascular space involvement (LVSI), lymph node 
status, differentiation grade, the FIGO stage at time of diagnosis (staging system of 1988 or 2009), 
adjuvant radiotherapy and the recurrence rate (vulvar -, groin - and/or distant) were extracted from 
the database.
Within the total group of 347 vulvar cancer patients, two different groups were defined: the clitoral 
group consisted of patients with a clitoral SCC (N=72) and the non-clitoral group (≥ 1mm from the 
clitoris) (N= 275) consisted of patients with tumours without clitoral involvement. The non-clitoral 
SCC group was divided in three different groups, namely perineal SCCs (all tumours with perineal 
involvement, except the tumours with simultaneous clitoral involvement) (N= 52), other central 
SCCs (≤ 1 cm from the midline (22)) without clitoral and/or perineal involvement (N= 117) and lateral 
SCCs (> 1 cm from the midline) (N= 106). 
statistical methods 
Patient and histopathological characteristics and adjuvant radiotherapy were compared between 
groups using Chi-square tests and t-tests for independent samples. Disease specific survival (DSS) 
was defined as survival from the date of diagnosis to the date of death due to vulvar SCC or the 
date of last follow-up. Censoring was applied to patients alive at last follow-up, patients who were 
lost to follow-up and patients who died of another disease. The DSS and recurrence rates were 
estimated according to the Kaplan-Meier method and were compared using the log-rank test. 
Univariate Cox regression was used to assess the prognostic value of patient and histopathological 
characteristics on the prognosis of vulvar cancer. Based on the subset of statistically significant 
variables, multivariable Cox regression with a forward stepwise procedure based on likelihood ratio 
statistics was used to identify those characteristics that independently contributed to the prognosis 
of vulvar SCC patients. Hazard ratios (HR) with 95% confidence intervals (CIs) are presented. A 
p-value of <0.05 was considered statistically significant. Analyses were performed using SPSS (PASW 
statistics, version 20).
RESULTS
Three hundred and forty-seven patients were included in this retrospective study; 72 patients had a 
clitoral SCC (21%, Group 1) and 275 patients had a tumour without clitoral involvement (79%, Group 
2). The median follow up time of the Clitoral group was 32 months (range 0-259) and the median 
follow up of the Non clitoral group was 49 months (range 0-276). The baseline characteristics of the 
study population are listed in table 1. Patients in the Clitoral group had larger tumours, deeper 
tumour invasion, more LVSI, more often positive surgical margins and surgical margins < 8 mm,  a 
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higher percentage of positive lymph nodes, and a higher percentage of a high FIGO stage (FIGO 
staging valid in year of diagnosis), compared to patients in the Non clitoral group. Compared to 
the Perineal group (N= 52), the group had more LVSI, a higher percentage of positive lymph nodes 
and a higher percentage of a high FIGO stage. The Central group with central SCCs without clitoral- 
and perineal involvement (N= 117) was also compared to the Clitoral group. The Clitoral group 
had larger tumours, deeper tumour invasion, a higher percentage of positive lymph nodes, and a 
higher percentage of a high FIGO stage. Finally, compared to the Lateral group, the Clitoral group 
had larger tumours, deeper tumour invasion, more often positive surgical margins and surgical 
margins < 8 mm, more often multifocal tumours, and a higher percentage of a high FIGO stage. 
Total number of patients that received adjuvant radiotherapy (location was not specified) was 24 
(33%) in the Clitoral group and 60 (22%) in the Non clitoral group (p-value: 0.04). 
The estimated 5 -, 10 - year and overall recurrence rates (vulvar/groin/distant) did not significantly 
differ between the Clitoral and the Non clitoral group; 5 year recurrence rate was, respectively, 51% 
and 42% (p-value: 0.10), the 10 year recurrence rate 63% and 59% (p-value: 0.13) and the overall 
recurrence rate 78% and 92% (p-value: 0.16). The adjuvant radiotherapy did not correlate with the 
recurrence rate.
The 5-year and the 10-year DSS rates of clitoral SCC were estimated 73% and 64%, respectively, 
and subsequently compared to DSS rates of perineal SCC (estimated 87% for 5- and 10-year DSS). 
The 10-year DSS rate of perineal SCC was significantly (p-value: 0.04) lower (Figure 1). The 5- and 
10-year DSS rates of the Clitoral group were lower, although not significantly (p-value: 0.09 and 0.07, 
respectively), compared to the Non clitoral group (estimated 5- and 10-year DSS rates of 79% and 
76%). Figure 2 displays the 10-year DSS. 
The influence of all variables on the prognosis (5- and 10-year DSS) of vulvar SCC was assessed. The 
results of the univariate analyses are displayed in table 2. Notably, clitoral involvement was not 
a significant prognostic factor: the 5- year DSS HR is 1.61 (95% CI 0.92-2.80), and the 10-year DSS 
HR is 1.63 (95% CI 0.96-2.77). The multivariable analysis showed that invasion depth, moderately 
and poorly differentiated tumours, and presence of positive lymph nodes, especially those with 
extranodal growth, were independent prognostic factors (table 3).
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table 1. Baseline characteristics of patients with primarily surgically treated vulvar SCC.
Clitoral non clitoral Perineal Central * lateral
n n/n(%) n n/n(%) n n/n(%) n n/n(%) n n/n(%)
Patient characteristics
Age (years) (mean (SD)) 72 68.7 (14.4) 275 67.3 (15.6) 52 65.4 (16.8) 117 68.3 (14.9) 106 67.0 (15.8)
tumour characteristics
Tumour size (mm) (mean (SD)) 72 34.8 (19.4) 273 27.6 (21.7)# 51 35.4 (31.5) 116 26.8 (17.6)# 106 24.6 (19.2)#
Focality
    Unifocality
    Multifocality
55/72(76)
17/72(24)
224/274(82)
50/274(18)
39/52(75)
13/52(25)
93/117(80)
24/117(20)
92/105(88)#
13/105(12)
Depth of invasion (mm) (mean 
(SD))
69 9.0 (7.2) 255 6.2 (5.6)# 51 7.8 (7.3) 107 6.1 (5.6)# 97 5.4 (4.3)#
Surgical margins
    ≥8 mm
    <8 mm
    Positive
37/72(51)
26/72(36)
9/72(13)
191/273(70)#
67/273(25)
15/273(5)
31/52(60)
17/52(33)
4/52(8)
80/117(68)
29/117(25)
8/117(7)
80/104(77)#
21/104(20)
3/104(3)
Differentiation grade
     Well
     Moderately
     Poorly
12/69(17)
44/69(64)
13/69(19)
55/244(23)
127/244(52)
62/244(25)
11/44(25)
22/44(50)
11/44(25)
17/108(16)
61/108(56)
30/108(28)
26/91(29)
44/91(48)
21/91(23)
LVSI
     No
     Yes
48/71(68)
23/71(32)
213/271(79)#
58/271(21)
42/50(84)#
8/50(16)
85/116(73)
31/116(27)
86/105(82)
19/105(18)
lymph node status
Lymph node metastases
     No
     Yes
     Yes; extranodal
35/72(49)
22/72(31)
15/72(20)
180/275(65)#
59/275(22)
36/275(13)
36/52(69)#
9/52(17)
7/52(14)
74/117(63)#
27/117(23)
16/117(14)
70/106(66)
23/106(22)
13/106(12)
Stage of disease
FIGO stage
    I-II
    III-IV
33/72(46)
39/72(54)
179/274(65)#
95/274(35)
33/51(65)#
18/51(35)
76/117(65)#
41/117(35)
70/106(66)#
36/106(34)
* Without perineal or clitoral involvement,  # p-value <0.05; Non clitoral, perineal, central and lateral were all 
compared to the  clitoral group
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Figure 1. Disease specific survival of clitoris SCC compared to perineal SCC.
Figure 2. Disease specific survival of clitoral SCC compared to vulvar SCC without clitoral 
involvement.
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table 2. Hazard ratios with 95% confidence interval of patient- and histopathological 
characteristics for 5- and 10 year disease specific survival in vulvar cancer patients using 
univariate Cox regression.
Variables 5-year DSS 10-year DSS
n Hr (95% Ci) n Hr (95% Ci)
Age (years) 347 1.03 (1.01-1.05)* 347 1.03 (1.01-1.05)*
Tumour size (mm) 345 1.03 (1.02-1.04)* 345 1.03 (1.02-1.04)*
Focality
       Uni 279 1.00 (ref) 279 1.00 (ref)
       Multi 67 1.09 (0.60-1.97) 67 1.05 (0.59-1.86)
Depth of invasion (mm) 324 1.11 (1.07-1.14)* 323 1.10 (1.06-1.13)*
Surgical margins
        0 mm             
     < 8mm
     ≥ 8mm
24
93
228
1.00 (ref)
0.31 (0.15-0.65)*
0.21 (0.10-0.41)*
24
93
228
1.00 (ref)
0.32 (0.15-0.66)*
0.24 (0.13-0.48)*
Differentiation grade
        Well 66 1.00 (ref) 66 1.00 (ref)
        Moderately 171 7.21 (1.74-29.93)* 171 5.42 (1.68-17.52)*
        Poorly 75 13.28 (3.14-56.20)* 75 9.08 (2.73-30.19)*
LVSI
         No
         Yes
260
81
1.00 (ref)
2.23 (1.34-3-73)*
260
81
1.00 (ref)
1.92 (1.16-3.17)*
Lymph node metastases
         No
         Yes
         Yes; extranodal 
215
81
51
1.00 (ref)
2.71 (1.45-5.08)*
9.30 (5.13-16.82)*
215
81
51
1.00 (ref)
2.48 (1.34-4.40)*
8.74 (5.00-15.33)*
FIGO stage
         Low (I-II)
         High (III-IV)
212
134
1.00 (ref)
4.78 (2.80-8.18)*
212
134
1.00 (ref)
4.27 (2.60-7.04)*
Clitoral involvement
         No
         Yes
275
72
1.00 (ref)
1.61 (0.92-2.80)
275
72
1.00 (ref)
1.63 (0.96-2.77)
HR= hazard ratio, CI= confidence interval, DSS = disease specific survival, N = total number of patients in analysis, 
LVSI= lymphovascular space invasion, * p-value <0.05
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table 3. Hazard ratios with 95% confidence interval of patient- and histopathological 
characteristics for 5- and 10 year disease specific survival in vulvar cancer patients using 
multivariable Cox regression.
Variables 5-year DSS
n= 257
10-year DSS
n= 253
Hr (95% Ci) Hr (95% Ci)
Age - -
Tumour size in mm - -
Depth of invasion in mm 1.06 (1.02-1.10) 1.05 (1.01-1.09)
Surgical margins
                0 mm             
             < 8mm
             ≥ 8mm
-
-
-
-
-
-
Differentiation grade
             Well 1.00 (ref) 1.00 (ref)
             Moderately 8.70 (1.18-64.29) 5.09 (1.21-21.41)
             Poorly 13.22 (1.74-100.34) 7.22 (1.65-31.60)
LVSI
             No
             Yes
-
-
-
-
Lymph node metastases
              No
              Yes
              Yes; extranodal
1.00 (ref)
1.55 (0.80-3.03)
4.49 (2.36-8.54)
1.00 (ref)
1.43 (0.75-2.73)
4.53 (2.43-8.43)
FIGO stage
              Low (I-II)
              High (III-IV)
-
-
-
-
Clitoral involvement
              No
              Yes
1.00 (ref)
1.19 (0.66-2.14)
1.00 (ref)
1.13 (0.64-2.00)
HR= hazard ratio, CI= confidence interval, DSS = disease specific survival, N = total number of patients in analysis, 
LVSI= lymphovascular space invasion
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DISCUSSION
In this retrospective study we showed that patients with vulvar SCC with clitoral involvement have 
a worse prognosis compared to patients without clitoral involvement. This is probably due to 
unfavourable characteristics of the clitoral SCCs (larger diameter of the tumour, deeper invasiveness 
with more LVSI resulting in a higher percentage positive lymph nodes) more than to the localization 
itself. Thereby, the 5- and 10- year DSS rates of patients with clitoral involvement were lower 
compared to non clitoral SCCs. Multivariable analysis showed that invasion depth, differentiation 
grade and lymph node status were independent prognostic factors in patients with vulvar SCCs. 
Vulvar SCCs with clitoral involvement were larger and deeper invaded compared to vulvar SCCs 
without clitoral involvement. An explanation might be the patients’ and doctors’ delay in the 
diagnostic process. A Danish study showed that the diagnostic delay in vulvar cancer exceeds that 
in ovarian, endometrial and cervical cancer, mainly caused by patients’ delay (23). Fear of impairing 
the clitoris function might be an explanation of patients’ delay. Fons et al. showed that “ the mean 
waiting time of four weeks before treatment of vulvar cancer in our clinic resulted in an average 
increase in tumour size of 50%”. This illustrates that vulvar tumours are very fast-growing tumours 
as soon as they are clinically detectable. However, this does not explain larger tumours in clitoral 
SCC. Diagnostic delay in clitoral SCC, specifically, might be caused by the difficulty to biopsy the 
lesion, especially for inexperienced doctors. 
Another hypothesis for the increased depth of invasion could be that clitoral tissue is more prone 
for tumour invasion. There are no comparative studies addressing this hypothesis. However, clitoral 
tissue is comparable to the tissue of the glans penis in men, and are both characterized by high 
circulation and a large number of nerves. It could be that the vascularization of these tumours is 
more optimal and stimulates faster and deeper tumour growth. There is no literature available to 
support this hypothesis. 
Furthermore, the group of patients with a clitoral SCC had more dVIN than uVIN adjacent to the 
tumour (results not shown). Differentiated VIN is highly proliferative and might be more likely to 
progress to invasive SCC than lichen sclerosus and uVIN. Furthermore, dVIN is frequently found 
adjacent to rapidly growing invasive vulvar SCC (24, 25). Specifically, patients with clitoral SCC had 
significant more dVIN compared to patients with a perineal SCC, who had more uVIN adjacent to the 
tumour. The uVIN related pathway in vulvar cancer is associated with better prognosis compared to 
the LS/dVIN pathway (26).
Our finding of more positive groin lymph nodes in patients with clitoral involvement is likely due 
to the size and invasion depth of the clitoral tumour (27). Another explanation could be a more 
direct lymphatic drainage from clitoris to groin nodes. However, Iversen et al. (28) assessed lymph 
drainage from different vulvar areas to pelvic lymph nodes and found no difference in uptake of 
99mTc-colloid between different injection sites (including clitoris) (28). The bilateral drainage from the 
clitoris (28) might explain the higher percentage of positive nodes. However, our study did not find 
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a difference in positive groin nodes between central and lateral tumours (not displayed in results). 
Our study found extranodal growth to be a prognostic factor and to be more often present in 
vulvar SCC with clitoral involvement. Fons et al. (8) also found positive groin nodes with extranodal 
growth to decrease survival. They did not find bilateral groin nodes to worsen the prognosis, as did 
our study. Furthermore, our results showed a lower percentage of positive groin nodes in patients 
with a perineal SCC (31%) compared to a clitoral SCC (51%). It might be that the lymph drainage 
from the perineum differs from the other tumour localizations of the vulva and is more comparable 
to anal tumours. In anal cancer, Bilimoria et al. (29) and Gerard et al. (30) found that respectively 
13% and 19.5% of patients has positive lymph nodes. As in vulvar SCC, inguinal groin node status 
is an important prognostic factor in anal cancer (30). Thereby, the treatment of the groins in anal 
cancer is radiotherapy, instead of lymphadenectomy in vulvar SCC. It would be interesting to assess 
whether perineal tumours behave more like anal cancer. 
The patients with a clitoral SCC in our study more often had positive surgical margins or margins 
< 8 mm. Several studies show that close surgical margins give a higher local recurrence rate (11, 
14), but the influence on survival remains a subject of debate. However, our results did not show 
significant differences in total recurrence rate and local recurrence rate between the clitoral and 
the non clitoral group (not shown in results). Furthermore, the gynaecologic oncologists did not 
experience more difficulty in the surgical removal of the clitoris in case of clitoral involvement.
The literature on clitoral SCC is scarce, however, three studies investigated the prognosis of different 
localizations of vulvar SCC. Boyce et al. (19) and Andreasson et al. (20) also found that clitoral SCCs 
had a higher percentage of positive groin nodes, which is consistent with our findings. However, 
it is difficult to compare these data to our own data, because these studies comprise a limited 
number of patients compared to our study population. The overall finding of decreased DSS can 
be explained by the higher percentage of positive nodes in the group of patients with clitoral SCC, 
which is also defined a prognostic factor in our study (9, 11-14). 
Magrina et al. (18) mentioned urethral involvement as prognostic factor, nevertheless, we did not 
analyse this factor in our study population, because only two patients had urethral involvement. 
Also, several studies showed age being an independent prognostic factor in vulvar cancer patients. 
However, in our study age was only found to be significantly correlated in the univariate analysis. 
Our study comprised a large number of patients with vulvar SCC and we showed that patients with 
clitoral involvement tend to have a worse prognosis. Nevertheless, this study analyzed the data 
retrospectively. The precise tumour localization was not always exactly described in patients’ charts. 
Consequently, the group of patients without clitoral involvement could also comprise tumours 
localized 1 mm from the clitoris. Our study could not make clear from which distance from the 
clitoris the survival rates increased. A prospective study on the precise localization of the primary 
tumour (in mm from clitoris, perineum and midline) may give us more insight in the reason for 
the possible differences in survival of the different localizations of vulvar SCC. This may help us in 
optimizing the counselling of vulvar cancer patients.  
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Furthermore, gynaecologists should realize that patients with vulvar SCC with clitoral involvement 
tend to have a worse prognosis. Advisory, to avoid diagnostic delay, patients with vulvar complaints 
should be seen on a vulvar outpatient clinic. In case of a clitoral SCC, patients should be prepared 
for positive groin nodes as well as its influence on the prognosis. 
CONCLUSION
Optimal management and follow-up of patients with primary vulvar SCC require understanding of 
the factors associated with prognosis. Quick referrals of patients with suspicion of vulvar cancer 
may prevent delay in diagnosis. Vulvar SCCs with clitoral involvement tend to have worse prognosis 
compared to tumours without clitoral involvement. This is probably caused by unfavourable 
histopathological characteristics of the clitoral SCCs more than the localization itself. A large 
prospective study is necessary to assess the exact influence of localization of the primary tumour 
on prognosis.
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AbSTRACT 
Purpose: Two etiologic pathways for vulvar squamous cell carcinoma (SCC) are described: in a 
background of lichen sclerosus and/or differentiated vulvar intraepithelial neoplasia and related 
to high-risk human papillomavirus (HPV) infection with high grade squamous intraepithelial lesion 
(HSIL) as precursor. The aim was to compare the predilection site and survival of HPV-related to 
non HPV-related vulvar SCCs.   
Patients and Methods: Data of patients treated for primary vulvar SCC at the Radboudumc between 
March 1988 and January 2015 were analyzed. All histological specimens were tested on HPV with 
the SPF10/DEIA/LiPA25 system assay and p16
INK4a immunohistochemical staining was performed 
using CINtec® histology kit. Vulvar SCCs were considered HPV-related in case of either >25% 
p16INK4a expression and HPV positive or >25% p16INK4a expression, and HSIL next to the tumour. The 
tumour localization, disease specific survival (DSS), disease free survival (DFS) and overall survival 
(OS) of patients with HPV-related and non HPV-related vulvar SCC were compared. 
Results: In total 318 patients were included: 55 (17%) patients had an HPV-related vulvar SCC (Group 
1) and 263 (83%) patients had a non HPV-related vulvar SCC (Group 2). The tumours in Group 
1 were significantly more often located at the perineum compared to Group 2, 30% and 14%, 
respectively (p = 0.001). The DSS, DFS and OS was significantly better in the HPV-related vulvar SCC 
patients. 
Conclusion: HPV-related vulvar SCCs are more frequently located at the perineum and have a 
favourable prognosis compared to non HPV-related vulvar SCCs. Both localization of the tumour and 
the HPV-related pathway could explain the favourable prognosis. HPV-related vulvar malignancies 
seem to be a separate entity within vulvar SCC.
Vulvar cancer: two pathways with different localization and prognosis    41
3
INTRODUCTION
Vulvar cancer is a rare disease, representing approximately 3-5% of the malignancies of the female 
genital tract (1), but with an increasing incidence rate from 2002 onwards (2). Around 80% of the 
malignant tumours of the vulva are squamous cell carcinomas (SCCs). Most SCCs of the vulva occur 
on the labia majora, but the labia minora, clitoris and perineum may also be primary sites. 
There are two different etiologic pathways for the development of vulvar SCC. The first pathway is 
the most common pathway, with its precursor lesion differentiated vulvar intraepithelial neoplasia 
(dVIN) and often occurs in the background of lichen sclerosus (LS). The second pathway is related 
to the high-risk human papillomavirus (hrHPV) infection and covers about 25-30% of all vulvar 
SCCs (3, 4). High grade squamous intraepithelial lesion (HSIL) of the vulva, formerly known as usual 
vulvar intraepithelial neoplasia, is the precursor lesion (5). Differentiated VIN is suggested to be 
highly proliferative and therefore more likely to progress to vulvar SCC compared to HSIL (6, 7). 
Remarkably, most vulvar SCCs are dVIN-related but most isolated premalignant lesions are HSILs 
(4, 8). In general, the possibility of HSIL progressing into vulvar SCC is low in comparison to dVIN (9), 
namely 9-16% in untreated patients and 3% in treated patients, compared to about 30% in case of 
dVIN (10). 
The role of HPV in cervical cancer is clearly established: an infection with hrHPV is the most 
important etiological step in the pathogenesis of cervical carcinoma (11-13). Most cervical (pre)
malignancies occur at the transformation zone: an area where squamous epithelium merges into 
columnar epithelium. The cervical transformation zone is most susceptible for an HPV infection 
because of the high cell turnover and close relation to the basal cell layer (14). The anus also has 
a similar transformation zone where hrHPV associated anal intraepithelial lesions (AIN) and anal 
cancer occur. The incidence of vulvar SCC is similar to that of anal cancer, however only a minority 
of all vulvar SCCs is caused by hrHPV infection. Nevertheless, the oncogenic pathway of how HPV 
causes vulva SCC remains unclear. Our hypothesis states that micro-traumata, due to, for example, 
friction caused by sexual intercourse, might facilitate access of HPV to the basal cell layer, may 
result in integration and finally cause vulvar SCC. A previous study by our study group investigated 
the influence of localization on the prognosis of vulvar SCC. Tumours with clitoral involvement had 
worse prognosis compared to other localizations on the vulva. Several tumour characteristics such 
as depth of invasion were less favourable and these characteristics were more often present in 
vulvar SCC located at the clitoris (15).
Several studies have evaluated the relationship between HPV infection and disease specific survival 
(DSS) in vulvar SCC. These studies showed contradictory results. The studies of Monk et al. (16) 
and Ansink et al. (17) suggest that HPV-positive vulvar SCC (established by HPV PCR only) has a 
better DSS, where patients with HPV negative vulvar SCC have an increased risk of recurrence 
and death from vulvar SCC. Van de Nieuwenhof et al. found dVIN-associated vulvar SCC to have a 
significantly worse DSS (18). However, Alonso et al. (19) retrospectively evaluated 98 patients and 
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found HPV-positive and negative vulvar SCCs to have a similar overall survival and disease free 
survival. Furthermore, Pinto et al. (20) reported HPV status in the tumour as not important in terms 
of prognosis. Two other studies found that not HPV positivity, but the overexpression of p16INK4A 
might be associated with higher survival rates and better prognosis in vulvar SCC (21, 22). 
The aim of the current study was to investigate the predilection site of HPV-related compared 
to non HPV-related vulvar SCC to better understand the oncogenesis of HPV-related vulvar SCC. 
Secondly, we assessed the disease specific survival (DSS), disease free survival (DFS) and overall 
survival (OS) in patients with HPV-related and non HPV-related vulvar SCC.
MATERIAL & METHODS 
Patients and data
Data of all consecutive patients diagnosed with vulvar SCC who were primarily surgically treated 
at the Department of Gynaecologic Oncology of the Radboud university medical center, The 
Netherlands, were prospectively collected and stored in our local vulvar SCC database. Data were 
collected by consulting the medical files and pathology reports of the patients (N = 520). For the 
current study we used data of patients who have been treated between March 1988 and January 
2015. In total 232 patients were treated between 1988 and 2006; we used the data of 130 patients, 
because these data were available and complete (18). From 2006 on, all vulvar SCC patients were 
included. All data were anonymously processed so no ethical approval was necessary.
Parameters extracted from the database included: patient characteristics (age at diagnosis, history 
of tobacco use, immune status, history of LS), histopathological characteristics (localization of 
the tumour, tumour diameter, dept of invasion, presence of dVIN or HSIL, type of VIN, focality, 
lymphovascular space invasion (LVSI), differentiation grade, presence of positive groin nodes, extra 
nodular growth in positive lymph nodes, and International Federation of Gynecology and Obstetrics 
(FIGO) stage 2009), treatment characteristics (adjuvant treatment, recurrences, and cause of death) 
and survival (DSS, DFS, and OS). The localization of the tumour was divided in four groups: clitoris, 
labium, perineum, and both clitoral and perineal involvement. 
histology
All histological specimens were collected from the archives of the department of Pathology at the 
Radboudumc. All slides were evaluated by two pathologists (JB and PB) on the presence of vulvar 
SCC. The histological specimens which contained vulvar SCC were used to determine the presence 
of HPV and to assess p16INK4a expression. The above mentioned pathologists also interpreted the 
degree of p16INK4a expression.
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hPV Presence and genotyPing
DNA was isolated from formalin fixed paraffin-embedded tissue sections (4µm) with 250µl 
Proteinase K solution and incubated overnight at 70°C. This was followed by heat inactivation 
of Proteinase K at 95°C for 10 minutes. RNaseP/IC qPCR was used to evaluate DNA quality and 
PCR inhibition (23). Each isolation and PCR run contained HPV positive and HPV negative controls. 
Specimens were tested for HPV DNA by PCR amplification/detection/typing using the HPV SPF10 
PCR-DEIA-LiPA25 version 1 assay (Labo Bio-medical Products, Rijswijk, The Netherlands). Briefly, the 
broad-spectrum HPV SPF10 PCR amplifies a 65 bp fragment of the L1 open reading frame and 
recognizing a broad spectrum of at least 65 different HPV genotypes. SPF10 DEIA was used for 
detection of generated amplimers. All SPF10 PCR DEIA-positive samples were used for subsequent 
genotyping by reverse hybridisation line probe assay (LiPA), allowing simultaneous typing of the 25 
mucosal HPV types (HPV6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 
59, 66, 68 or 73, 70 and 74). The combined HPV SPF10 PCR-DEIA-LiPA25 system for detection and 
genotyping of HPV has been described in detail elsewhere (24-26). Only the hrHPV positive vulvar 
SCC samples were considered HPV positive.
P16inK4a immunohistochemical exPression
Tissue sections (4 µm) of the archival paraffin-embedded tissue samples of vulvar SCC were 
mounted onto SuperFrost glass slides (Menzel-Gläser, Braunschweich, Germany) and dried 
overnight at 37°C.
In total 379 samples were stained. One hundred and thirty samples were stained earlier in light 
of previous conducted research (18). Immunohistochemistry for p16INK4a of the remaining 249 
samples was performed using the automated Ventana XT system (Ventana Medical Systems, Inc., 
Tucson, AZ). The reaction was developed using CINtec® p16 histology kit (Ventana Medical Systems, 
Inc.). All sections were then counterstained with hematoxylin, dehydrated, and cover-slipped.
Interpretation of p16INK4A: nuclear and cytoplasmic p16INK4A staining were both considered as a 
positive reaction. The results were reported in a semi quantative fashion: negative (-) if <5% of the 
cells had nuclear or cytoplasmic staining, slightly positive (1+) if 5 to 25% of the cells were stained, 
moderately positive (2+) if staining was present in 25 to 75% of the cells, and markedly positive (3+) 
if >75% of the cells showed nuclear or cytoplasmic staining (27, 28). 
hPV-related and non hPV-related
Based on the existing literature on HPV-related malignancies, we believe that p16INK4A expression 
in the tumour is essential in the subdivision of HPV-related and non HPV-related vulvar SCC. 
P16INK4A expression is a surrogate marker of HPV infection. HPV infection leads to the inhibition of 
retinoblastoma protein pRB via HPV E7 protein which then leads to increased p16INK4A expression 
through a feedback mechanism. Based on this mechanism an HPV-related vulvar SCC is not likely to 
have a negative p16INK4A expression. We discussed the subdivision of the vulvar SCCs in a group of 
experts on HPV-related (pre)malignancies consisting of a medical microbiologist (WM), pathologists 
(PB, HB) and gynaecologic oncologists (JdH, LM) and decided on the following:
 Vulvar SCCs with >25% p16INK4A expression and HPV presence, and with >25% p16INK4A , HPV absence, 
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but HSIL presence were considered HPV-related (Group 1). Group 2 consisted of patients with non 
HPV-related vulvar SCC, including tumours with negative/≤25% p16INK4A expression independent of 
HPV status, and with >25% p16INK4A expression, HPV absence, dVIN presence and a history of LS. The 
cut-off point used for the p16INK4A expression was comparable to work of Van den Nieuwenhof et al. 
(18) and more recently Halec et al. (29). 
statistical analysis
All statistical analysis were performed using IBM SPSS Statistics version 20 (Armonk, NY: IBM Corp). 
A p-value of <0.05 was considered to be statistically significant. Patient, histopathological and 
localization characteristics were compared between the two groups using Chi-square tests and the 
independent samples t-tests. Disease specific survival (DSS) was defined as survival from the date 
of diagnosis to the date of death due to vulvar SCC or the date of last follow-up. Censoring was 
applied to patients alive at last follow-up, patients who were lost to follow-up and patients who died 
of another cause. Disease free survival (DFS) defined as disease free from date of treatment to the 
date of recurrence or death due to vulvar SCC or the date of last follow-up. Censoring was applied 
to patients recurrence free at last follow-up, patients who were lost to follow-up and patients who 
died of another cause. Overall survival (OS) was defined as survival from the date of diagnosis to the 
date of death (any cause) or the date of last follow-up. Censoring was applied to patients alive at last 
follow-up and patients who were lost to follow-up. The DSS, DFS and OS were estimated according 
to the Kaplan-Meier method and were compared using the log-rank test. 
Multivariable Cox regression with a forward stepwise procedure based on likelihood ratio statistics 
was used to identify those characteristics that independently contributed to the prognosis of vulvar 
SCC patients. Hazard ratios (HR) with 95% confidence intervals (CIs) are presented.
RESULTS 
Of the 520 patients in our database, 367 patients were included in this study. The remaining 
153 patients were excluded because the data of patients treated between 1988-2006 were not 
complete (N=102), they did not have a SCC (N=8), did not undergo surgery (diagnosed elsewhere) 
(N=10), and because no sufficient histological material was available for further research (N= 33). 
Of the 367 patient included, 49 patients could not be divided into groups, because p16INK4A staining 
could not be performed or properly be evaluated, because no histological material was left, the 
material was misplaced in the archive or the tumour was cut out of the paraffin-embedded tissue 
(N=20) and no clear division could be made based on p16INK4A expression, HPV status, premalignancy 
present, and history of LS (N=29). Of the remaining 318 patients, 55 patients had an HPV-related 
vulvar SCC (Group 1, 17%) and 263 patients had a non HPV-related vulvar SCC (Group 2, 83%). The 
baseline characteristics are shown in table 1.
In Group 1 51 patients (94%) tested hrHPV positive with HPV 16 and 33 as the predominant 
genotypes. In Group 2 241 patients (92%) tested hrHPV negative and 22 patients hrHPV positive 
with HPV 16 as predominant genotype. Figure 1 shows the HPV status, p16INK4A expression and 
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premalignancy present for the HPV-related and the non HPV-related vulvar SCC group. The 7.2 
percent hrHPV negative samples in the HPV-related group had >75% p16INK4A expression and all 
had HSIL next to the tumour. High-risk HPV negativity could be explained by false negative test 
result or the material did not contain HPV DNA anymore. In the non HPV-related group 20/22 
(91%) patients, who tested hrHPV positive had no p16INK4A expression. Two patients were hrHPV 
positive and had >25% p16INK4A expression in the non HPV-related group, but due to a history of 
LS and dVIN next to the tumour, the non HPV-related pathway was more likely in these cases. HPV 
positivity in the non HPV-related group may be explained by an additional transient HPV infection 
next to the tumour. The median follow-up of patients in Group 1 was 58 months (range 0-250) 
and in Group 2 was 37 months (range 0-293). Patients in Group 1 were significantly younger, more 
often immunocomprised and smoked/had a history of smoking more often than patients in Group 
2. Patients in Group 2 more often had LS in their history, had larger and deeper invading tumours, 
higher percentage of LVSI, a higher percentage of positive lymph nodes consequently leading to a 
higher FIGO stage, and more recurrences compared to patients in Group 1. 
Figure 1. HPV status, p16INK4A expression and premalignancy present in 318 patients with 
vulvar squamous cell carcinoma.
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table 1.  Overview of patient, tumour, and treatment characteristics of 318 patients with HPV- 
related (Group 1) and non HPV-related (Group 2) vulvar squamous cell carcinomas 
Group 1 (n=55) Group 2 (n= 263)
n Median (range) n/n (%) n Median (range) n/n (%) P-value
Patient 
Age (in years) 55 58 (33-90) 263 72 (30-95) 0.005
Smoking
      - Non smoking
      - Smoking or stopped
51
33/51 (65)
18/51 (35) 
231
177/231 (77)
54/231 (23)
<0.001
immune status
      - Not disturbed
      - Disturbed
55
49/55 (89)
  6/55 (11)  
262
256/262 (98)
6/262 (2)
0.002
History of lichen sclerosus
      - Yes
      - No
50
5/50 (10)
45/50 (90)
238
97/238 (41)
141/238 (59)  
<0.001
tumour
largest tumour 
diameter (in mm)
51 20 (2-120) 242 29.5 (2-150) 0.005
invasion depth (in mm) 53 4 (0.8-21.5) 256 6 (0.5-37) 0.002
Focality
      - Unifocal
      - Multifocal
54
40/54 (74)
14/54 (26)
262
212/262 (81)
  50/262 (19)
0.255
lVSi
      - Yes
      - No
55
9/55 (16)
46/55 (84)
256
78/256 (31)
178/256 (69)
0.034
Positive groin nodes
      - Yes
      - No
52
11/52 (21)
41/52 (79)
251
113/251 (45)
138/251 (55)
0.001
Positive groin nodes with 
extranodal growth
      - Yes
      - No
11
3/11 (27)
8/11 (73)
113
41/113 (36)
72/113 (64)
0.076
Differentiation grade
      - Well
      - Moderate
      - Poor
45
6/45 (13)
25/45 (56)
14/45 (31)
250
50/250 (20)
148/250 (59)
52/250 (21)
0.248
FiGo stage
      - I-II
      - III-IV
52
41/52 (79)
11/52 (51)
251
137/251 (55)
114/251 (45)
0.001
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Group 1 (n=55) Group 2 (n= 263)
n Median (range) n/n (%) n Median (range) n/n (%) P-value
treatment
Adjuvant radiotherapy
      - Yes
      - No
55
9/55 (16)
46/55 (84)
263
76/263 (29)
186/263 (71)
0.141
recurrence
      - Yes
      - No
55
11/55 (20)
44/55 (80)
263
94/263 (36)
169/263 (64)
0.024
Deceased
      - Alive
      - Deceased
55
41/55 (74)
14/55 (26)
260
135/260 (52)
125/260 (48)
0.002
Cause of death
      - Vulvar cancer
      - Intermittent disease
      - Unknown
14
7/14 (50)
6/14 (43)
1/14 (7)
127
90/125 (72)
29/125 (23)
6/127 (5)
0.230
LVSI = lymphovascular space invasion, FIGO = International Federation of Gynecology and Obstetrics
table 1. Continued
Figure 2. Disease specific survival (5-year and total) in patients with HPV-related and non HPV-
related vulvar squamous cell carcinoma
1.0
non HPV-related
0.8
0.6
0.4
0.2
0
0 10 20 30 40 50 60
HPV-related
5-year disease specific survival
Follow-up in months
Cu
m
 s
ur
vi
va
l
P-value = 0.001
Vulvar cancer: two pathways with different localization and prognosis    49
3
Group 1 (n=55) Group 2 (n= 263)
n Median (range) n/n (%) n Median (range) n/n (%) P-value
treatment
Adjuvant radiotherapy
      - Yes
      - No
55
9/55 (16)
46/55 (84)
263
76/263 (29)
186/263 (71)
0.141
recurrence
      - Yes
      - No
55
11/55 (20)
44/55 (80)
263
94/263 (36)
169/263 (64)
0.024
Deceased
      - Alive
      - Deceased
55
41/55 (74)
14/55 (26)
260
135/260 (52)
125/260 (48)
0.002
Cause of death
      - Vulvar cancer
      - Intermittent disease
      - Unknown
14
7/14 (50)
6/14 (43)
1/14 (7)
127
90/125 (72)
29/125 (23)
6/127 (5)
0.230
LVSI = lymphovascular space invasion, FIGO = International Federation of Gynecology and Obstetrics
Figure 2. Continued
1.0
non HPV-related
0.8
0.6
0.4
0.2
0
0 50 100 150 200 250 300
HPV-related
Total disease specific survival
Follow-up in months
Cu
m
 s
ur
vi
va
l
P-value = 0.001
50  Chapter 3
3
1.0
non HPV-related
0.8
0.6
0.4
0.2
0
0 10 20 30 40 50 60
HPV-related
5-year disease free survival
Follow-up in months
Cu
m
 s
ur
vi
va
l
P-value < 0.001
1.0
non HPV-related
0.8
0.6
0.4
0.2
0
0 50 100 150 200 250 300
HPV-related
Total disease free survival
Follow-up in months
Cu
m
 s
ur
vi
va
l
P-value = 0.001
Figure 3. Disease free survival (5-year and total) in patients with HPV-related and non HPV-
related vulvar squamous cell carcinoma
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Figure 4. Overall survival (5-year and total) in patients with HPV-related and non HPV-related 
vulvar squamous cell carcinoma
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table 2 shows the localization of the vulvar tumour in patients with HPV-related and non HPV-
related vulvar SCCs. HPV-related vulvar SCCs were more often located on the perineum than non-
HPV-related vulvar SCCs, 37% and 13.3%, respectively. Non HPV-related vulvar SCCs were more 
often located on the clitoris.
table 2. Tumour localization compared between HPV-related and non HPV-related vulvar 
SCCs. 
 
HPV-related (n=54)* non HPV-related (n=263) P-value
n (%) n (%)
Tumour localization <0.01
Perineum 20 (37.0) 35 (13.3)
Clitoris 7 (13) 81 (30.8)
Labium 26 (48.1) 146 (55.5)
Clitoris and perineum 1 (1.9) 1 (0.4)
*in 1 patient the localization of the tumour is unknown
The 5-year and total DSS rates significantly differed between the HPV-related and non HPV-related 
vulvar SCC patients, 89% versus 63% and 72% versus 35%, respectively (Figure 2). Furthermore, 
the DFS also significantly differed between the two groups. The 5-year and total DFS rates were 76% 
versus 46% and 28% versus 13%, respectively (Figure 3). The 5-year and total OS also significantly 
differed between the two groups: 85% versus 57% and 53% versus 16%, respectively (Figure 4). To 
distinguish between the influence of HPV relation and localization, survival rates between tumours 
with (N = 55) and without perineal involvement (N = 262) were compared. The 5-year and total DSS 
rates, 80% versus 65% (p-value: 0.036) and 61% versus 37% (p-value: 0.029) , respectively, and 
5-year and total OS rates, 77% versus 59% (p-value: 0.025) and 44% versus 23% (p-value: 0.029), 
respectively, were significantly better in the patients with vulvar SCCs with perineal involvement. 
The DFS rates were also better in the group of patients with vulvar SCCs with perineal involvement: 
61% versus 50% (p-value: 0.058) and 22% versus 14% (p-value: 0.035), respectively. Comparing the 
HPV-related with perineal involvement (N = 20) to the non HPV-related vulvar SCCs with perineal 
involvement (N = 35) showed significantly better survival rates for the HPV-related vulvar SCCs.
Multivariable Cox regression including the variables perineal involvement and HPV-related vulvar 
SCC, showed that HPV relation is an independent prognostic factor for 5-year and total DSS, DFS, 
and OS.
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DISCUSSION
Our study has shown that HPV-related vulvar SCCs were more often located on the perineum 
compared to the non HPV-related SCCs and the DSS and DFS was significantly better in hrHPV-
related vulvar SCC patients compared to patients with non HPV-related vulvar SCC. Not the 
localization of the tumour, but the HPV-related pathway appeared to be the explanation for a 
favourable prognosis.
The last decade the incidence of vulvar SCC has increased significantly. The two main causes 
are the ageing of the population and HPV infections. In our study 17% of the vulvar SCCs were 
considered HPV-related. This is a lower percentage than described in previous publications (3, 4). 
An explanation for this difference might be that we consider p16INK4A expression playing a key role in 
dividing the groups in our study, where in previous studies only the presence of HPV was assessed. 
HPV positivity itself is not proving a causal relationship between HPV and the vulvar SCC.  If we 
would divide our groups only based on hrHPV presence, eight percent of the samples would be 
”misplaced”. A similar distribution considering  p16INK4A expression was made in a recent study by 
Halec et al. (29) and they found an HPV-attributable fraction in vulvar SCC of 21% worldwide. Our 
results show that patients with HPV-related vulvar SCC tend to be younger and have a history of 
smoking more often than patients with non HPV-related vulvar SCC. This is in concordance with the 
existing literature (30-32). The occurrence of HPV-related vulvar SCC at relatively young age may be 
explained by a higher prevalence of HPV infection at a young age (33, 34). Smoking is described as 
possible cofactor for HPV infection, but the data on the influence of smoking on HPV-related vulvar 
SCC are limited (35-37). Associations between smoking and anal and head and neck cancer have 
been established (38-42). 
 In our study, non HPV-related tumours were larger and deeper invading, more positive lymph nodes 
were found and the positive nodes more often showed extranodal growth resulting in higher FIGO 
stages and more often adjuvant radiotherapy. This finding might be explained by diagnostic delay 
(both patients’ and doctors’) or more aggressive growth pattern of non HPV-related tumours (43-
45). Patients’ and doctors’ delay in vulvar SCCs is known to be notorious prolonged (43, 44). Patients 
often are ashamed and inexperienced doctors might not recognize vulvar SCC. Patients with non 
HPV-related tumours are older and might feel more ashamed or hesitance to talk about vulvar 
complaints. It is shown that diagnostic delay is associated with an age above 60 years (45). Non 
HPV-related tumours are often preceded by dVIN. Compared to HSIL, dVIN more often develops 
into cancer probably because dVIN is more difficult to diagnose. Furthermore, p53 positivity is more 
often found in non HPV-related vulvar SCC and is associated with poor prognosis and postulated as 
a marker for more aggressive biologic behaviour (46). 
The predilection site of HPV-related tumours in our study was the perineum. This might be explained 
by micro-traumata due to sexual intercourse. The perineum may function as a transformation zone, 
which facilitates access of HPV to the basal cell layer, HPV ultimately integrates and may cause 
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vulvar SCC. It may be difficult to know where the tumour originates exactly: in some cases there is 
a debate whether the tumour is an anal or vulvar cancer. The distinction between anal and vulvar 
cancers is important since the treatment modalities are different; vulvar SCC is primarily surgically 
treated and anal cancer with chemoradiation. However, in case of an anal tumour <2 cm and with 
limited invasion (<1 cm), and patients with poor general condition, or HIV positive patients with 
impaired immune system, radiotherapy alone or surgery are treatments of choice (47).
Patients with HPV-related vulvar SCC in our large study showed better DSS, DFS and OS rates, which 
is in concordance with only part of the literature (21, 46, 48). There are studies on vulvar SCC with 
controversial results regarding the relationship between HPV infection and prognosis in vulvar SCC 
(16-20), however none of these studies included p16INK4A expression as a criterion to divide vulvar 
SCCs into two oncogenetic pathways. In our study p16INK4A expression was essential in classifying a 
tumour as HPV-related or non HPV-related, because we stated that a tumour with negative p16INK4A 
expression was not caused by hrHPV. P16INK4A expression was used as a surrogate marker of HPV 
infection, because HPV infection leads to the inhibition of the retinoblastoma protein pRB via HPV E7 
protein which then leads to increased p16INK4A expression through a feedback mechanism. In several 
other areas, such as the head and neck region (oropharyngeal and sinonasal tumours (49-51)), HPV-
related tumours have consistently shown a better prognosis than non HPV-related tumours (15-17, 
52). Furthermore, studies show HPV-related head and neck SCCs to have an improved response to 
conventional radiotherapy (49, 53, 54). The biologic basis for the improved response is not totally 
clear, but most likely based on an intact p53 protein. Novel treatment options like HPV vaccination, 
targeting viral oncoproteins, and immune therapy are currently investigated (55). Thereby, studies 
show that cell expression of p16ink4A is an independent prognostic factor for treatment response 
to radiotherapy (15,40). Lee et al. (48) found similar results in patients with vulvar SCC. HPV DNA 
positivity and p16ink4A positivity were significantly associated with better DFS and lower rates of in-
field relapse in patients treated with radiotherapy. In the future, the localization of the tumour, HPV 
status and p16INK4A expression might  be useful for the therapeutic process of vulvar SCC, especially 
in determining the role of radiotherapy.
CONCLUSION
This study shows that there are two distinctly different pathways in vulvar SCC with different survival 
rates and localizations. HPV-related vulvar SCCs were more often located on the perineum and 
patients with HPV-related vulvar SCC have a better prognosis. Not the localization on the perineum 
but the HPV infection seems to be the explanation for a more favourable prognosis. More insight in 
the precise role of HPV in the oncogenesis of vulvar SCC is necessary to ultimately apply changes in 
the therapeutic possibilities of HPV-related vulvar SCC. 
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AbSTRACT
Renal transplantations (RTs) are performed routinely in many countries. After RT, the administration 
of lifelong immunosuppressive therapy is required. As a consequence, renal transplant recipients 
(RTRs) have a high risk to develop virus-associated (pre)malignancies, such as Human papillomavirus 
(HPV) related anogenital (pre)malignancies. It is known that the majority of the RTRs are infected with 
HPV and that these women have a 14-fold increased risk of cervical cancer, up to 50-fold of vulvar 
cancer and up to 100-fold of anal cancer. Often, treatment of these lesions requires concessions and 
may be suboptimal as radiation therapy and extensive surgery may damage the renal transplant. 
Therefore, prognosis may be compromised due to inadequately treated malignancies. Especially 
for these immunocompromised patients prevention is of utmost importance. Yearly cervical 
cancer screening for RTRs is advised, but appears to be executed poorly. For the future, optimizing 
screening and prevention of anogenital (pre)malignancies is an important issue for women after 
RT. This review gives a broad overview of all aspects regarding HPV-related (pre)malignancies of the 
female anogenital tract in RTRs.
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INTRODUCTION
renal transPlantation
In 1954 the first renal transplantation (RT) was performed between identical twins. Five years 
later, a succesful RT was made between non-identical twins. Following this, promising attempts to 
transplant other organs, such as pancreas, liver, heart and lung were made. At present, solid organ 
transplantations are performed routinely in many countries: about 18,000 RTs are performed each 
year in the European Union (500 million inhabitants) according to the European Committee on 
Organ Transplantation (CD-P-TO) (1). After solid organ transplantation, the administration of lifelong 
intense immunosuppressive therapy is required. 
immunosuPPressiVe theraPy
Immunosuppressive therapy has developed over the years from whole-body irradiation, 
splenectomy, thymectomy, and thoracic duct drainage towards combination therapy with several 
immunosuppressive drugs. Most post-RT regimens now combine a corticosteroid, a calcineurine 
inhibitor (cyclosporine or tacrolimus) and an adjunctive agent (azathioprine, mycophenolatemofetil 
or sirolimus), resulting in a 1-year patient and renal transplant survival exceeding 90%. In the last 
two decades, the incidence of acute rejection has fallen towards 10-15% (2). Initially, the clinical 
management of organ transplant recipients was dominated by acute post-operative problems, acute 
rejection, infection and cardiovascular disease. However, the improvement of immunosuppressive 
protocols and anti-infectious therapy has led to a decrease of these problems (3, 4). 
malignancies after renal transPlantation in general
ePiDeMioloGy
As a consequence of the improved long term survival of renal transplant recipients (RTRs), there 
is a tremendous increase in the incidence of post-transplant malignancies. Although the late 
consequences of RT are likely to be underreported, it is known that the overall incidence rate of cancer 
in RTRs is at least three- to fivefold increased compared to the general population with similar age 
and gender distribution (5-8). However, the elevated risk for specific cancers, such as nonmelanoma 
skin cancer (NMSC), cancer of the lip, Kaposi sarcoma, post-transplant lymphoproliferative disease 
(PTLD) and Human Papillomavirus (HPV) related anogenital malignancies is known to be even 
higher (5-11). Besides NMSC, which is extremely common in RTRs, the cumulative risk to develop 
any malignancy has been estimated at 20% after 10 years of chronic immunosuppression. Over 
the next 20 years, mortality from cancer may exceed that from cardiovascular disease among 
transplant recipients (4). 
AetioloGy
The aetiology of post-transplant malignancies is multifactorial, with a main role for the use of 
immunosuppressive medication. The duration and dose of immunosuppressants is clearly 
linked to the appearance of post-transplant cancer (4, 12, 13). Various immunosuppressants 
(e.g. azathioprine and cyclosporine) may have direct carcinogenic effects by inhibiting DNA-repair 
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capacity or by the production of growth factors, which may lead to irreversible DNA alteration and 
subsequent carcinogenesis (6, 14-17). 
In addition, immunosuppressive agents may indirectly contribute to the development of cancer, 
as an impaired surveillance ability of T-cells may disrupt anti-tumour immune surveillance and 
may potentiate oncogenic stimuli as chemical carcinogens, ultraviolet (UV) light and viruses (4, 18, 
19). Viruses that are associated with the development of cancer in RTRs are the Epstein-Barr virus 
which can induce PTLD and the hepatitis B/hepatitis C virus which are linked to the development of 
hepatocellular carcinoma (20-25). Besides, various subtypes of HPV are associated with squamous 
cell carcinomas (SCCs) of the cervix, vulva, perineum and anus (18, 26). It is also suggested that 
HPV infection may act as cofactor with UV-radiation in the carcinogenesis of extragenital NMSC, 
but the exact mechanism remains a subject for debate (27-32). There appears to be no correlation 
between patients who develop anogenital cancer and those who develop extragenital NMSC after 
RT and vice versa (33). Therefore, assuming that HPV plays a role in the carcinogenesis of NMSC, it 
is very probable that the HPV subtypes which are responsible for the occurence of NMSC are other 
subtypes than the oncogenic high-risk HPV subtypes which are causally linked to the development 
of anogenital cancers.
This review will provide an overview of different aspects of various HPV-related (pre)malignancies 
of the female anogenital tract in RTRs. It will include cervical, vulvar and anal (pre)malignancies in 
general and in RTRs and additionally, the difficulties in treatment of these lesions in RTRs. Finally, 
our vision to the future regarding screening and prevention of anogenital (pre)malignancies in RTRs 
will be marked.
data sources
Relevant publications were identified by an extensive literature search in the computerised 
bibliographical database PubMed (date of last search June 1st 2011). As keywords we used ‘renal’ or 
‘kidney’, combined with ‘transplantation’, ‘graft’ or ‘transplant recipient’. Subsequently, these terms 
were combined with cancer, neoplasm, malignancy, intraepithelial neoplasia or carcinoma in situ. 
Thereafter, a combination with Alpha papillomavirus, Human Papillomavirus, vulva, vulvar, cervix, 
cervical, uterine cervical, cervix uteri, anus, anal canal, anal, urogenital, anogenital, female genital 
tract, female genitalia, gynaecologic, gynaecology, vaccine or vaccination was made.
Additional papers were identified using the ‘related articles’ button in PubMed and reference lists 
from selected articles were scrutinised in order to identify other relevant articles that had been 
overlooked in the database search. table 1 gives an overview of the articles used in the paragraphs 
on cervical, vulvar and anal (pre)malignancies in RTRs.
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table 1. Overview of studies concerning HPV infections and HPV-related anogenital 
malignancies in RTRs
Author year type of study number of patients
Buell [4] 2005 Review -
Vajdic [7] 2006 Population based cohort (RTR) 28855
Chapman [8] 2004 Population based cohort (RTR) 13000
Penn [9] 1996 Population based cohort (RTR) 6707
Penn [10] 2000 Population based cohort (RTR) 9032
Penn [11] 1986 Population based cohort (RTR) 65
Meeuwis [33] 2010 Hospital based cohort (RTR) 224
Rose [97] 2006 Case control (RTR:ICI) 88:88
Morrison [98] 1996 Cohort (RTR) 21
Alloub  [99] 1989 Case control (RTR:ICI) 49:69
Brown  [100] 2000 Case control (RTR:ICI) 20:13
Busnach  [101] 2006 Case control (HIV and TR) HIV: 8074, TR: 2878
Fairley [102] 1994 Case control (RTR:D:ERF) 69:89:22
Gentile [103] 1991 Hospital based cohort (RTR) 39
Halpert [104] 1991 Hospital based cohort (RTR)
Case control (RTR:ICI)
105
81:81
Veroux [105] 2009 Hospital based cohort (RTR) 35
Nappi [106] 2005 Case control (HIV:ICI) 75:75
Petry [107] 1994 Hospital based cohort (HIV and RTR)
Case control (RTR with cervical lesion: ICI with 
cervical lesion)
HIV: 48, RTR: 52
11:21
Nieuwenhof [111] 2009 Population based cohort (ICI) 1893
Meeuwis [113] 2012 Hospital based cohort (RTR) 6
Porreco [164] 1975 Population based cohort (RTR) 224
Penn [165] 1986 Review -
Birkeland [166] 1995 Population based cohort (RTR) 5692
Collett [167] 2010 Population based cohort (RTR) 25104
Nieuwenhof [175] 2009 Hospital based cohort (ICI) 130
Fairley [178] 1994 Population based cohort (RTR) 15820
Rascente [179] 2005 Hospital based cohort (RTR) 265
Bobrowska [180] 2005 Case report (RTR) 1
Volgger [181] 1997 Case report (RTR) 1
Ogunbiyi [202] 1994 Case control (RTR:ICI) 133:145
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Author year type of study number of patients
Ogilvie [203] 2008 Hospital based cohort (RTR) 40
Patel [204] 2010 Hospital based cohort (RTR) 108
Adami [205] 2003 Population based cohort  (TR) 5931
Blohme [206] 1985 Hospital based cohort (RTR) 934
Sunesen [208] 2010 Population based cohort (TR) 5113
RTR: renal transplant recipient, ICI: immunocompetent individual, HIV: Human immunodeficiency virus, 
TR: transplant recipient, D: dialysis, ERF: end-stage renal failure
HUMAN PAPILLOMAVIRUS
Viral characteristics
HPV is a double stranded DNA virus that can infect basal epithelial cells of all human squamous 
epithelia. The HPV genome encodes for 9 viral proteins; the specific early (‘E’)-region encodes for 
regulatory, transforming and replication viral proteins which are expressed in un- to moderately 
differentiated basal replicating cells. The late (‘L’)-region encodes for viral capside proteins which 
are only expressed in highly differentiated epithelial cells, resulting in a high number of HPV copies 
in superficial epithelial layers (see Figure 1) (34).
Viral proteins E6 and E7 are known cancer promoting genes. The E6 protein may inactivate p53 (a 
tumour suppressor protein), which results in chromosomal instability and diminished apoptosis. 
The E7 protein may suppress the retinoblastoma protein (pRB)-pathway which leads to enhanced 
cell proliferation (34, 35). 
ePidemiology of hPV infections
Worldwide, the overall HPV prevalence is around 10% (36). Up to 80% of sexually active women 
have been genitally infected by one or more HPV subtypes during their life (37, 38). The majority of 
HPV infections are transient; these infections will be cleared by the immunesystem without causing 
any abnormality (39, 40). The mean duration of a cervical HPV infection in the general population is 
thought to vary between 8 and 13 months (41). 
The prevalence of any HPV infection in the general population ranges between 2 and 44%, with a 
peak incidence in the young age groups (42) and, in most regions, a subsequent peak in women 
aged 45 years or older (36). Recently, HPV point prevalence in women between 18 and 29 years 
of age showed to be 19% (42). Prevalence in women between 40 and 50 years of age, which is 
the average age for RT, is about 10% (43). The HPV prevalence is not only age dependent, but 
also country dependent. Africa registers the highest prevalence (32%), Asia the lowest (6%) and 
table 1. Continued
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Southern Europe registers the second lowest prevalence. An HPV infection with subtype 16 occurs 
most frequently (41, 44-46).
Figure 1. HPV-mediated progression to cervical cancer
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer. Woodman CB, Collins SI, Young 
LS. The natural history of cervical HPV infection: unresolved issues. Nature Reviews Cancer 7, 11-22 (January 2007), 
copyright 2007.
Basal cells in the cervical epithelium rest on the basement membrane, which is supported by the dermis. Human 
Papillomavirus (HPV) is thought to access the basal cells through micro-abrasions in the cervical epithelium. 
Following infection, the early HPV genes E1, E2, E4, E5, E6 and E7 are expressed and the viral DNA replicates 
from episomal DNA (purple nuclei). In the upper layers of epithelium (the midzone and superficial zone) the viral 
genome is replicated further, and the late genes L1 and L2, and E4 are expressed. L1 and L2 encapsidate the 
viral genomes to form progeny virions in the nucleus. The shed virus can then initiate a new infection. Low-grade 
intraepithelial lesions support productive viral replication. The progression of untreated lesions to micro invasive 
and invasive cancer is associated with the integration of the HPV genome into the host chromosomes (red nuclei), 
with associated loss or disruption of E2, and subsequent up regulation of E6 and E7 oncogene expression.
LCR = Long control region
68  Chapter 4 
4
transmission
HPV is mainly transmitted by sexual intercourse (47). However, as HPV has rarely been detected 
in the cervix of virgins, other ways of transmission e.g. through contaminated hands, might play 
a role (48-50). Winer et al. showed that about 60% of type-specific HPV detected in fingertips 
was detected in a concurrent genital sample. As redetection of the HPV-DNA in fingertips at a 
subsequent visit was low, this finding pleads for deposition of HPV-DNA from the genitals rather 
than true fingertip infection (51). Besides, several studies suggest a perinatal mechanism of viral 
transmission; one study showed that 38% of the infants were HPV-DNA positive at 24 hours after 
birth (48). Furthermore, another study showed 33% presence of HPV in the oral pharyngeal cavity 
of the neonates (49). Incidence of HPV infection in neonates of HPV-positive women is significantly 
higher after vaginal birth compared to birth after caesarean section. However, as the incidence 
after caesarean section is also fairly high (52), it has been postulated that intrauterine transmission 
of HPV is possible. This is stated in previous studies which found HPV-DNA in the amniotic fluid and 
in blood from the umbilical cord (49, 53). So, until now there is no evidence that newborn infants of 
HPV-positive women would be protected by Caesarean section (49, 53).
hPV subtyPes
Since the improvement of DNA technology, over 100 distinct HPV subtypes have been described 
and probably more will follow. HPV can be classified into two groups: cutaneous and mucosal 
HPV subtypes. Cutaneous subtypes are predominantly found in cutaneous verrucae and mucosal 
subtypes predominate in anogenital lesions (28, 54). 
Mucosal HPV subtypes can be divided in high-risk (subtype 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 
53, 56, 58, 59, 66, 68, 73, and 82) and low-risk (subtype 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and 
CP6108) subtypes (55-60). Persistent infection with high-risk HPV (hrHPV), especially subtype 16 
and 18, has an essential role in the carcinogenesis of anogenital malignancies (61). The low-risk 
HPVs, especially HPV 6 and 11, are responsible for about 90% of the condylomata acuminata (61, 
62), which are not considered as precursor lesions of cervical cancer. 
Persistence, latency, integration and Viral load
HPV persistence is commonly defined as having two or more positive tests (63, 64), time to clearance 
(65-67) or proportion of HPV-positive visits (68, 69). Defining HPV persistence is complicated by 
differences in HPV tests, testing intervals, HPV categorization and status for analysis. However, the 
most important difficulty in defining HPV persistence is the lack of knowledge on the behaviour 
of an HPV infection. The magnitude of the effect of HPV persistence seems to be stronger with 
longer duration of the infection, wider HPV testing interval, and higher-grade cervical disease (70). 
Persistent HPV infections are strongly associated with the development of cervical intraepithelial 
neoplasia (CIN) 2-3 and are considered to drive progression of CIN into invasive cervical cancer (71). 
Laboratory evidence shows that persistent HPV oncogene expression is critical for the maintenance 
and progression of CIN (72).
As mentioned earlier, the prevalence of HPV shows a second peak in women aged over 45 years 
(36). This phenomenon could be attributed to several mechanisms, such as reactivation of latent 
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infections acquired earlier in life due to gradual loss of type-specific immunity, acquisition of new 
infections due to new sexual partners later in life or a cohort-effect (45). 
Latency implies that no HPV-DNA is detectable by conventional molecular tests, but that very 
small foci of cells maintain infection at low DNA copy numbers (63). Several animal studies showed 
that papillomaviruses have the ability to persist in the absence of clinical signs of disease. For 
example, infection of the skin of domestic rabbits with cottontail rabbit papillomavirus can induce 
an asymptomatic infection, which can be activated by exposure to exogenous factors, such as 
ultraviolet light, and leads to lesions/symptoms (73, 74). Furthermore, respiratory papillomatosis 
(RRP) is associated with benign papillomas of the larynx, which can recur rapidly. A latent infection 
has been accounted responsible for the rapid recurrence, because viral transcripts were often 
found in clinically normal tissue of RRP patients (75-79). Moreover, studies in immunocompromised 
patients hint also to the possibility of latent HPV infections. Theiler et al. (80) conducted a study in a 
group of immunocompromised patients, namely HIV positive women, where the prevalence of HPV 
infections is very high. The results suggest that HIV infected women with a previous HPV infection 
that was presumably cleared, may still develop an active HPV infection in the absence of further 
sexual exposure. It remains unclear if this theory applies to all immunocompromised patients such 
as transplant patients. Figure 2 shows a potential model of HPV infection in immunocompromised 
patients. 
Trottier et al. (81) analyzed the association between latent/new infection and new sexual partners 
at the time the infections were detected. They found that the magnitude of the association in 
older women with new partners was comparable between putatively latent infections (same HPV 
subtypes) and new infections (with different HPV subtypes), which favours the notion of true 
transmission rather than reactivation. Muñoz et al. (82) showed that new sexual partners increased 
the incidence of HPV infections in older women. 
Finally, a cohort-effect needs to be taken into account concerning the second peak in HPV 
prevalence, meaning that age-related variations in prevalence may reflect the diverse HPV exposure 
of successive birth cohorts. 
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Figure 2. A potential model of HPV infection in immunocompromised patients 
So far, a definitive conclusion on whether reactivation of latent HPV infections or newly acquired 
HPV infections causes the second prevalence peak in women over 45 years has not yet been made 
and the matter needs to be elucidated more in future studies. Furthermore, it is not clear whether 
the differences between a latent and active cervical infection are qualitative or quantitative (34). 
A persistent infection with hrHPV may lead to integration of the viral DNA into the human 
genome. Integration of HPV-DNA in the human genome is not a normal part of the HPV cycle and 
is characterized by deletion of viral genes that are essential for synthesis of an infectious virus. 
In general, only integration of hrHPV subtypes leads to increased expression and stability of the 
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transcripts encoding for the E6 and E7 oncoproteins, which may bind and disrupt the function of 
key cellular proteins like p53 and pRb. High-risk HPV-DNA integration causes cellular immortality, 
deregulated proliferation and increased genomic instability of host cells (35). Integrated HPV-DNA 
is often found in high-grade pre-invasive lesions and even more frequent in cervical cancer (83-86). 
These findings show that integration can be postulated as a possible driving factor in the transition 
of high-grade intraepithelial lesions to invasive disease. Lesions containing HPV in its episomal form 
are thought to pursue a less aggressive course (85, 87-89). On the other hand, Pirami et al. (89) 
showed that in cervical cancers not all the HPV was present in integrated form, which suggests 
that integration is certainly fundamental, but not obligatory in the development of cervical cancer. 
Unpublished data from our research group showed that HPV-DNA integration is significantly higher 
in cervical glandular lesions (93%) than in squamous cell lesions (37%), particularly obvious for HPV 
16. Figure 1 presents a clear overview of the process of HPV-DNA integration. 
After infecting the basal epithelial layer, the virus replicates and produces viral particles. The 
amount of viral particles can be measured in a cervicovaginal sample and is defined as viral load. It 
was hypothesized that a higher viral load would be associated with more severe cervical disease. 
However, it is now clear that the relationship between viral load and disease is more complex. Cross-
sectional studies reported an increase in viral load with increasing disease severity, while others 
found either no association or a higher viral load in women with low-grade squamous intraepithelial 
lesions than in those with high-grade squamous intraepithelial lesions (90-94). A measurement of 
the viral load is therefore not yet clinically relevant to determine the severity of the disease (95). 
To recapitulate, persistence is defined as having two or more positive tests, time to clearance or 
proportion of HPV-positive visits. Latency implies that no HPV-DNA is detectable, but very small foci 
of cells maintain infection. Integration is characterized by deletion of viral genes leading to disruption 
of the function of p53 and pRb, eventually causing cellular immortality, deregulated proliferation 
and genomic instability.
hPV and renal transPlant reciPients
RTRs have a higher risk of HPV infections compared to immunocompetent women. The question 
rises whether this group of patients has a higher incidence of HPV infections or not.
HPV is sexually transmitted, but whether the HPV infections in RTRs are newly acquired or 
reactivated latent infections is unknown and has not been studied yet. Two studies suggest a more 
conservative sexual behaviour in RTRs than the general population, which may plead against newly 
acquired infections (96, 97). Hence, the hypothesis of a latent state of HPV infection seems more 
plausible. Unlike in HIV positive women, the transplant recipients have not been studied extensively 
on the latent state of HPV infections yet. It is hypothesized that the behaviour of HPV infections is 
quite similar to that in HIV positive women; however, this has to be further examined.
The incidence of mucosal HPV infections in RTRs varies between 22 and 63% (98-104). Furthermore, 
RTRs are more often affected with multifocal HPV infections compared with the general population 
(98-104). A recent study among 35 RTRs found that 62.8% of the RTRs were positive for HPV-
DNA and that 59% of the HPV-positive RTRs exhibited a hrHPV genotype (104). It is hypothesized 
that transplant recipients may not only have more risk to develop an HPV infection, but that the 
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infections may also have a higher aggressiveness and that the evolvement to (pre)malignancies may 
also go faster (105, 106). 
In the general population, it is known that a patient with a hrHPV-related (pre)malignant 
anogenital lesion frequently develops other lesions of the vulva, cervix or anus; metachronously or 
synchronously. Accordingly, up to 71% of patients with vulvar dysplasia or cancer have a previous 
concomitant or subsequent history of vaginal intraepithelial neoplasia, CIN or cervical cancer (107-
110). Those multifocal lesions frequently contain identical HPV subtypes even after an interval 
of more than 10 years (107). In contrast, it has recently been shown that multifocal anogenital 
lesions in RTRs frequently contain different HPV subtypes, including subtypes that are untypical 
for high-grade lesions in immunocompetent patients (111, 112). Therefore, it is hypothesized that 
RTRs would be target for repeated or recurrent infections with various HPV subtypes that induce 
independent lesions (111, 112).
 
CERVICAL (PRE)MALIGNANCIES
ePidemiology
Cervical cancer is a major health problem, with more than 500,000 new cases occurring each year 
worldwide, especially in developing countries. In 2008 about 250,000 deaths from cervical cancer 
were reported, making it the third leading cause of cancer death in women in the world (113). In 
developed countries, cervical cancer has been considered a preventable cancer because of its long 
pre-invasive state, cervical screening cytology programmes to detect pre-invasive lesions at an early 
stage and the possibility to treat these premalignancies. Virtually all cervical cancers are caused by 
hrHPV infection, which implies that cervical cancer does not and will not develop in the absence 
of the persistent presence of HPV DNA (114). HPV 16 accounts for 50 – 60% of the cervical cancer 
cases in most countries, followed by HPV 18 (10 – 20%), HPV 45 (4-8%) and HPV 31 (1-5%) (43, 114, 
115). Only the minority of patients with hrHPV infections will develop cervical cancer eventually. 
Probably other factors (e.g. viral persistence, viral load, integration, genetic predisposition and 
smoking) exert influence on the development into cervical cancer (98, 99, 116).
oncogenesis
The primary site for cervical cancers is the cervical transformation zone (border between the 
glandular and squamous epithelium). The transformation zone is assumed to be more susceptible 
to oncogenic influences, like hrHPV infection, due to the high cell-turnover (117). Virtually all cases 
of cervical cancer develop through the following distinct and sequential steps: acute infection with 
hrHPV followed by detectable viral persistence linked to the development of CIN and subsequent 
invasion (118) (Figure 3). About 10% of the hrHPV infections that persist for several years is linked 
to a high risk of CIN. Furthermore, the lag time between infection and histological evidence of CIN 
can be short, often within 5 years in immunocompetent female patients (119).
Cervical intraepithelial neoplasia is the non-invasive precursor lesion of cervical cancer. The CIN 
lesions are classified as CIN 1, CIN 2 and CIN 3 on the basis of the presence of mitotic activity and 
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nuclear atypia within respectively the basal third, two thirds and whole thickness of the epithelium 
(120). table 2 gives an overview of the different terms that are used to describe the histological and 
cytological abnormalities of premalignant stages of cervical cancer.
table 2. Different cytology nomenclature
Adapted from Bekkers RL, Massuger LF, Bulten J, Melchers WJ. Epidemiological and clinical aspects of human 
papillomavirus detection in the prevention of cervical cancer. Rev Med Virol. 2004;14:95-105.
Papanicolaou Dysplasia Cin Bethesda 
Pap 1 Normal Normal Within normal limits
Benign atypia Inflammatory atypia Benign cellular changes
Pap 2 Atypical cells 
AGC
Squamous atypia ASC-US
ASC-H
AGC (NOS)
Pap 3A1 Mild dysplasia CIN 1 Low-grade SIL
Pap 3A2 Moderate dysplasia CIN 2
High-grade 
Pap 3B Severe dysplasia
CIN 3 SIL
Pap 4 CIS
Pap 4 AdenoCIS Glandular cell abnormality
Pap 5 Invasive carcinoma
CIN: Cervical intraepithelial lesion, CIS: Carcinoma in situ, Pap: Papanicolaou classification of cervical scrapes, 
ASC-US: Atypical squamous cells of undetermined significance, ASC-H: Atypical squamous cells cannot exclude 
high-grade SIL, AGC (NOS): Atypical glandular cells (not otherwise specified), SIL: Squamous intraepithelial lesion
Squamous and glandular cells from the transformation zone of the cervix may be collected with 
cervical scrapes. In several review articles, the risk of eventually developing invasive cervical cancer 
was estimated to be 1% in patients with CIN 1, 5% in patients with CIN 2, and 15% in patients with 
CIN 3. Fortunately, a great part of CIN lesions regresses spontaneously in time; 30-62% of the CIN 
1 lesions, in 17-54% of the CIN 2 lesions and in up to 30% of the CIN 3 lesions (121-123). It has 
been estimated that 10-20% of the CIN 3 lesions will finally progress to invasive disease when left 
untreated (123). Therefore, CIN 3 lesions are always treated and patients with CIN 1 and/or CIN 2 
lesions preferably end up in follow-up care. Currently, CIN 3 lesions are mostly treated by large loop 
excision of the transformation zone (LLETZ). 
74  Chapter 4 
4
Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC and Castle PE. Human Papillomavirus Testing in 
the Prevention of Cervical Cancer. J Natl Cancer Inst (2011) 103 (5): 368-383, reprinted by permission of Oxford 
University Press.
left graph: Proportion of prevalent carcinogenic HPV in fections that clear, persist, or progress to cer vical 
intraepithelial neoplasia grade 3 (CIN3) in the first 3 years after first detection, based on all infections found at 
baseline screening in the Guanacaste Natural History Study. The great majority represented “new” infections. 
Persistence without CIN3 is surprisingly uncommon. Uncommon reappearances of HPV types following clearance 
did not predict risk of CIN3. right graph: Proportion of un treated CIN3 lesions that invade to cancer within 30 
years following the initial diagnosis [based on data from New Zealand]. 
Eighty-five percent of the cervical cancers are squamous cell carcinomas (SCCs) and a small 
group (10-20%) consists of adenocarcinomas. The incidence of cervical adenocarcinoma has 
been increasing in the past decades (124-130). The overall prevalence of HPV infection in cervical 
adenocarcinomas ranges between 40-100% (131-137). Several studies show a predominance of 
HPV subtype 18 (133, 135, 138), others an equal distribution between HPV subtype 16 and 18 (131, 
134, 136) and there are studies that show a predominance of HPV subtype 16 (132, 137), though 
not in the same proportion as in SCC.  As the treatment of cervical SCCs and adenocarcinomas is 
identical and the majority of cervical cancers are SCCs the following sections of this review will only 
focus on cervical SCCs.
After the histologically confirmed diagnosis of cervical SCC, usually clinical staging is performed. 
The stage of the tumour is determined following the FIGO clinical staging for cervical cancer (139). 
Examination under anaesthesia is generally performed to be informed on possible invasion of 
parametria and vagina.
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Figure 3. Risks of Human papillomavirus (HPV) persistence and progression and cervical 
cancer progression model
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Treatment of cervical cancer consists primarily of surgery or (chemo)radiation therapy. In tumours 
limited to the cervix or with minimal expansion to the proximal vagina, radical surgery will be 
performed with post-operative radiotherapy in about 20%; based on lymph node metastases and/
or unfavourable tumour parameters. In case of expansion outside the cervix the primary treatment 
consists of radiotherapy combined with chemotherapy and/or hyperthermia.
In general, the prognosis of cervical cancer is good with an overall 5-year survival of 65% and for 
stage I disease a 5-year survival up to 97.5% (140). On the other hand, the morbidity after treatment 
is impressive with infertility, ovarian dysfunction, micturation- and defecation problems and sexual 
discomfort as the most imposing complications (141). 
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Figure 3. Continued
In the top of the figure the three steps in cervical carcinogenesis are described, namely acute Human papillomavirus 
(HPV) infection, HPV persistence associated with the development of cervical precancer (cervical intraepithelial 
neoplasia grade 3 [CIN3] in particular), and inva sion. The graph shows that Infection and clearance are extremely 
common and together contribute to the sharp peak of HPV prevalence in the years following average age of first 
sexual intercourse in the population. The average age at CIN3 diagnosis depends on the intensity of the screening 
effort in the population. Typically, it takes decades for a CIN3 lesion to grow and eventually invade, although there 
are rare and rapid exceptions.
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screening
All women between 30 and 60 years of age in the Netherlands receive an invitation from the 
regional screening organization or from their general practitioner for cervical screening, once 
every five years. The participation rate of the screening programme is about 65% (142). About half 
of all women with newly diagnosed invasive cervical cancer never participated in any screening 
programme (143-145). As previous stated, HPV causes almost all cervical cancers and is therefore 
the main factor in the oncogenesis of cervical cancer. The clinical sensitivity of hrHPV detection is 
higher than the cytology (~90% versus ~60%), but the specificity is slightly lower (70-90% versus 90-
100%)(56, 146-151). Recently, it has been decided to introduce the hrHPV test as primary screening 
tool in the Netherlands (152). 
Currently, physician-collected cervical specimens are considered as the gold standard collection 
method for HPV detection (153). Recently, a self-sampling method was introduced to reach also the 
non-responder group of the population screening. Self-sampling is a specimen collection method 
that is highly accepted by women and the sensitivity of self-sampling is sufficient to be used as an 
appropriate alternative for physician sampling in low-resource settings or to increase screening 
rates (154-157). The implementation of self-sampling in the Netherlands in a recent study showed 
a response rate between 27.5-31.3% in the non-responders of the standard population screening 
(158-160).
cerVical (Pre)malignancies in renal transPlant reciPients
At the age of 29 years, a female patient underwent a renal transplantation, because of loss of renal 
function due to IgA-nephropathy. After seven years, she was diagnosed with hrHPV 16 positive cervical 
cancer stage IB2 which was treated with neoadjuvant chemotherapy and surgery (without the removal of 
the left pelvic lymph nodes because of the location of the renal transplant in the pelvis). Radiotherapy was 
contraindicated, because of the localisation of the renal transplant in the pelvis. The tumour board chose, 
in consultation with the patient, for no adjuvant treatment. The cancer recurred after one year (see Figure 
4) and the patient died of disease at the age of 38 years.
The role of HPV in the oncogenesis of cervical cancer has urged investigators to theorize that 
the immunosuppressed state poses transplant patients at risk to HPV infection with subsequent 
cancer development. Already in 1975, Porreco et al. (22) described a 14-fold increased incidence 
of intraepithelial lesions of the cervix in RTRs compared with an age matched group in the general 
population. Also, Alloub et al. (98) showed a significant higher prevalence rate of CIN lesions 
between women with renal transplants (49%) compared with controls (10%). More recently, we 
published data that support the findings of these earlier studies. We detected CIN lesions in 8 of 
224 patients (3.6%). When compared with the general population, these RTRs had at least a 2- to 
6-fold increased risk of developing CIN (33). 
In 1986, Penn already showed that 11% of women with post-transplant malignancies had cervical 
cancer (161). In the following years, several other studies showed an increased incidence of cervical 
cancer after renal transplantation with standardized incidence rates (SIRs) described between 2.3 
and 8.6 (4, 7, 162, 163). 
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Cervical cancer in RTRs may lead to major dilemmas regarding treatment decisions. As described 
earlier, there are several treatment options, but in RTRs the renal transplant is a barrier for many 
of these treatments. The dilemma rises whether to treat the patient optimally for cervical cancer 
or to maintain the function of the renal transplant. For example, radiotherapy of the pelvic area 
is not possible without compromising renal function leading to a dysfunctional renal transplant. 
Furthermore, radical surgery is difficult because the pelvic nodes can hardly be reached. 
Figure 4. Recurrent disease of cervical cancer in a renal transplant patient
The transversal section of a T2-weighted MRI shows recurrent disease of cervical cancer on the vaginal vault. 
MRI: Magnetic resonance imaging, 1: Vagina filled with contrast fluid, 2: Recurrent disease
VULVAR (PRE)MALIGNANCIES
ePidemiology
Vulvar cancer is a rare disease which accounts for approximately 3-5% of all gynaecological cancers, 
with an incidence of about 2/100,000 (110, 164). In the Netherlands, about 300 new cases of vulvar 
SCC are diagnosed per year (110, 164). In the general population, 54% of patients with vulvar SCC 
are above the age of 70 years and only 15% of the patients are under the age of 50 years (110). 
About 80% of vulvar malignancies are SCCs. The remaining 20% comprise a variety of tumours 
ranging from mainly basal cell carcinoma to more rare tumours such as malignant melanoma, 
adenocarcinoma of Bartholin’s gland and Paget’s disease (165). In this paper we will focus on the 
SCC and its precursor lesions of the vulva. There has long been a three-grade system to define 
these vulvar cancer precursors (vulvar intraepithelial neoplasia [VIN] grade 1-3), analogous with CIN 
lesions. However, as clinicopathological data did not support the concept of a continuum spectrum 
1
2
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of VIN lesions leading to vulvar cancer, the International Society for the Study of Vulvovaginal Disease 
(ISSVD) modified the classification of VIN. VIN 1 was abandoned and VIN 2 and 3 were consolidated 
into one category simply termed VIN. Subsequently, as the single diagnostic category VIN included 
two different vulvar premalignancies that have a different malignant potential, the classification was 
modified into VIN usual type (uVIN) and VIN differentiated type (dVIN) (166).
oncogenesis
Vulvar SCC originates from two separate pathways. The first is an HPV-independent pathway and 
occurs in a background of non-neoplastic epithelial disorders (e.g. lichen sclerosus). This form is 
usually seen in older women and encompasses the majority of vulvar SCCs in the general population 
(~80%) (167, 168). Differentiated VIN is presumed to be the precursor lesion of the HPV-negative 
vulvar SCC (110, 169).
The second pathway is an HPV-dependent pathway, caused by a persistent infection with hrHPV. 
hrHPV subtypes 16 and 33 are the most commonly seen genotypes in vulvar lesions present in 
about 60% and 20% of HPV-dependent vulvar carcinomas in the general population, respectively. 
Other less common hrHPV subtypes like 18, 52 and 58 have also been reported (107, 167, 170, 
171).The premalignant stage for this tumour is uVIN (167, 172). See Figure 5 for an example of uVIN 
of the clitoris. Figure 6 represents clinical pictures of a uVIN lesion in a female RTR with widespread 
condylomata acuminata. The oncogenesis of this type of vulvar SCC has a remarkable resemblance 
to the development of CIN into cervical cancer. The immune system seems to play an important role 
in the progression of uVIN to invasive disease (173). HPV-dependent vulvar SCCs primarily affect 
younger women and comprehend the minority of vulvar malignancies in the general population 
(in about 20% of all vulvar SCCs there appears to be a causal relation between hrHPV and vulvar 
SCC carcinogenesis) (167, 171). Oppositely, HPV-dependent vulvar SCCs seem to comprehend the 
majority of vulvar carcinomas in immunocompromised women.
VulVar (Pre)malignancies in renal transPlant reciPients
At the age of 32 years, a female patient underwent a renal transplantation because of chronic 
pyelonefritis with negligible renal function. After an interval of 12 years after transplantation, she 
was diagnosed with HPV 16 related uVIN that recurred after two years. Both lesions were treated 
with laser therapy. Thereafter, she was lost for follow up and 4 years later she presented with vulvar 
cancer. She had a radical vulvectomy and bilateral inguinofemoral lymphadenectomy. All lymph 
nodes were negative so no radiotherapy was indicated. There was no evidence of disease after 5 
months of follow up.
Vulvar (pre)malignancies in RTRs are only sparsely described in the current literature. However, 
it is known that RTRs have an obviously increased risk for (HPV-related) vulvar (pre)malignancies. 
Several studies show that 100% of the vulvar lesions among RTRs are HPV-positive, compared to 
approximately 20% of the vulvar carcinomas in the general population (99, 112, 171). Figure 7 
shows an example of a vulvar SCC in a RTR.
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Figure 5. Clinical picture of usual VIN of the clitoris in a female RTR (indicated by the arrow).
VIN: vulvar intraepithelial neoplasia, RTR: renal transplant recipient
Figure 6. Clinical pictures of widespread vulvar and perineal condylomata acuminata 
in a female RTR (A). During inspection of the affected area, usual VIN was detected at the 
commissura posterior of the vulva (B).
RTR: renal transplant recipient, VIN: vulvar intraepithelial neoplasia
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Figure 7. Clinical picture of a vulvar SCC (indicated by the arrow) surrounded by usual VIN 
(particularly posterior at the inner side of the right labium minus) in a female RTR.
SCC: squamous cell carcinoma, VIN: vulvar intraepithelial neoplasia, RTR: renal transplant recipient
There is no regular screening tool for VIN; symptoms are frequently absent or variable and 
suspicious vulvar lesions are not always histopathologically examined. Therefore, this disease is 
likely to be underreported; both in the general population and in RTRs. A recent retrospective 
cohort study on 224 female RTRs detected four patients with dysplasia of the vulva (33). The fact 
that all of the lesions were HPV-related (uVIN) types underlines the preponderance of the HPV-
dependent pathway of the development of vulvar SCC in RTRs. 
Vulvar cancer has a relatively high prevalence in RTRs compared to the general population and 
belongs to the predominant malignancies in RTRs (7, 9, 10). The ANZDATA Registry, which contains 
data of more than 13,000 RTRs (110,395 person years) transplanted between 1980 and 2003, 
reported SIRs varying between 45.6 and 55.8 for vulvar cancer (8, 174). Correspondingly, a recent 
comparison of the standardized age-adjusted prevalence rates of vulvar cancer in a cohort of 224 
female RTRs and in the general population of the Netherlands showed a 50-fold increased risk to 
develop vulvar cancer (33). Adami et al. showed a standardized incidence rate of 26.2
In general, vulvar SCCs develop rather late after transplantation with an average time to cancer 
ranging between 10 and 20 years, although one case is reported of vulvar cancer even 33 years 
after RT (7, 33, 112, 175).
High-risk HPV 16 and 33 are most frequently detected in vulvar cancers of RTRs, but also less 
common hrHPV subtypes are seen which is comparable to the general population (99, 112). 
Multicentric lesions (involving perineum, anus, uterine cervix or vagina) are frequently seen in RTRs 
with HPV-dependent vulvar disease. Those multicentric lesions either originate synchronously or 
metachronously and are probably the result of incapacity to clear the HPV infection and higher 
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susceptibility for newly acquired infections (11, 112, 176). Immunocompromised patients tend to 
be much younger than patients in the general population with vulvar malignancies (10). The median 
age at diagnosis of vulvar cancer appeared to be approximately 40 years in a Dutch cohort of 
female RTRs, which is remarkably young compared to the median age at diagnose of the general 
Dutch population (~ 70 years) (110, 112). Additionally, vulvar cancer in RTRs may behave more 
aggressively and may be associated with a worse prognosis compared to the general population, 
but this should be further studied (177). 
Just as in immunocompetent patients, surgery is the cornerstone of treatment for vulvar cancer in 
RTRs, sometimes combined with radio- and/or chemotherapy. However, one should realise that 
standard treatment may harm the renal transplant which may result in an alternative treatment 
schedule to save the function of the transplant kidney. 
ANAL (PRE)MALIGNANCIES
ePidemiology
Tumours of the anal region can be divided into several distinctive histological types, according to 
the anatomy of different zones of the anal canal. The anal canal extends from the perianal skin 
(squamous mucosa) via the transitional zone (transition from squamous to non squamous mucosa) 
to the rectal mucosa. Tumours arising above the dentate line (the line which indicates the end of the 
squamous mucosa and the beginning of the transitional zone) are usually mixed adenosquamous 
carcinomas.
Carcinoma of the anus is a rare disease in the general population and accounts for less than 1.5% of 
all gastrointestinal tract malignancies (178). The incidence of anal cancer is rising and is now about 
1.5 – 2.0 per 100,000 in the general population (179, 180). However, this incidence is higher for 
high-risk populations such as men who practice anoreceptive intercourse and immunosuppressed 
patients such as HIV-infected patients and solid organ transplant recipients (178, 181, 182). For 
example, the incidence in HIV-negative men who have sex with men is about 40 per 100,000 and for 
HIV-positive men who have sex with men the incidence is about 80 per 100,000 (183). Women with 
a history of HPV related vulvar or cervical cancer also have substantially higher incidences of anal 
cancer (184, 185). The incidence of invasive cancer is consistently higher for women (about 66% of 
cases) compared to men (about 34% of cases) (179, 180, 186). 
The most frequently diagnosed anal tumours are SCCs, which account for 70-85% of all anal 
cancers (180, 187). In general, mixed adenosquamous carcinomas and SCCs have similar biology 
and prognosis. On the opposite, anal adenocarcinomas behave like rectal cancer (178, 187). In a 
case-control study, Frisch et al. (188) detected HPV-DNA in 88% of 388 patients with anal cancer, 
but in none of the control patients with rectal adenocarcinoma. Another case-control study by 
Daling et al. (189) showed only 40% of anal adenocarcinomas positive for HPV versus 92.2% of anal 
SCCs. Similarly, although a role for HPV in rectal cancer is suggested, a causal relationship has never 
been established (190-193). Therefore, anal adenocarcinomas and rectal cancer beyond the scope 
of this chapter. 
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oncogenesis
Anal SCC has, just as cervical cancer, a strong etiologic association with HPV infection. The precursor 
lesion for anal cancer is anal intraepithelial neoplasia (AIN). Natural history studies adapted similar 
histology grades for AIN as for CIN. AIN 1 is an indication of active HPV infection and not a cancer 
precursor as is CIN1. AIN 2 mimics CIN 2 and is unpredictable for cancer progression. AIN 3 lesions 
have a nearly complete association with HPV infection, but have, unlike CIN 3, relatively low rate of 
malignant transformation in immunocompetent patients (183).
In general, malignant progression from high-grade AIN (AIN2/3) to anal SCC is reported in about 
10% of the cases. However, progression is more likely in the presence of immunosuppression; 
about 50% within 5 years (194, 195). 
The association between HPV and anal cancer is established in various population-based 
epidemiological studies. Of all anal cancers 71 – 88% is attributable to HPV, with a preponderance 
of hrHPV subtypes (188, 189, 196, 197). These population-based studies, including specific high-risk 
patients such as HIV-positive patients or men who practice anoreceptive intercourse, showed that 
HPV subtype 16 seems to be the predominant genotype associated with anal cancer, detected in 
66 – 73% of HPV-positive anal cancer cases; followed by HPV subtype 18 in 5.2 – 6.9% (188, 189, 
196, 197) and HPV subtype 33 in 3.3 – 5.9% (188, 196, 197).  
anal (Pre)malignancies in renal transPlant reciPients
A female patient with end stage renal disease due to chronic membranous glomerulonephritis 
received a renal allograft at the age of 34 years. Since then, she was maintained on oral prednisolone 
and azathioprine daily. Almost 4 years later, she was diagnosed with an HPV 6 & 16 positive CIN3 
lesion, which was managed by diathermic stripping (ablatio cervicis). Seven years thereafter, she 
was found to have a moderately differentiated, HPV 58 positive SCC of the anus which was treated 
with radiation therapy. Multiple cutaneous SCCs developed before and after the diagnosis of anal 
cancer. Six months after initial treatment, the anal cancer recurred and was surgically treated. 
Nevertheless the patient died of recurrent disease 1.5 years later, at the age of 47 years. 
Ogunbiyi et al. (198) were the first who established that RTRs are at significant higher risk of 
developing AIN and having anal HPV infection compared with the general population (20% versus 
1% and 47% versus 12% respectively). Comparably, AIN was diagnosed in 18.3% of RTRs in another 
cohort (199). It is established that AIN in RTRs is significantly associated with anal hrHPV infection, 
duration of immunosuppression, previous condylomata acuminata and anoreceptive intercourse 
(200). 
A few studies have been conducted on the appearance of anal cancer following RT, showing an 
obviously elevated risk for the development of these tumours. Reported risk ratios have a broad 
range, varying between 10 and 100-fold (163, 201-204). In Figure 8, clinical pictures of a female RTR 
who synchronously developed uVIN and anal SCC are shown. 
The optimal treatment for AIN is difficult to determine as large series comparing treatments with 
prolonged follow up are lacking (205). Different strategies can be employed, for example expectant 
management for low- grade AIN, imiquimod 5% cream, infrared coagulation, or local resection (205-
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207). Also, early stage cancer is generally treated with local resection. In case of more advanced 
stage disease, local resection is usually replaced by or combined with radiation therapy with or 
without chemotherapy. However, obtaining complete remission of anal cancer in RTRs is challenging 
as radiation therapy may have toxic effects on the renal transplant and therapeutic compromises 
are frequently needed. 
Figure 8. Clinical pictures of usual VIN (A) and anal SCC (B) that were diagnosed in a female 
RTR at the same moment. 
VIN: vulvar intraepithelial neoplasia, SCC: squamous cell carcinoma, RTR: renal transplant recipient
PREVENTION
The increased risk for anogenital malignancies that is associated with long term immunosuppressive 
therapy use and the difficulties in treatment of these lesions have consequences for the long term 
survival of RTRs. Therefore, prevention of these cancers and their precursors should be given high 
priority. 
Primary PreVention
Currently, two HPV vaccines that may prevent a majority of cases of HPV 16 and 18 related 
anogenital (pre)malignancies are available in many countries. These vaccines have been shown to 
be highly effective in the general population and also seem promising for RTRs. However, there are 
no publications about effectiveness or safety of these HPV vaccines among patients with end stage 
A b
*
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renal disease and RTRs until now. Those patients may have a decline in vaccine-induced immunity 
(reduced response and/or rapid decline of antibody levels), which is perceived by vaccination against 
hepatitis B (208, 209). Currently, several studies are conducted on the safety and immunogenicity 
of the HPV vaccines in immunocompromised patients (www.clinicaltrial.gov). Besides, it may be 
possible that there is also room for therapeutic HPV vaccination for RTRs with high-grade anogenital 
lesions in the future. Kenter et al. (210) recently showed promising results of such vaccination for 
the treatment of high-grade VIN lesions in immunocompetent individuals and more studies on this 
theme are in progress. The value of therapeutic HPV vaccination in immunocompromised patients 
should be topic of further investigation.
At this moment, organized prophylactic vaccination in women before RT under a conceptual setting 
of annual cervical screening is unlikely to be cost effective in preventing cervical lesions (209). 
Nonetheless, the benefits of the quadrivalent vaccine may also be directed at HPV 6 and 11-related 
condylomata acuminata and vaccine-subtype specific lesions of the vulva, vagina and anus. When 
including these data, cost effectiveness analyses would possibly be more favourable (209). The 
content of this discussion will definitely change in a few years, as organised HPV vaccination 
programmes for young adolescents will become implemented in a growing number of countries. 
However, vaccination will not control anogenital cancer completely. Therefore, a proactive policy 
regarding screening of the anogenital tract will remain important. 
secondary PreVention
Based on the evidence of the higher risk for malignancies, several publications have suggested 
intensifying the cervical cancer screening in the transplantation population, although there is no 
consistent evidence that this will lead to a reduction in cervical cancer incidence and subsequent 
mortality (22, 33, 99, 103). By now, several European and American guidelines (e.g. the European 
Best Practice Guidelines, the “Kidney Disease: Improving Global Outcomes”-foundation and the 
American Society of Transplantation) recommend to perform at least annual cervical cancer 
screening with pelvic examination and Pap smear in female RTRs (211-213). According to Wong 
et al. (209), annual screening for cervical cancer using conventional cytology in female RTRs is cost 
effective when compared with no screening. 
Until now, there is only limited evidence regarding the implementation of this policy. Courtney et al. 
(214) showed that the uptake of annual cervical cancer screening in the RTR population of Northern 
Ireland is low. Of the 173 female RTRs eligible for cervical cancer screening, only 10% undertook the 
advised number of screening procedures and 32% had never had a cervical smear performed at 
all. Additionally, we demonstrated that the mean number of cervical smears per RTR per year in the 
Netherlands was 0.2, which is significantly less than the recommended yearly interval. Even 37% of 
the RTRs who should undergo yearly cervical smears had never had a cervical screening after their 
transplantation (33). A reasonable explanation for the discordance between the recommendations 
and the observed practice might be that both patients and healthcare professionals underestimate 
the importance of anogenital screening and focus primarily on the preservation of renal function.
Additionally, regular surveillance of the anogenital region of female RTRs is important (212, 213). 
Annual screening for cervical cancer provides an excellent opportunity to perform a thorough 
external examination of the anal and vulvar regions, for example with digital photo’s during follow-up.
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CONCLUSION / FUTURE PERSPECTIVES
This review focused on hrHPV infections and anogenital (pre)malignancies in female RTRs. These 
immunocompromised patients have a high incidence of anogenital hrHPV infections and it is known 
that they have a 14-fold increased risk for cervical cancer, up to 50-fold increased risk for vulvar 
cancer and up to 100-fold increased risk for developing anal cancer compared to the general 
population.
Unfortunately, the treatment options in this particular population are limited due to the localization 
of the renal transplant. To spare the renal transplant, concessions in the treatment plan are 
necessary although this may lead to an elevated mortality rate due to suboptimal treatment. 
As a consequence of the obviously elevated risk and the restrictions in the treatment of RTRs, 
additional attention to screening and prevention of anogenital (pre)malignancies is required. At 
present we have to tighten up the annual screening with external anogenital inspection, pelvic 
examination and cervical smear. It would be worthwhile to evaluate the feasibility of gynaecological 
examination and treatment before transplantation to diminish the early development of anogenital 
(pre)malignancies after transplantation. Furthermore, it is a challenging task for further research to 
get more insight in the incidence, prevalence and genotype of genital HPV infection before and after 
RT in women with end stage renal disease in the setting of a prospective study. Herewith, a base 
for additional research may be found in the field of prophylactic hrHPV vaccination in patients who 
are waiting for transplantation. 
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AbSTRACT
Female renal transplant recipients (RTRs) have an increased risk for developing human 
papillomavirus (HPV) related (pre)malignant lesions of the genital tract. This study aims to assess 
the genital prevalence of HPV before and after renal transplantation (RT). In female patients who 
were counselled for renal transplantation at the Radboud university medical center Nijmegen, 
the Netherlands, gynecological examination was performed at first visit, and 1 and 2 years later. 
HPV self-sampling and questionnaires on sexual behaviour were performed every 3 months. In 
65 patients who underwent RT, the hrHPV prevalence as assessed with the highly sensitive SPF10 
-LiPA25 test, increased significantly from 19% before to 31% after RT (p=0.045). Based upon the 
clinically validated Cobas 4800 HPV test, the hrHPV prevalence increased from 10% before to 14% 
after RT (p=0.31). During follow-up no changes in sexual behaviour were reported. Thirty-three 
patients who did not undergo RT showed a hrHPV prevalence of 21% at study entry and of 27% 
after 12 months with the sensitive test, and a stable prevalence of 16% with the clinically validated 
test. The results of this study indicate that activation of latent HPV infections may contribute to the 
increased risk of HPV-related (pre)malignant lesions in female RTRs.
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INTRODUCTION
Organ transplantation is the treatment of choice for patients with failing kidneys, heart, lungs, pancreas 
or liver. To prevent rejection, organ transplant recipients have to use lifelong immunosuppressive 
therapy. This makes them more susceptible for the development of malignancies with standardized 
incidence ratios (SIRs) ranging from 2.1 to 4.0 (1-6). 
It is well known that high-risk human papillomaviruses (hrHPVs) are causative in the development 
of genital premalignant or malignant lesions ((pre)malignancies), mainly due to HPV 16 and HPV 18. 
In fact, 95% of all cervical malignancies and about 20% of the vulvar malignancies are hrHPV-related 
(7). We previously showed that using a highly sensitive detection assay, the point prevalence of 
genital HPV infections in women aged 18-29 in the Netherlands is 19%, with an HPV 16 and HPV 
18 prevalence of 2.8% and 1.4%, respectively (8). The majority of hrHPV infections in the general 
population will be cleared within one year. It is thought that only those women in whom the virus 
is persistently present over a longer period, have an increased risk of genital (pre)malignancies. 
HPV positive anogenital tract (pre)malignancies (e.g. cervix, vulva and anus) are found at a 
significantly higher rate in renal transplant recipients (RTRs) than in immunocompetent individuals 
with SIRs between 1.0-2.5 for cervical cancer and between 7.3 and 23.9 for vulva/vaginal cancer (1, 
3, 5, 6, 9), and belong to the most frequent (pre)malignancies in RTRs (10-12). In observational and 
other studies on posttransplant malignancies in female RTRs, 11% developed cervical cancer and 
4% developed vulvar cancer (13). Another study of our group showed that (pre)malignancies are 
primarily diagnosed early (within 3 years) or late (>10 years) after transplantation (14). 
Data on the prevalence of genital HPV infections in RTRs are scarce. One study showed a prevalence 
of HPV of 62.8% in 35 female RTRs (15). In contrast with the general population in whom about 20% 
of the vulvar lesions is HPV positive, Brown et al. found that all vulvar lesions in transplant patients 
were HPV positive (16). Recently, Meeuwis et al. (17) showed a cervico-vaginal HPV prevalence of 
27.1% in a large cohort of female RTRs after renal transplantation (RT).
The HPV prevalence in female RTRs has been mainly assessed after the transplantation. The natural 
course of hrHPV infections from the time before to the period after RT is unknown. Therefore, 
the aim of this study was to assess the prevalence of genital HPV in female RTRs before and 
after transplantation. More specifically, we were interested to investigate whether the use of 
immunosuppressive therapy has an effect on the prevalence of hrHPV. Knowledge with respect to 
the biological behaviour of genital HPV infections might provide a scientific basis for rational means 
to prevent anogenital malignancies in the future, such as HPV vaccination and screening.
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PATIENTS AND METHODS
study PoPulation and immunosuPPressiVe treatment
Between February 28th, 2012 and April 1st, 2015, female patients with end-stage renal disease (ESRD), 
who had an appointment at the outpatient clinic of the Department of Nephrology at the Radboud 
university medical center (Radboudumc) to judge whether they were appropriate candidates for RT 
were invited to participate in this study. See Figure 1 for inclusion and exclusion criteria. All patients 
underwent renal transplantation in the Radboudumc. After transplantation, patients were treated 
with tacrolimus, mycophenolate mofetil and prednisone as immunosuppressive therapy. From 
August 2014, induction therapy with basiliximab was added to the immunosuppressive therapy. 
Acute rejection episodes were treated with methylprednisolone followed by antithymocyte globulin 
in case of steroid resistant rejection. This study was approved by the local medical ethics committee 
[protocol number: 2011/425]. 
gynaecological examination
Patients who returned the informed consent form were examined by the clinical researcher of 
the department of Obstetrics & Gynaecology. This first appointment with the researcher included: 
detailed medical history, dermatological and gynecological examination with inspection of the 
external genitalia and perianal area, inspection of the vagina and cervix (vaginal vault in absence of 
the uterus), and collection of cytology by a smear of the cervix or the vaginal vault. This complete 
gynecological examination was repeated at 1 and 2 years after inclusion in the study. 
cytology
The Bethesda system 2001 was used for cytological classification. In case of normal cytology no 
further tests or treatments were necessary. When the cytology showed atypical squamous cells of 
undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL), the smear 
was repeated after 6 months according to hospital protocol. In case of high-grade squamous 
intraepithelial lesion (HSIL) a colposcopic examination was performed and patients were treated 
according to current guidelines.
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Figure 1. Scheme of the inclusion
36 patients were HPV tested every 3 months
7 patients were examined once at the first 
visit to the outpatient clinic and only more if 
they would undergo RT
65 patients underwent 
renal transplantation
- One patient died after 
transplantation due to 
brain tumour
15 patients were found 
unfit for transplantation and 
excluded.
7 patients were not examined, 
because:
- Appointment was cancelled
- Sickness patient 
- Patient reconsidered participation 
before first examination
49 patients did not receive study 
information, because:
- Not familiar with Dutch language
- Disabled (physically and/or 
mentally)
- Not willing to undergo 
gynaecological examination
inclusion criteria:
- Female ≥ 18 years
- Eligible for RT at Radboudumc
- Mentally capable 
- Sufficient knowledge of the Dutch 
language
- Signed informed consent
exclusion criteria:
- Not willing to undergo 
gynaecological examination
- Pregnant
- Within 3 months from delivery/
miscarriage
123 patients were examined by the researcher
130 patients signed informed consent
351 patients referred to the Radboudumc
43 patients were not 
transplanted, because:
- Donor not approved
- No replacement 
therapy necessary
- Waiting list 
Eurotransplant
- Other reasons
302 patients received study information
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self-samPling
The patient was asked to self collect a cervico-vaginal sample with a collection device (a small brush 
packaged in an individual sterile cover, Rovers Evalyn brush®, Rovers medical Devices B.V. Oss, 
the Netherlands (18)) at the first visit and at home every 3 months during follow-up. Therefore, 
patients were sent an HPV self-sample kit every three months. This kit contained a collection device, 
detailed instructions on how to perform the cervico-vaginal self-sampling (written and in cartoon) 
and a return package consisting of a leak-proof seal bag, absorption sheet and an easy-slider plastic 
return envelope. 
sPecimen PreParation and dna extraction
The dry Evalyn Brush was resuspended in 1·5 ml Thin Prep. The vials were vortexed for 3x15s, 
stored overnight at 4°C, and again vortexed for 2x15s. From each resuspended dry specimen, 200 
μl was used for DNA extraction with the MagNaPure 96 (Roche Molecular Diagnostics, Indianapolis, 
Indiana, USA). The purified DNA was eluated in 50μl TE-buffer.
hPV detection and genotyPing
For the HPV detection on the collected self-sampling material, two HPV detection methods were 
used. The first is the highly analytical sensitive short-PCR-fragment assay (SPF10 -LiPA25; Labo Bio-
medical Products B.V., Rijswijk, The Netherlands). This assay has been widely used for epidemiological 
and vaccination studies, because of its very high analytical sensitivity (19). This assay was included 
to identify the smallest foci of detectable HPV. However, because of its high analytical sensitivity, 
the SPF10 -LiPA25assay has a very low clinical specificity (19). As a second test we therefore used 
the clinically validated Cobas 4800 HPV test (Roche), which enables to detect chronic productive 
infections that are potentially related to cervical abnormalities (20). The data obtained with this test 
may guide future clinical management of transplant patients.
The SPF10 -LiPA25 assay amplifies a small fragment of 65-bp from the L1 open reading frame and 
allows detection of a broad range of HPV genotypes (21-23). Next, HPV DNA enzyme immunoassay 
(DEIA) was used, which comprises a defined cocktail of digoxigenin-labelled probes to detect a 
broad spectrum of HPV mucosal genotypes. All HPV DNA-positive samples were genotyped 
subsequently with a line probe assay (LiPA25) by reverse hybridization with type-specific probes for 
mucosal HPV genotypes 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 
66, 68/73, 70, 74 (22). The LiPA strips were interpreted visually, using the standard reference guide. 
When samples tested positive using the DEIA, but showed no results on the LiPA strip, the SPF10 
amplimer was analyzed by direct sequence analysis with the BigDye Terminator cycle sequencing 
kit (Applied Biosystems, Nieuwerkerk a/d Ijssel, The Netherlands). The sequences were used as a 
query for screening in the GenBank database (www.ncbi.nlm.nih.gov) with BLAST software (24). HPV 
genotypes were assigned when a complete match between the 22-bp interprimer region and an 
HPV sequence in GenBank was found. 
Genotypes not available on the LiPA strip and without a complete match in GenBank were 
considered HPV genotype ‘X’. Low risk HPV (lrHPV) genotypes were defined as genotype 6, 11, 34, 
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40, 42, 43, 44, 54, 74, 84, 89, 90 and ‘X’. High risk HPV genotypes were defined as genotype 16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59. HPV genotypes 53, 66, 68, 69, 70 and 73 are nowadays 
classified as possible/probable high risk HPV (phrHPV) genotypes (25). For analytical purposes, they 
were defined as hrHPV genotypes in this study. HPV genotypes 3, 12, 20 and 76 were identified 
by sequencing as cutaneous genotypes. These HPV genotypes were regarded as contamination 
during sample handling (self-sample) and were not taken into account in the calculation of HPV 
prevalence rates.
The self-sampling material of all included patients at first examination and of all the patients who 
underwent a RT, before and after transplantation, was also tested with the clinically validated Cobas 
4800 HPV test (Roche) according to the manufacturer’s recommendations in the laboratory of 
the Department of Medical Microbiology, Radboudumc (20). The Cobas 4800 HPV test provides 
separate results for HPV 16, 18, and a pool of 12 other hrHPV types (31, 33, 35, 39, 45, 51, 52, 56, 
59, 66, and 68) (26).
Questionnaires
Patients filled out questionnaires on relations/sexual behaviour at start of the study and at every 
three-monthly self-sampling moment, and they were specifically asked whether there were any 
changes in their relationship and/or sexual behaviours. The questionnaires are available as 
Supplemental material.
statistical analysis 
Data of all women who gave informed consent and underwent gynecological examination, including 
an HPV test, were included in the analyses. The prevalence of HPV infection after transplantation 
was only assessed in patients who underwent a transplantation within three years after inclusion 
in the study. In the primary analysis we compared the HPV prevalence before (measurement 
closest to RT in 6 month period preceding RT) and after (latest measurement in the period between 
month 3 and month 12 after RT) transplantation in patients with both measurements available. In 
a secondary analysis we used a scoring system to quantify the degree of HPV positivity in multiple 
measurements before and after RT; a score of 0 corresponding with 100% negative measurements 
and a score of 100 with 100% positive measurements. Patients who were included in the study, but 
did not undergo a RT during the follow-up period were used as a control group. In these patients, 
HPV prevalence at first examination and the latest measurement in 12 month period were used in 
the analysis.
A model based on the generalized estimating equations (GEE), with a binomial distribution and 
identity link was used to analyze the pre- and posttransplant prevalence and the change in 
prevalence. The mean scores calculated from multiple measurements before were compared 
with the mean scores after RT by a paired samples t-test. Continuous variables were described 
by medians (and range) or means (and standard deviation). Discrete variables were described by 
frequencies and percentages. The genotype of each HPV infection was assessed and described 
per time point. The results from the questionnaires asking for sexual behaviour were summarized 
according to the transplantation status of the patient. All data were anonymously stored in an 
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electronic database. Statistical analysis was performed using IBM SPSS Statistics 20 (Armonk, NY: 
IBM Corp). Two-sided p-values <0.05 were regarded as statistically significant.
RESULTS
During the study period, 351 patients were referred to the outpatient clinic of the Radboudumc 
to judge whether they were appropriate candidates for RT. During the study period, 65 patients 
underwent a RT. The remaining 58 patients did not receive a kidney graft for various reasons; 15 
patients were found unfit for transplantation and were excluded. See Figure 1 for an overview of the 
inclusions. In total 13 patients (three underwent RT) were lost to follow up: four patients died (three 
patients due to cardiac problems and one patient developed a brain tumour), five patients left the 
study because it was too time consuming or their physical condition was impaired, three patients 
did not respond to reminders, and one patient due to psychiatric problems. The general patient 
characteristics, details on their renal disease and treatment, and gynecological characteristics at 
first contact are summarized in table 1.
The median follow up after transplantation (last follow up date 12th of October 2015) was 15 months 
(range 0-29 months). Five patients did not have any measurement after transplantation and one 
patient did not have any measurements before transplantation. Finally, HPV prevalence before and 
after transplantation was determined in 59 patients with both the clinically validated HPV test and 
the highly sensitive HPV test. 
 
As assessed with the highly sensitive HPV test, the overall HPV prevalence increased from 25% 
(95% CI 14-37%) before transplantation to 39% (95% CI 27-51%) after transplantation using the 
definition of the primary outcome measure (p= 0.04; table 2). The hrHPV prevalence increased 
from 19% (95% CI 9-29%) before transplantation to 31% (95% CI 19- 42%) after transplantation 
(p=0.045). The hrHPV prevalence before transplantation (median time to transplantation: 30 days 
(1 to 180 days)) determined with the clinically validated HPV test, was 10% (95% CI 2-18%). With 
this test, the hrHPV prevalence after transplantation (median time from transplantation: 300 days 
(120 -360 days)), was 14% (95% CI 5-22%) (p=0.31). Four patients already used immunosuppressive 
drugs for chronic renal disease at the time of transplantation. Exclusion of these four patients did 
not change the results. Since there was a variable number of measurements per patient before 
as well as after transplantation, we used a score system to quantify the degree of HPV positivity in 
multiple measurements. 
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table 1. Patient characteristics of female patients with end stage renal disease at first contact 
at the outpatient clinic
transplanted 
patients (n=65)
not transplanted 
patients (n=43)
p-value
Median 
(range)
% (n/n) Median 
(range)
% (n/n)
General characteristics
Age (years) 50.0 (19-73) 54.0 (21-70) 0.54
Smoking
       - Yes
       - No
       - Unknown
28 (18/65)
72 (47/65)
0 (0/65)
23 (10/43)
74 (32/43)
2 (1/43)
0.66
renal Disease
       - Polycystic kidney    
         disease
      - Chronic interstitial 
        nephritis
      - Focal segmental
        glomerulosclerosis
      - Chronic 
        glomerulonephritis
      - Urinary tract 
        anomaly
      - Haemolytic uremic  
        syndrome
      - Chronic 
        pyelonephritis
      - Diabetic 
        nephropathy
      - Renovascular 
        disease
      - Other
      - Unknown
23 (15/65)
6 (4/65)
 6(4/65)
22(14/65)
6  (4/65)
5 (3/65)
6 (4/65)
 
3 (2/65)
 
5 (3/65)
12 (8/65)
6 (4/65)
28 (12/43)
2 (1/43)
2 (1/43)
12 (5/43)
12 (5/43)
2 (1/43)
0 (0/43)
2 (1/43)
19 (8/43)
16 (7/43)
5 (2/43)
0.27
Use of iSD in the past
      - No 
      - Yes
72 (47/65)
28 (18/65)
84 (36/43)
16 (7/43)
0.17
Current use of iSD
      - No
      - Yes
92 (60/65)
8 (5/65)
95 (41/43)
5 (2/43)
0.97
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transplanted 
patients (n=65)
not transplanted 
patients (n=43)
p-value
Median 
(range)
% (n/n) Median 
(range)
% (n/n)
interval last iSD 
treatment to first 
examination (months)
31.0 (0-115) 27.5 (0-76)
Previous rt
      - No
      - Yes
88 (57/65)
12 (8/65)
88 (38/43)
12 (5/43)
0.92
Dialysis
      - Haemodialysis
      - Peritoneal dialysis
      - Both
52 (34/65)
53 (18/34)
41 (14/34)
6 (2/34)
42 (18/43)
61 (11/18)
33 (6/18)
6  (1/18)
0.29
Duration of dialysis 
(months)
12.5 (3-96) 14.0 (1-120) 0.33
Gynaecological
Cervical smear
         - WNL
         - ASC-US/LSIL
         - HSIL
         - No uterus: 
           not performed
90 (59/65)
5 (3/65)
5 (3/65)
0 (0/65)
91 (39/43)
2  (1/43)
0 (0/58)
7 (3/43)
0.13
ISD = immunosuppressive drugs, RT = renal transplantation, WNL = within normal limits, including normal vaginal 
cytology in absence of an uterus, ASCUS-US/LSIL = atypical squamous cells of undetermined significance/low-grade 
squamous intraepithelial lesion, HSIL = high-grade squamous intraepithelial lesion
table 1. Continued
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table 2. HPV prevalence before and after transplantation in 59 female renal transplant 
recipients
Comparison HPV prevalence 
before rt
HPV prevalence 
after rt
Difference p-value
SPF10 -liPA25 system n % (95% Ci) % (95% Ci) % (95% Ci)
Overall (lr + hr)
      - All
      - No ISD use at time of RT
59
55
25(14-37)
25 (14-37)
39 (27-51)
40 (27-53)
14 (1-26)
15 (1-28)
0.038
0.038
hrHPV
      - All
      - No ISD use at time of RT
59
55
19 (9-29)
18 (8-28)
31 (19-42)
31 (19-43)
12 (0-23)
13 (0-25)
0.045
0.044
Cobas 4800 n % (95% Ci) % (95% Ci) % (95% Ci)
hrHPV
      - All
      - No ISD use at time of RT
59
55
10(2-18)
11 (3-19)
14 (5-22)
15(5-24)
3 (-3-10)
4 (-3-11)
0.313
0.313
RT = renal transplantation, lr = low risk, hr = high risk, ISD = immunosuppressive drugs, CI = confidence interval
The mean score for overall HPV positivity before transplantation was 25.5 (mean number of 
measurements before was 2.26 (range 1-9) in a time period of 1 day to 2 years before transplantation) 
and the mean score after transplantation was 32.9 (mean number of measurements after was 4.14 
(range 1-8) in a time period of >1 month to 2 years after transplantation) with a mean difference of 
7.4 (95% CI -3.1-17.9; p=0.163). For hrHPV positivity the mean score before transplantation with the 
sensitive HPV test was 17.9 and after transplantation 22.0 with a mean difference of 4.1 (95% CI -4.6-
12.9; p=0.349). With the clinically validated HPV test the mean score was 10 before transplantation 
and 12.5 after transplantation with a mean difference of 2.5 (95% CI -3.5-8.5) (p= 0.41). 
In 12/59 patients (20%) the HPV status changed (tested with SPF10 -LiPA25 assay) from negative 
before transplantation to positive after transplantation. We specified the characteristics of these 
patients in table 3. This change in HPV status was not associated with treatment for acute rejection 
after transplantation. In none of the 12 women who went from HPV negative to HPV positive we 
found SIL after transplantation. Notably, lrHPV was detected in two of these women and follow-up 
time was relatively short for development of (pre)malignant lesions. In 4/59 patients (7%) the HPV 
status changed from positive before RT to negative after RT. Furthermore, a wide range of HPV 
types were found: hrHPV types 16, 31, 52, 66, 45, 68, 53, 58, 18, 51, 34, 56 and 59 and lrHPV types 
6, 11, 40, 42, 89, 61, 84, 54, 74, and 44 and type X. None of these HPV subtypes was predominantly 
present. As assessed with the highly sensitive HPV test, the overall HPV prevalence in the patients 
who did not undergo RT (N= 33), was 27% (95% CI 12-42%) at first examination and 33% (95% CI 
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table 3. Patient- and test characteristics of newly HPV-positive patients after renal transplantation 
Age rD Previous 
tx
Cytology 
pre-rt
Pre-rt 
HPV status
Post-rt HPV 
status
Cytology 
post-rt
Change 
sexual 
behaviour
Bethesda ≤6 months 
pre-rt#
3-12 months 
post-rt
≥ 3-12 months post-RT Bethesda
SPF Cobas SPF SPF SPF SPF# Cobas SPF SPF SPF SPF
1 53 Other WNL neg neg pos X neg pos X pos 61 neg Pos 61 Pos 61 Pos X Pos 6 WNL No
2 51 Diabetic 
nephropathy
1x 2010 WNL neg neg pos 45 neg pos 11/45 pos 45 pos Pos 18b/45 neg neg neg WNL No
3 28 Urinary tract 
anomaly
WNL neg neg pos X neg neg pos X neg neg Pos 53 neg neg NA No
4 40 Polycystic kidney 
disease
WNL neg neg neg pos 68 pos 68 pos 6,68 neg Pos 68 Pos 68 Pos 68 x WNL No
5 58 Polycystic kidney 
disease
NA neg neg pos 68 x x pos 68 neg x x x x NA No
6 57 Polycystic kidney 
disease
WNL neg neg neg neg pos 16 neg neg neg Pos 54/74 neg WNL No
7 47 FSGS WNL neg neg neg neg neg pos 6 neg neg neg neg x WNL No
8 57 Chronic 
glomerulonephritis
WNL neg neg neg neg neg pos 16 neg neg neg neg x WNL No
9 48 Other WNL neg neg neg neg neg pos 18 neg Pos X Pos X x x WNL Yes, more often 
with same 
partner
10* 52 Chronic 
glomerulonephritis
WNL neg pos pos 16/59 x x pos 59 neg x x x x WNL Unknown
11 34 Other 1x 1997 WNL neg neg pos 51 x x pos 51 neg Pos 
18/31/35/45/68
x x x NA No
12 61 Chronic 
pyelonephritis
NA neg neg neg neg x pos 16,31 neg x x x x NA No
* Only patient who used Basiliximab, # = measurements used in primary analysis, bold results = last measurement 
in period 3-12 months after RT and used in primary analysis, RD = renal disease, FSGS = focal segmental 
glomerulosclerosis, Tx = transplantation, RT = renal transplantation, Bethesda = Bethesda system 2001 was used for 
cytological classification,  SPF = SPF10-LiPA25 system assay, Cobas = Cobas 4800 assay, WNL = within normal limits, NA 
= not available, x = self-sample not available
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table 3. Patient- and test characteristics of newly HPV-positive patients after renal transplantation 
Age rD Previous 
tx
Cytology 
pre-rt
Pre-rt 
HPV status
Post-rt HPV 
status
Cytology 
post-rt
Change 
sexual 
behaviour
Bethesda ≤6 months 
pre-rt#
3-12 months 
post-rt
≥ 3-12 months post-RT Bethesda
SPF Cobas SPF SPF SPF SPF# Cobas SPF SPF SPF SPF
1 53 Other WNL neg neg pos X neg pos X pos 61 neg Pos 61 Pos 61 Pos X Pos 6 WNL No
2 51 Diabetic 
nephropathy
1x 2010 WNL neg neg pos 45 neg pos 11/45 pos 45 pos Pos 18b/45 neg neg neg WNL No
3 28 Urinary tract 
anomaly
WNL neg neg pos X neg neg pos X neg neg Pos 53 neg neg NA No
4 40 Polycystic kidney 
disease
WNL neg neg neg pos 68 pos 68 pos 6,68 neg Pos 68 Pos 68 Pos 68 x WNL No
5 58 Polycystic kidney 
disease
NA neg neg pos 68 x x pos 68 neg x x x x NA No
6 57 Polycystic kidney 
disease
WNL neg neg neg neg pos 16 neg neg neg Pos 54/74 neg WNL No
7 47 FSGS WNL neg neg neg neg neg pos 6 neg neg neg neg x WNL No
8 57 Chronic 
glomerulonephritis
WNL neg neg neg neg neg pos 16 neg neg neg neg x WNL No
9 48 Other WNL neg neg neg neg neg pos 18 neg Pos X Pos X x x WNL Yes, more often 
with same 
partner
10* 52 Chronic 
glomerulonephritis
WNL neg pos pos 16/59 x x pos 59 neg x x x x WNL Unknown
11 34 Other 1x 1997 WNL neg neg pos 51 x x pos 51 neg Pos 
18/31/35/45/68
x x x NA No
12 61 Chronic 
pyelonephritis
NA neg neg neg neg x pos 16,31 neg x x x x NA No
* Only patient who used Basiliximab, # = measurements used in primary analysis, bold results = last measurement 
in period 3-12 months after RT and used in primary analysis, RD = renal disease, FSGS = focal segmental 
glomerulosclerosis, Tx = transplantation, RT = renal transplantation, Bethesda = Bethesda system 2001 was used for 
cytological classification,  SPF = SPF10-LiPA25 system assay, Cobas = Cobas 4800 assay, WNL = within normal limits, NA 
= not available, x = self-sample not available
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17-49%) approximately 12 months later (median time 360 days (range 270-360 days)) (p=0.41). The 
hrHPV prevalence in these patients was 21% (95% CI 7-35%) at first examination and 27% (95% 
CI 12-42%) approximately 12 months later (p=0.41). The hrHPV prevalence determined with the 
clinically validated HPV test remained stable over this period and was 16% (95% CI 3-29%).
During the study period eight recipients of a transplant kidney had abnormal cytology: three patients 
with ASC-US/LSIL and five patients with HSIL. Six of these patients had abnormal smears before 
transplantation and two patients developed cytological abnormalities after transplantation (2 HSIL 
(one preceded by ASC-US/LSIL)). All patients with HSIL tested HPV positive with the highly analytical 
sensitive HPV test as well as with the clinically validated test. They all underwent colposcopy with 
tissue sampling for histology. One patient was diagnosed with cervical intraepithelial neoplasia (CIN) 
1, one patient with CIN2, one patient with CIN3 and one patient ultimately developed a stage IBI 
cervical cancer. The patient who developed the cancer underwent her second RT during the study 
period. Both patients who developed HSIL after transplantation were hrHPV positive when the 
cytological abnormality was diagnosed (type 16 and type 18). None of the patients developed vulvar 
abnormalities during the follow-up period. 
At their first visit, patients received a questionnaire about their relationships and sexual behaviour. 
The answers on this questionnaire are summarized in table 4. Every 3 months the patients were 
asked whether their relationships and/or sexual behaviour had changed. Of the 65 patients in 
whom a transplantation was performed, 11 patients (16.9%) reported a change in sexual behaviour 
after transplantation: eight became more sexually active while three patients reduced their sexual 
activities. Only one of the eight female RTRs who reported an increase in sexual activities converted 
from HPV negative to HPV positive after transplantation. 
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table 4. History of- and current sexual behaviour of patients with end stage renal disease at 
first contact
transplanted 
patients n=65
not transplanted 
patients n=43
P-value
Median (range) % (n) Median (range) % (n)
Marital status
      - Married
      - Living together
      - Relationship
      - Divorced
      - Widow
      - Single
69 (45)
12 (8)
3 (2)
2 (1)
0  (0)
14 (9)
63 (27)
16 (7)
5 (2)
5 (2)
5 (2)
7 (3)
0.43
Age first intercourse (years) 17 (13-24) 18 (14-26) 0.64
Sexually active <16 years
      - Yes
      - No
      - Unknown
19 (12)
63 (41)
19 (12)
16 (7)
67 (29)
16  (7)
0.72
lifetime sex partners 3 (1-14) 3 (0-55) 0.41
Gender sex partner
      - Men
      - Women
      - Both
      - Unknown
77 (50)
3 (2)
3 (2)
17 (11)
77 (33)
0 (0)
5 (2)
19 (8)
0.47
Condom use
      - No
      - Yes
      - Unknown
69 (45)
14 (9)
17 (11)
72 (31)
19 (8)
9 (4)
0.95
ever diagnosed with StD
      - Yes
      - No
      - Unknown
8 (5)
75 (49)
17 (11)
5 (2)
77 (33)
19  (8)
0.68
Sex partners last 6 months 1 (0-1) 1 (0-10) 0.51
Sexual contact last 6 
months (per month)
1 (0-12) 1 (0-20) 0.41
STD = sexually transmitted disease
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DISCUSSION
This study is the first longitudinal investigation of the cervico-vaginal hrHPV prevalence in RTRs 
before and after RT. Although the study population was limited, we made a number of interesting 
observations. First, The pre-transplant hrHPV prevalence of 10% (measured with the clinically 
validated Cobas 4800 HPV test) in our cohort was higher than the age-specific hrHPV prevalence in 
the general population. After transplantation, the hrHPV prevalence was 14%. When an analytically 
more sensitive HPV test was used, the hrHPV prevalence increased significantly from 19% before to 
31% after transplantation without changes in sexual behaviour. Apparently there was reactivation 
of latent HPV infections after RT.
 The Cobas 4800 HPV test will be used in the coming Dutch national screening program. In our 
study all women with clinically relevant cytological abnormalities tested positive with the Cobas 
4800 HPV test. However no significant increase in hrHPV prevalence was found with this test 
during the first year after transplantation. It is possible that the hrHPV infections due to increased 
replication after transplantation is likely to result in an increased detection rate with the Cobas 
4800 HPV test after a longer follow-up. On the other hand, using the SPF10 -LiPA25 assay, which 
has a higher analytical sensitivity, we found a significant increase in the prevalence of hrHPV (from 
19% to 31%). The prevalence of hrHPV found with this assay after RT is comparable with earlier 
findings of our study group with the same test in a cohort of 218 female RTRs at different time 
intervals after transplantation, where a prevalence of 27.1% was observed (17). The increase of 
hrHPV prevalence after transplantation was not associated with changes in relationships or sexual 
behaviour. Moreover, the hrHPV prevalence did not change significantly in the control group of 
patients who did not undergo a RT. Therefore, it is likely that latent HPV infections were reactivated 
because of immunosuppressive therapy. 
Latent viral infections are characterized by a state of reversible non-productive infection of 
individual cells (27). Although, the existence of HPV latency is still under debate; epidemiological 
studies convincingly showed that in women who cleared a specific HPV type (tested HPV negative), 
a recurrent detection of the same genotype can occur without report of (new) sexual contacts (28-
31). Several studies suggested a role for host immunity in reactivating HPV infections in patients 
with HIV and in patients who use immunosuppressive drugs (32-35). The clinical implications of a 
reactivation as compared to a recently acquired HPV infection are not clear. However, the increased 
risk of high grade neoplasia among HIV-infected and organ transplant recipients, suggests that an 
HPV reactivation carries similar or increased risk of disease development as compared to a de novo 
infection (36). The clinical relevance of our findings is supported by several studies that show an 
increase in cervical- and vulvar cancer rate in RTRs 10 years after the transplantation (14). 
A remarkable finding was the high overall HPV prevalence in patients with ESRD, irrespective of 
receiving a transplant kidney or not. We had anticipated an overall HPV prevalence of around 10%, 
according to the overall HPV prevalence in women around 50 years of age (based on HPV testing in 
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140,000 women with different HPV assays) in the general population (37, 38). A similar observation 
with an high overall HPV prevalence was made by Fairley et al. (39), who showed an overall HPV 
prevalence of 20% in women on maintenance dialysis and of 22% in renal transplant recipients 
compared to 4.5% in women with moderately impaired renal function (serum creatinine 150-390 
µmol/L). This may be explained by the fact that cellular immunity is frequently impaired in patients 
with severe renal failure (40). Other known risk factors for obtaining an HPV infection, such as 
smoking (41-44) and promiscuous sexual behaviour (8), were not more prevalent in our patients 
as compared to the general population. In accordance with the higher prevalence of hrHPV, it 
has been shown that dialysis patients have an increased risk of cancer, including cervical- and 
vulvovaginal cancer (45).
In our study approximately 9% of the patients, who underwent transplantation, had cytological 
abnormalities at first examination. The incidence of cytological abnormalities in the general 
population is 7%, but in women aged 50-59 years, which is comparable to the median age of our 
study population, it is only about 3.5% (46). At first examination approximately 50% of the patients 
with cytological abnormalities were on dialysis. This could be an explanation, but the number of 
patients was too low to assess dialysis as a risk factor. There is no clear explanation for the relatively 
high percentage of cytological abnormalities in RT patients compared to the group of patients, who 
did not undergo RT. 
 The results of our study suggest that the start of intensive therapy with immunosuppressive 
drugs increases the HPV prevalence after transplantation. The higher prevalence during 
immunosuppression can be explained by several non mutually exclusive factors, such as a higher 
susceptibility to become infected with HPV, a higher risk on persistence of the HPV infection or 
reactivation of a latent HPV infection. In a small study on HPV subtypes (6, 11, 16 and 18) in female 
RTRs (16), hrHPV 16 and 18 were found at a higher rate in transplant recipients (55%) compared 
with their immunocompetent counterparts (15%), placing these patients at increased risk for 
aggressive anogenital tract (pre)malignant lesions (16). Notably, at first examination in our study 
no difference in HPV prevalence was observed between the patients with current or prior use 
of immunosuppressive drugs compared to those who did never use immunosuppressive drugs. 
Furthermore, Meeuwis et al. (17) showed that the duration of immunosuppressive treatment and 
the experience of an acute rejection with subsequent intensifying of immunosuppressive therapy 
were not related to the risk of HPV positivity. The increased hrHPV prevalence in female patients 
with ESRD raises the question whether screening for HPV in this patient group would be useful.
Prophylactic vaccines against hrHPV genotypes 16 and 18 are highly effective for the 
prevention of persistent infections and anogenital cancer. However, recent data showed 
suboptimal immunogenicity of the quadrivalent HPV vaccine in patients who were treated with 
immunosuppressive drugs after organ transplantation (47). Vaccination in patients with renal 
failure prior to transplantation could be more successful. However, a barrier for implementing HPV 
vaccination in these women is the wide variety in HPV types found in patients with ESRD. Our study 
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showed 24 different HPV types, which is in accordance with a recent cohort study on HPV infections 
in female RTRs (17). Recently, a nonavalent HPV vaccine has been developed to protect against an 
additional five oncogenic types (31, 33, 45, 52, and 58 next to 6, 11, 16, and 18) and showed an 
overall vaccine efficacy of 96.7% in women aged 16-29 years in the general population (48). Notably, 
approximately 60% of the HPV positive patients were infected with genotypes not covered by the 
nonavalent vaccine. The protective effect of this vaccine in patients with ESRD, especially in sexually 
active patients, has yet to be demonstrated in prospective studies. 
Nowadays, several European and American guidelines (49-51) recommend intensified cervical 
cancer screening in female RTRs (14, 16, 52, 53). High-risk HPV testing will take an important role 
in the new cervical screening program in the Netherlands, which will be implemented in 2017. If 
women test hrHPV negative, no cytological evaluation is necessary and they will receive another 
invitation in five years. In case of hrHPV positivity, there will be cytological evaluation. Cervical 
cytology will be repeated after six months in case of normal cytology and women will be referred to 
the gynaecologist in case of abnormal cytology. If the cytology is normal after six months, women 
return to the regular program (interval of five years). A five year screening interval in hrHPV positive 
RTRs seems relatively long in comparison to existing guidelines. The results of our study emphasize 
the importance of hrHPV testing in the follow up of patients who underwent a RT. However, the 
precise design of gynecological screening in female RTRs needs to be further discussed. 
Our study is the first to prospectively assess HPV prevalence before and after transplantation, 
which has given us more information on the natural behaviour of HPV in RTRs. We used a highly 
sensitive test to detect HPV DNA in cervico-vaginal samples. We did not assess the HPV serology 
before transplantation because the use of HPV serology to detect naturally acquired HPV infections 
is not widely accepted. The presence of serum antibodies indicates past infection, but estimates 
of proportions of women who seroconvert after infection range from 55- to 85%, depending on 
study design and methods employed. Antibody formation in response to natural infection is a slow 
process that could extend to over a year (54-56). Consequently, the pre-transplant serology does 
not allow reliable interpretation of type-specific acquisition of HPV after transplantation.
A limitation of our study is the relatively short follow up. Longer follow-up of the hrHPV positive 
patients is necessary to determine if reactivation of latent hrHPV infections leads to dysplasia or 
cancer. 
CONCLUSION
In this cohort of patients with ESRD, the hrHPV prevalence was higher than the age-specific hrHPV 
prevalence in the general population. An increase in hrHPV prevalence after transplantation, 
without any change in sexual behaviour, suggests reactivation of latent HPV infections during 
immunosuppression. This could contribute to the increased risk of HPV related cervical- and vulvar 
(pre)malignancies in female RTRs. 
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SUPPLEMENTAL MATERIAL 
Supplement 1. Additional information to Table 2; HPV prevalence over time in female patients 
with end-stage renal disease who did not undergo renal transplantation
Assay HPV prevalence at 
first examination
HPV prevalence 
within 12 months
Difference p-value
SPF10 -liPA25 system n % (95% Ci) % (95% Ci) % (95% Ci)
Overall (lr + hr) 33 27(12-42) 33 (17-49) 6 (-8-20) 0.41
hrHPV 33 21 (7-35) 27 (12-42) 6 (-8-20) 0.41
Cobas 4800 n % (95% Ci) % (95% Ci) % (95% Ci)
hrHPV 31* 16 (3-29)  16 (3-29) 0 (-13-13) 1.00
lr = low risk, hr = high risk, CI = confidence interval, * in two patients no test results were available
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qUESTIONNAIRE 
“HPV inFeCtionS BeFore AnD AFter renAl trAnSPlAntAtion”
Questionnaire study “HPV infections before and after renal transplantation” 
 
Dear Madam, 
 
We appreciate your participation in the study “HPV infections before and after renal 
Transplantation”. We would like to ask you kindly to fill out this questionnaire.  
 
In the square below an explanation on filling out the questionnaire is given: 
 
• The questionnaire contains two sections: one with questions on quality of life and one about 
sexual relations.  
• We advise you to answer these personal questions in a personal space.  
• For the sake of the study outcome it is mandatory that you fill out all the questions and always 
answer them truthfully.  
• Would you please check or circle one answer per question unless indicated otherwise.  
• It takes about 10 minutes to fill out the questionnaire.  
• Only the researchers mentioned in the information folder have access to your personal 
information.  
 
 
If you completely filled out the questionnaire, would you sent it to the researcher in the attached 
return envelope? No stamp is necessary.  
 
 
Thank you for your cooperation! 
 
 
 
Your unique code number: 
 
 
 
 
 
 
In case of any questions, you can contact the researcher through the following email address:  
onderzoek@obgyn.umcn.nl 
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Section 1: Questions on quality of life (SF-36) 
 
In this questionnaire we will be asking about your health. Please answer each question by checking 
the box or circling the number. When you are not sure what to answer, try to choose the answer 
most applicable.  
In general, would you say your health is: 
� Excellent 
� Very good 
� Good 
� Fair 
� Poor 
 Compared to one year ago, how would you rate your health in general now? 
� Much better now than one year ago 
� Somewhat better now than one year ago 
� About the same 
� Somewhat worse now than one year ago 
� Much worse now than one year ago 
 
The following items are about activities you might do during a typical day. 
Does your health now limit you in these activities? If so, how much? (Please circle the number) 
0 1 2 
Yes, limited a lot Yes, limited a little No, not limited at all 
 
Daily activities 
 
a. Vigorous activities       0 1 2 
Such as running, lifting heavy objects,  
participating in strenuous sports 
 
b. Moderate activities       0 1 2 
Such as moving a table, pushing a vacuum cleaner,  
bowling, or playing golf 
 
c. Lifting or carrying groceries      0 1 2 
 
d. Climbing several flights of stairs     0 1 2 
 
e. Climbing one flight of stairs      0 1 2 
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f. Bending, kneeling, or stooping      0 1 2 
 
g. Walking more than a mile      0 1 2 
 
h. Walking several blocks          0 1 2 
 
i. Walking one block       0 1 2 
 
j. Bathing or dressing yourself      0 1 2 
During the past 4 weeks, have you had any of the following problems with your work or other regular activities as a 
result of your physical health? 
 
0 1 
Yes No 
 
a. Cut down the amount of time you spent     0 1 
on work or other activities 
 
b. Accomplished less than you would like      0 1 
 
c. Were limited in the kind of work or other activities   0 1 
 
d. Had difficulty performing the work     0 1 
or other activities (for example, it took extra effort) 
During the past 4 weeks, have you had any of the following problems with your work or regular daily activities as a result 
of any emotional problems (such as feeling depressed or anxious)? 
0 1 
Yes No 
a. Cut down the amount of time you spent    0 1 
on work or other activities 
 
b. Accomplished less than you would like      0 1 
 
c. Didn’t do work or other activities as carefully as usual   0 1 
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During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal 
social activities with family, friends, neighbors, or groups? 
� Not at all 
� Slightly 
� Moderately 
� Quite a bit 
� Extremely 
 
How much bodily pain have you had during the past 4 weeks? 
� None 
� Very mild 
� Mild 
� Moderate 
� Severe 
� Very severe 
 
During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and 
housework)? 
� Not at all 
� A little bit 
� Moderately 
� Quite a bit 
� Extremely 
 
These questions are about how you feel and how things have been with you during the past 4 weeks. For each question, 
please give the one answer that comes closest to the way you have been feeling. 
0 1 2 3 4 5 
All of the time Most of the 
time 
A good bit of 
the time 
Some of the 
time 
A little of the 
time 
None of the 
time 
 
How much of the time during the past 4 weeks…. 
 
a. Did you feel full of pep?   0 1 2 3 4 5 
 
b. Have you been a very nervous person?  0 1 2 3 4 5 
 
 
c. Have you felt so down in the dumps that 0 1 2 3 4 5 
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nothing could cheer you up? 
d. Have you felt calm and peaceful?  0 1 2 3 4 5 
 
e. Did you have a lot of energy?   0 1 2 3 4 5 
 
f. Have you felt downhearted and blue?  0 1 2 3 4 5 
 
g. Did you feel worn out?     0 1 2 3 4 5 
 
h. Have you been a happy person?  0 1 2 3 4 5 
 
i. Did you feel tired?    0 1 2 3 4 5 
 
During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your 
social activities (like visiting friends, relatives, etc.)? 
� All of the time 
� Most of the time 
� Some of the time 
� A little of the time 
� None of the time 
 
How TRUE or FALSE is each of the following statements for you. 
0 1 2 3 4 
Definitely true Mostly true Don’t know Mostly false Definitely false 
 
a. I seem to get sick a little easier than   0 1 2 3 4 
other people 
 
b. I am as healthy as anybody I know   0 1 2 3 4 
 
c. I expect my health to get worse    0 1 2 3 4  
 
d. My health is excellent        0 1 2 3 4 
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Section 2: Questions on sexual relations 
We know that there is a causal connection between sexual relations and the prevalence of HPV 
infections. The information on sexual relations is mandatory for our study to differentiate between 
use of immunosuppressant drugs and sexual relations as a cause for obtained an HPV infection.  
 
 
Definitions: 
In all the below mentioned questions ‘sexual contact’ means: 
1. Genital contact: contact between the genitals of 2 persons, without the penis entering the 
vagina or anus. 
2. Oral sex: contact between mouth and genital. 
3. Vaginal sex: when the penis enters the vagina. 
4. Anal sex: when the penis enters the.  
How old were you when you had your first sexual contact with another person? 
……………years old 
I never had sexual contact with another person (go to question 24)  
How old was the person you had sexual contact with? 
………. years old 
Were you the first sexual partner of your first sexual partner?  
Yes 
No 
I don’t know 
With how many different persons did you had sexual contact before your 16th birthday (including all steady partners and 
flings)? 
Number of sexual partners: …………………………. 
I did not have sexual contact before my 16th birthday. 
With how many different persons did you had sexual contact in your life (including all steady partners and flings)? 
Total number of sexual partners: …………………..  
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Was the sexual contact only with men, women, or both? 
Man/men 
Woman/women 
Both 
In the past 6 months, with how many different persons did you have sexual contact? (including all steady partners and 
flings) 
Number of sexual partners………………………. 
In the past 6 months, how often did you have sexual contact? (Including all steady partners and flings)? 
………times a day 
………times a week 
………times a month 
How often did you use condoms during sexual contact? 
Never 
Sometimes (less than 50%) 
Often (more than 50%) 
Always 
Were you ever diagnosed with a sexually transmitted disease (STD) by a physician?  
Yes, once 
Yes, multiple times 
No, go to question 24 
Which STD were you diagnosed with? 
Genital warts 
Chlamydia 
Gonorrhoea 
Genital herpes  
Syphilis  
HIV infection (the virus that causes AIDS) 
Other, namely:………………………………………………………………………………… 
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How long ago were you diagnosed with the STD? (in case of multiple STDs please mention the last one) 
………weeks 
………months 
………years 
Which date was the first day of your last menstruation?  
__ __ - __ __ - __ __ __ __  (day – month - year) 
I am not menstruating anymore, because……………………………………………………………. 
In the past 6 weeks, did you experience any of the following complaints? (multiple answers are possible)  
Blood loss between 2 menstruations  
Blood loss during or after vaginal sex 
More vaginal discharge than usual 
Pain or burning sensation during micturation  
Peeing more often than usual  
Pain in your lower abdomen  
None of the above mentioned complaints  
 
 
This is the end of the questionnaire.  
 
Would you please check if you filled out all of the questions? 
 
You can return the questionnaire to us without costs in the attached return envelope. No stamp is 
necessary.  
 
Thank you very much! 
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Dear Madam, 
 
We appreciate your participation in the study “HPV infections before and after renal 
Transplantation”. We would like to ask you kindly to fill out this questionnaire.  
 
In the square below an explanation on filling out the questionnaire is given: 
 
• The questionnaire contains two sections: one with questions on quality of life and one about 
sexual relations.  
• We advise you to answer these personal questions in a personal space.  
• For the sake of the study outcome it is mandatory that you fill out all the questions and always 
answer them truthfully.  
• Would you please check or circle one answer per question unless indicated otherwise.  
• It takes about 5 minutes to fill out the questionnaire.  
• Only the researchers mentioned in the information folder have access to your personal 
information.  
 
 
If you completely filled out the questionnaire, would you sent it to the researcher in the attached 
return envelope? No stamp is necessary.  
 
 
Thank you for your cooperation! 
 
 
 
Your unique code number: 
 
 
 
 
 
 
In case of any questions, you can contact the researcher through the following email address:  
onderzoek@obgyn.umcn.nl 
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Change in (sexual) relations  
Did anything change in your relationship/sexual relations compared to the last time you filled out a questionnaire?  
� No, you don’t need to answer any more questions 
� Yes 
 
In the past 3 months, with how many different persons did you have sexual contact? (including all steady partners and 
flings) 
Number of sexual partners………………………. 
 
In the past 3 months, how often did you have sexual contact? (Including all steady partners and flings)? 
………times a day 
………times a week 
………times a month 
 
How often did you use condoms during sexual contact? 
Never 
Sometimes (less than 50%) 
Often (more than 50%) 
Always 
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Here you can write down any changes that were not mentioned in the previous questions.  
 
 
 
 
 
 
This is the end of the questionnaire.  
 
Would you please check if you filled out all of the questions? 
 
You can return the questionnaire to us without costs in the attached return envelope. No stamp is 
necessary.  
 
Thank you very much! 
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Questionnaire study “HPV infections before and after renal transplantation” 
 
Dear Madam, 
 
We appreciate your participation in the study “HPV infections before and after renal 
Transplantation”. We would like to ask you kindly to fill out this questionnaire.  
 
In the square below an explanation on filling out the questionnaire is given: 
 
• The questionnaire contains two sections: one with questions on quality of life and one about 
sexual relations.  
• We advise you to answer these personal questions in a personal space.  
• For the sake of the study outcome it is mandatory that you fill out all the questions and always 
answer them truthfully.  
• Would you please check or circle one answer per question unless indicated otherwise.  
• It takes about 10 minutes to fill out the questionnaire.  
• Only the researchers mentioned in the information folder have access to your personal 
information.  
 
 
If you completely filled out the questionnaire, would you sent it to the researcher in the attached 
return envelope? No stamp is necessary.  
 
 
Thank you for your cooperation! 
 
 
 
Your unique code number: 
 
 
 
 
 
 
In case of any questions, you can contact the researcher through the following email address:  
onderzoek@obgyn.umcn.nl 
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Section 1: Questions on quality of life (SF-36) 
 
In this questionnaire we will be asking about your health. Please answer each question by checking 
the box or circling the number. When you are not sure what to answer, try to choose the answer 
most applicable.  
In general, would you say your health is: 
� Excellent 
� Very good 
� Good 
� Fair 
� Poor 
 Compared to one year ago, how would you rate your health in general now? 
� Much better now than one year ago 
� Somewhat better now than one year ago 
� About the same 
� Somewhat worse now than one year ago 
� Much worse now than one year ago 
 
The following items are about activities you might do during a typical day. 
Does your health now limit you in these activities? If so, how much? (Please circle the number) 
0 1 2 
Yes, limited a lot Yes, limited a little No, not limited at all 
 
Daily activities 
 
k. Vigorous activities       0 1 2 
Such as running, lifting heavy objects,  
participating in strenuous sports 
 
l. Moderate activities       0 1 2 
Such as moving a table, pushing a vacuum cleaner,  
bowling, or playing golf 
 
m. Lifting or carrying groceries      0 1 2 
 
n. Climbing several flights of stairs     0 1 2 
 
o. Climbing one flight of stairs      0 1 2 
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p. Bending, kneeling, or stooping      0 1 2 
 
q. Walking more than a mile      0 1 2 
 
r. Walking several blocks          0 1 2 
 
s. Walking one block       0 1 2 
 
t. Bathing or dressing yourself      0 1 2 
During the past 4 weeks, have you had any of the following problems with your work or other regular activities as a 
result of your physical health? 
 
0 1 
Yes No 
 
e. Cut down the amount of time you spent     0 1 
on work or other activities 
 
f. Accomplished less than you would like      0 1 
 
g. Were limited in the kind of work or other activities   0 1 
 
h. Had difficulty performing the work     0 1 
or other activities (for example, it took extra effort) 
During the past 4 weeks, have you had any of the following problems with your work or regular daily activities as a result 
of any emotional problems (such as feeling depressed or anxious)? 
0 1 
Yes No 
d. Cut down the amount of time you spent    0 1 
on work or other activities 
 
e. Accomplished less than you would like      0 1 
 
f. Didn’t do work or other activities as carefully as usual   0 1 
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During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal 
social activities with family, friends, neighbors, or groups? 
� Not at all 
� Slightly 
� Moderately 
� Quite a bit 
� Extremely 
 
How much bodily pain have you had during the past 4 weeks? 
� None 
� Very mild 
� Mild 
� Moderate 
� Severe 
� Very severe 
 
During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and 
housework)? 
� Not at all 
� A little bit 
� Moderately 
� Quite a bit 
� Extremely 
 
These questions are about how you feel and how things have been with you during the past 4 weeks. For each question, 
please give the one answer that comes closest to the way you have been feeling. 
0 1 2 3 4 5 
All of the time Most of the 
time 
A good bit of 
the time 
Some of the 
time 
A little of the 
time 
None of the 
time 
 
How much of the time during the past 4 weeks…. 
 
j. Did you feel full of pep?   0 1 2 3 4 5 
 
k. Have you been a very nervous person?  0 1 2 3 4 5 
 
 
l. Have you felt so down in the dumps that 0 1 2 3 4 5 
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nothing could cheer you up? 
m. Have you felt calm and peaceful?  0 1 2 3 4 5 
 
n. Did you have a lot of energy?   0 1 2 3 4 5 
 
o. Have you felt downhearted and blue?  0 1 2 3 4 5 
 
p. Did you feel worn out?     0 1 2 3 4 5 
 
q. Have you been a happy person?  0 1 2 3 4 5 
 
r. Did you feel tired?    0 1 2 3 4 5 
 
During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your 
social activities (like visiting friends, relatives, etc.)? 
� All of the time 
� Most of the time 
� Some of the time 
� A little of the time 
� None of the time 
 
How TRUE or FALSE is each of the following statements for you. 
0 1 2 3 4 
Definitely true Mostly true Don’t know Mostly false Definitely false 
 
e. I seem to get sick a little easier than   0 1 2 3 4 
other people 
 
f. I am as healthy as anybody I know   0 1 2 3 4 
 
g. I expect my health to get worse    0 1 2 3 4  
 
h. My health is excellent        0 1 2 3 4 
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Section 2: Change in (sexual) relations  
We know that there is a causal connection between sexual relations and the prevalence of HPV 
infections. The information on sexual relations is mandatory for our study to differentiate between 
use of immunosuppressant drugs and sexual relations as a cause for obtained an HPV infection.  
 
Did anything change in your relationship/sexual relations compared to the last time you filled out a questionnaire?  
� No, you don’t need to answer any more questions 
� Yes 
 
In the past 3 months, with how many different persons did you have sexual contact? (including all steady partners and 
flings) 
Number of sexual partners………………………. 
In the past 3 months, how often did you have sexual contact? (Including all steady partners and flings)? 
………times a day 
………times a week 
………times a month 
 
How often did you use condoms during sexual contact? 
Never 
Sometimes (less than 50%) 
Often (more than 50%) 
Always 
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Here you can write down any changes that were not mentioned in the previous questions.  
 
 
 
 
 
 
This is the end of the questionnaire.  
 
Would you please check if you filled out all of the questions? 
 
You can return the questionnaire to us without costs in the attached return envelope. No stamp is 
necessary.  
 
Thank you very much! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Here you can write down any changes that were not mentioned in the previous questions.  
 
 
 
 
 
 
This is the end of the questionnaire.  
 
Would you please check if you filled out all of the questions? 
 
You can return the questionnaire to us without costs in the attached return envelope. No stamp is 
necessary.  
 
Thank you very much! 
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AbSTRACT
Background: Renal transplant recipients (RTRs) have an increased risk of Human Papillomavirus 
(HPV) related anogenital (pre)malignancies. Several guidelines recommend to perform annual 
cervical cancer screening in female RTRs, but the participation rate is low. The aim of this study is to 
identify barriers and facilitators for annual gynaecological screening in female RTRs from a patient 
and professional perspective and to present suggestions to increase the participation rate.
Methods: A qualitative study was performed with Dutch female RTRs transplanted at the Radboud 
university medical center and nephrologists specialized in renal transplantation care using 
explorative semi-structured interviews in focus groups. 
Results: In total, 14 female RTRs and 13 nephrologists participated. Both nephrologists and female 
RTRs mentioned similar barriers: uncomfortable and less reliable examination by a general 
practitioner (GP) compared to examination by a gynaecologist, limited knowledge of professionals, 
and limited information supply to patients on increased risk for developing HPV related genital 
(pre)malignancies. RTRs focused more on unpleasantness of the examination itself. RTRs and 
nephrologists reported the same facilitators: a reminder, a checklist, integration of gynaecological 
examination in annual check-up, self-sampling and information supply at the right moment. 
Conclusions: Female RTRs should receive a checklist one year after transplantation mentioning all 
necessary future examinations. Furthermore, introducing HPV self-sampling in the annual check-
up by the nephrologist might obviate barriers and meet the main facilitators. Implementing these 
changes might improve the participation rate of female RTRs in annual gynaecological screening.
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INTRODUCTION
Each year, about 78,000 renal transplantations (RTs) are performed worldwide (1), of which 
more than 1,000 are performed in the Netherlands (2), requiring the lifelong administration of 
immunosuppressive therapy. The current immunosuppressive regimes have led to a 1-year patient 
and graft survival of more than 90%. Therefore, the long-term side-effects of immunosuppressive 
medication need more attention. It is generally accepted that renal transplant recipients (RTRs) have 
an increased risk of developing Human Papillomavirus (HPV) related anogenital (pre)malignancies. 
The prevalence of cervical HPV infections in female RTRs varies between 22 and 63% (3-9), which 
is higher compared to the general female population (10). In general, HPV is the main factor in the 
oncogenesis of cervical (pre)malignancies. In addition, HPV is responsible for about 30% of vulvar 
malignancies and for nearly all premalignant usual vulvar intraepithelial neoplasia  lesions. In female 
RTRs the contribution of HPV is even more important, as nearly 100% of the cervical- and vulvar 
(pre)malignancies are HPV-related. 
It is generally accepted that RTRs may not only have a higher risk for developing an HPV infection, 
but the HPV infections and/or premalignancies may also progress into malignant disease within a 
shorter interval (11, 12). Madeleine et al. (13) showed that time from transplantation to anogenital 
(pre)malignancies ranged from 2.6 to 5.3 years. Moreover, female RTRs are more difficult to treat 
optimally for genital (pre)malignancies (surgery more complicated; radiotherapy contraindicated) 
because of the renal transplant in the pelvis: there is a need for early detection of genital (pre)
malignancies, which can be established by improving gynaecological screening. Several European 
and American guidelines (14-16) recommend to perform intensified cervical cancer screening in 
female RTRs (4, 8, 17, 18). Without specific screening of the vulvar area. Gynaecological screening 
should be defined as inspection of the vulvar- and perianal area and cervical smear. The definition 
of ‘intensified’ is unclear, because no consensus on the execution of cervical screening for the 
general population in various countries. There are differences in terms of invitation methodology, 
target population (start between 18-30 years until 59-70 years), screening intervals (once a year 
until once every 5 years), and organization. 
Besides the uncertainty about the appropriate screening interval for RTRs, the participation rate 
of female RTRs in gynaecological screening is too low. Courtney et al. (19) showed that the uptake 
of the advised annual cervical cancer screening in the RTR population of Northern Ireland is low: 
only 10% of patients follow the advice and 32% never had a cervical smear performed at all. 
Meeuwis et al. (17) showed that only 38% of Dutch RTRs transplanted between 1991 and 1995 
underwent cervical screening once every 5 years, and 37% never had cervical screening after their 
transplantation at all. 
 
Currently, the exact reasons for this low screening uptake is unclear. A Dutch study reported that 
in the general population women’s beliefs about cervical screening and attendance are the best 
predictors of screening uptake (20, 21). One study among RTRs in Sydney showed that awareness of 
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increased cancer risk and cancer screening is primarily focused on skin cancer. Thereby, recipients 
prioritized current health issues over future risks (22). Before changes can be made to improve 
screening uptake, there has to be more insight in the barriers female RTRs currently experience. 
The aim of this study is to identify barriers and facilitators for annual gynaecological 
screening in Dutch female RTRs from both a patients’ and professionals’ perspective. 
PATIENTS AND METHODS
StUDy DeSiGn AnD SettinG
A qualitative study was performed using explorative semi-structured interviews in focus groups, 
two with female RTRs and two with nephrologists specialized in renal transplantation care. We let 
the participants talk freely with structured guidance from the interviewer using an interview guide. 
We chose a group setting as we expected it would be useful to obtain detailed information about 
personal and group feelings, perceptions and opinions related to gynaecological screening. In the 
Netherlands, RTs are performed in eight university hospitals, including the Radboud university 
medical center (Radboudumc) with approximately 130 transplantations per year in adults (40% 
female). 
StUDy PoPUlAtion
female renal transPlant reciPients
Fifty women who underwent a RT between 1968 and 2013 at Radboudumc were invited for 
participation. The 50 female RTRs participated in previously conducted research with HPV self-
sampling (self-collected cervicovaginal sample) by our study group (23) and gave permission for 
further research.  
Professionals
A total of 67 nephrologists in the Radboudumc (N=12) and affiliated centres (N=55) were invited by 
email to participate in a separate focus group interview. 
DAtA ColleCtion
Written informed consent was obtained from all participants and confidentiality was assured. Both 
focus groups with the female RTRs were guided by a chairman (K.M.), and two researchers (F.H. 
and R.H.) attended as observers. The focus groups with the nephrologists were performed by two 
chairmen (F.H. and J.H) and observed by two researchers (M.L. and F.H.). All of the focus groups 
were audiotaped. The chairman guided the focus groups with open-ended questions, to ensure 
the participants to speak freely. 
interView guide
The interview guide for both the patients and professionals was based on literature and expert 
opinions in the fields of nephrology, gynaecology and qualitative research. This guide included 
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questions on participation in regular gynaecological screening (particularly for patients), and on 
improving the participation rate. We used the modified framework of Grol & Fleuren to classify the 
influencing factors in the following domains: patient, professional, organisation, and finance (24-26). 
interView female renal transPlant reciPients
Female RTRs were asked to introduce themselves by telling their age and date of transplantation. 
Furthermore, a couple of questions were asked to assess the knowledge on gynaecological screening, 
particularly on the reasons for and content of annual gynaecological screening. The patients 
elaborated on their own experiences with gynaecological examination. The remaining part of the 
focus group targeted the bottlenecks in annual gynaecological screening and the information supply 
to female RTRs. The focus group ended with the question how the participation of gynaecological 
screening could be improved and what the role of (self-)sampling on HPV might be. 
interView Professionals
The focus group interviews with nephrologists also started with knowledge questions about 
the reasons for annual gynaecological screening, the abnormalities caused by HPV and what 
gynaecological screening should contain. Every nephrologist was asked how and whether they 
inform their patients about gynaecological screening. The remaining part of the focus group 
targeted the bottlenecks in annual gynaecological screening and who is responsible for effectuating 
gynaecological screening. The focus group ended with the question how the participation of 
gynaecological screening might be improved and the possible role of (self-)sampling on HPV.
AnAlySeS
All focus group interviews were fully transcribed and independently analyzed by two researchers 
(F.H. and M.L.). The analyses were conducted with the aid of the qualitative analysis tool of ATLAS.
ti GmbH Version 6 (Berlin, Germany). The influencing factors at the level of patient, professional, 
organisation, and finance were used to distribute the relevant remarks of the female RTRs and 
the nephrologists. We analyzed the influencing factors on participation in annual gynaecological 
screening and on factors that may increase the participation rate. Furthermore, we discussed our 
findings until we achieved mutual agreement. After constant iteration of these steps, ‘selective 
coding’ led to a deep understanding of the barriers and facilitators. 
RESULTS
PArtiCiPAntS
female renal transPlant reciPients
Finally, 16/50 (32%) women gave their agreement, of which two eventually were unable to attend. 
One focus group contained four and the other 10 women. The group interviews took 60 – 90 
minutes. Characteristics of the participating RTRs are summarized in table 1. The median age of 
the female RTRs was 53.5 years (range 36-75) (at time of RT 43.5 years (21-55)). Furthermore, 64% 
of these RTRs underwent annual cervical screening.
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table 1. Characteristics of the participating female renal transplant recipients (N=14) 
Median (range) % (n/n)
Current age (years) 53.5 (36-75)
Age at transplantation (years) 43.5 (21-55)
Age renal transplant (years) 11.5 (2-23)
Cervical screening frequency
      - Once a year
      - Once every 5 years
      - Once every 4 months
      - Once after RT
      - Variable
64.3 (9/14)
14.3 (2/14)
7.1 (1/14)
7.1 (1/14)
7.1 (1/14)
Abnormal cytology after RT 35.7 (5/14)
RT = renal transplantation
nePhrologists
A total of 13 nephrologists participated: in one focus group interview seven nephrologists (male: 
female ratio 5:2) working in affiliated hospitals participated; the other focus group comprised six 
nephrologists (male: female ratio 5:1) of the Radboudumc. Both interviews took 45 minutes. 
BArrierS AnD FACilitAtorS FroM FeMAle rtrS’ PerSPeCtiVe 
We have identified 21 barriers and 18 facilitators influencing participation in annual gynaecological 
screening. Factors cited in both focus groups are described in the text and marked in the table 
(table 2). Some illustrative quotations from all focus groups with female RTRs are included in 
Figure 1.
domain 1: determinants at Patient leVel
In all focus groups participants emphasized that the main barrier for undergoing gynaecological 
examination was the painful and unpleasant examination itself. Some female RTRs are not aware 
of the risks of gynaecological abnormalities after transplantation. Other patients were not informed 
on the risks, or too preoccupied with the transplantation that they forgot this information. The 
following barriers were mentioned: lack of time and/or priority of gynaecological examination, 
laziness or negligence, being dependent on others for the hospital visits, a possible religion or 
language barrier or not experiencing any symptoms.
The main facilitator was internal motivation to preserve their general health. A couple of female 
RTRs stated that they were motivated to participate in screening because they feel a responsibility 
to the donor. Self-sampling was considered as a good external motivator. Female RTRs described 
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the HPV self-sampling as less painful, more convenient, more private and less time consuming 
compared to a conventional cervical smear. 
domain 2: determinants at Professional leVel
Female RTRs reported insufficient information supply by professionals on the risks of HPV-related 
gynaecological abnormalities and the necessity of annual examination as main barriers. Some 
stated that they have never been informed by their nephrologist, especially the women that were 
transplanted more than 10 years ago. Some mentioned that screening on skin malignancies has 
a higher priority. Other barriers mentioned were: no initiative of the professional to remind them, 
inexperienced professionals performing the examination and wrong timing of information supply. 
The participants mentioned that the participation rate might increase by proper information at 
the right moment. Nowadays, patients are extensively informed about the transplantation and the 
impact of immunosuppressant use before transplantation. The patients mentioned that they miss 
some repetition of this information supply. It is suggested that the professional (nephrologist or 
nurse) repeats the education approximately 6 months after transplantation. Information supply by 
the professional after renal transplantation was stated as the main facilitator.
domain 3: determinants at organisational leVel
Three barriers and two main facilitators were mentioned in this domain. The main barrier lies in the 
organizational structure of the general practitioner’s (GP’s) practice. The cervical smear is mostly 
performed by the GP’s assistant. Female RTRs experience the examination more painful when 
performed by the assistant. Other barriers were: no reminder when the gynaecological examination 
should be scheduled and lack of clarity where  to go (GP or gynaecologist). 
The first main facilitator concerned the introduction of a reminder that may consist of an automatic 
calling system, which is set on annual appointments, and/or a reminder by the nephrologist. The 
second main facilitator included a checklist for (female) RTRs including all examinations they have to 
undergo in which timeframe after transplantation. The checklist should be integrated in (electronic) 
patient files and pop up when the patient visits the nephrologist. Other facilitators that were 
mentioned: own choice for the location of gynaecological examination, information supply through 
different channels including social media, an information flyer at the outpatient clinic and flexibility 
in making an appointment at the GPs.
domain 4: determinants at financial leVel
In general, the patients mentioned the lack of reimbursement of transport to the hospital for visits 
for gynaecological screening as a barrier on this level. However, the participating RTRs mentioned 
that they already spent their own contribution on visits to the nephrologist and medication. The 
self-sampling method was thought to be cheaper. 
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table 2. Barriers and facilitators for gynaecological screening for female renal transplant 
recipients (N=14) 
Barriers
organisational Patient Professional Financial
1. Examination by GP or assistant* 1. Unpleasant examination* 1. No/limited information supply to patients* 1. Lack of reimbursement*
2. Unclear commu-nication after RT* 2. Lack of knowledge* 2. No initiative of professional* 2. Expensive care*
3. No reminder* 3. No time/priority* 3. Inexperienced professional performing examination*
4. Inflexible calling system GP 4. Laziness/negligence*   
Dependent on others*
4. Too much information at once
5. Distance to hospital 5. Unpleasant posture during examination 5. Wrong moment of information supply*
6. Religion/language barrier* 6. Lack of knowledge professional
7. Negative first experience  with gynaecological examination 7. Examination by a man
8. Fear / shame
9. No complaints*
10. Too many examinations
11. Denial
Facilitators
organisational Patient Professional Financial
1. Reminder* 1. General health preservation* 1. Right moment of education* 1. Self sampling cheaper
2. Checklist* 2. Self sampling* 2. Information given by nephrologist*
3. Location own choice* 3. Kidney preservation 3. Manner of education*
4. Information through (social) media* 4. Responsibility to donor* Keep control/alert* 4. Examination by a woman
5. Flexibility GP* 5. Material hospital more
    comfortable
6. Information flyer* 6. Responsibility to others
7. Frequent general/gyn
    examination (1-year)
8. Group education
* mentioned in both focus groups, GP = general practitioner, RT = renal transplantation
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table 2. Barriers and facilitators for gynaecological screening for female renal transplant 
recipients (N=14) 
Barriers
organisational Patient Professional Financial
1. Examination by GP or assistant* 1. Unpleasant examination* 1. No/limited information supply to patients* 1. Lack of reimbursement*
2. Unclear commu-nication after RT* 2. Lack of knowledge* 2. No initiative of professional* 2. Expensive care*
3. No reminder* 3. No time/priority* 3. Inexperienced professional performing examination*
4. Inflexible calling system GP 4. Laziness/negligence*   
Dependent on others*
4. Too much information at once
5. Distance to hospital 5. Unpleasant posture during examination 5. Wrong moment of information supply*
6. Religion/language barrier* 6. Lack of knowledge professional
7. Negative first experience  with gynaecological examination 7. Examination by a man
8. Fear / shame
9. No complaints*
10. Too many examinations
11. Denial
Facilitators
organisational Patient Professional Financial
1. Reminder* 1. General health preservation* 1. Right moment of education* 1. Self sampling cheaper
2. Checklist* 2. Self sampling* 2. Information given by nephrologist*
3. Location own choice* 3. Kidney preservation 3. Manner of education*
4. Information through (social) media* 4. Responsibility to donor* Keep control/alert* 4. Examination by a woman
5. Flexibility GP* 5. Material hospital more
    comfortable
6. Information flyer* 6. Responsibility to others
7. Frequent general/gyn
    examination (1-year)
8. Group education
* mentioned in both focus groups, GP = general practitioner, RT = renal transplantation
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table 3. Barriers and facilitators for gynaecological screening for nephrologists (N=13)
Barriers
organisational Patient Professional Financial
1. Examination by GP or assistant* 1. No time/priority* 1. Lack of knowledge professional* 1. Expensive specialist care*
2. Inflexible calling system GP* 2. Too many examinations* 2. Inexperienced professional performing examination*
3. No reminder  3. Unpleasant examination* 3. No evidence for policy 
4. Lack of communication with hospital by 
GP*
4. Laziness/negligence*   4. No/limited information supply to patients
5. Unclear communication after RT  5. Lack of knowledge* 5. No initiative of professional*
6. Transmission of care: responsibility*  6.Negative first experience with gynaecological examination 6. Too much information at once
7. Dependent on others* 7. Wrong moment of information supply        
8. Examination by a man
Facilitators
organisational Patient Professional Financial
1. Reminder* 1. Self sampling* 1. Nephrologist know the risks* 1. Self sampling cheaper
2. Frequent general/gyn examination (1-year)* 2. General health preservation* 2. Information given by nephrologist*
3. Information flyer 3. Keep control/alert 3. Examination by gynaecologist*
4. HPV status is known   4. GP system accessible for hospital
5. Checklist 5. Right moment of education*
6 Group education 6. Examination by GP is adequate
* mentioned in both focus groups, GP = general practitioner, RT = renal transplantation, HPV = Human Papillomavirus
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table 3. Barriers and facilitators for gynaecological screening for nephrologists (N=13)
Barriers
organisational Patient Professional Financial
1. Examination by GP or assistant* 1. No time/priority* 1. Lack of knowledge professional* 1. Expensive specialist care*
2. Inflexible calling system GP* 2. Too many examinations* 2. Inexperienced professional performing examination*
3. No reminder  3. Unpleasant examination* 3. No evidence for policy 
4. Lack of communication with hospital by 
GP*
4. Laziness/negligence*   4. No/limited information supply to patients
5. Unclear communication after RT  5. Lack of knowledge* 5. No initiative of professional*
6. Transmission of care: responsibility*  6.Negative first experience with gynaecological examination 6. Too much information at once
7. Dependent on others* 7. Wrong moment of information supply        
8. Examination by a man
Facilitators
organisational Patient Professional Financial
1. Reminder* 1. Self sampling* 1. Nephrologist know the risks* 1. Self sampling cheaper
2. Frequent general/gyn examination (1-year)* 2. General health preservation* 2. Information given by nephrologist*
3. Information flyer 3. Keep control/alert 3. Examination by gynaecologist*
4. HPV status is known   4. GP system accessible for hospital
5. Checklist 5. Right moment of education*
6 Group education 6. Examination by GP is adequate
* mentioned in both focus groups, GP = general practitioner, RT = renal transplantation, HPV = Human Papillomavirus
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BArrierS AnD FACilitAtorS FroM nePHroloGiStS’ PerSPeCtiVe 
In total, 15 barriers and 15 facilitators influencing the participation rate in annual gynaecological 
screening were mentioned. Factors mentioned in both focus groups are described in the text and 
marked in the table (table 3). Some illustrative quotations from all focus groups with nephrologists 
are included in Figure 1.
domain 1: determinants at Patient leVel 
All nephrologists mentioned that the female RTRs do not make time for gynaecological screening, 
because their priorities lay elsewhere. After transplantation there are more important issues such 
as medication, risk of rejection of the transplant graft, recovering after surgery, and a new diet. 
Female RTRs do not think about long-term risks. The second barrier is thought to be the quantity 
of examinations the patients need to undergo. RTRs have to visit different specialists a year and 
gynaecological screening can be one in excess. Other barriers were unpleasant examination, 
laziness/slackness/negligence of the patient, lack of knowledge on the risks, and dependency of 
others. 
Overall, there were two facilitators in both focus groups: HPV self-sampling and health preservation. 
Female RTRs experience self-sampling as less painful and self-sampling can easily be implemented 
at home or in the outpatient visit. The preservation of general health was the other main facilitator 
mentioned by the nephrologists. The nephrologists consider prevention of a gynaecologic (pre)
malignancies worthwhile because limited treatment options due to the renal transplant located in 
the pelvis.
domain 2: determinants at Professional leVel
The main barrier is the lack of knowledge of the professional, especially the GP, on the risks of 
gynaecological (pre)malignancies after renal transplantation. Most nephrologists know the 
increased risk on cervical and vulvar cancer. As GPs do not see many (female) RTRs, they are 
probably not aware of all associated risks after renal transplantation. Performance of gynaecological 
examination by an inexperienced professional was mentioned as another barrier. The quality of the 
examination of the vulvar area, because it is difficult for untrained professionals to recognize vulvar 
abnormalities, was the greatest concern.
The nephrologists mentioned their own knowledge on the risks of gynaecological abnormalities as 
the main facilitator. Arising from this, information given by the nephrologists to the patient should 
also facilitate participation in gynaecological screening. Examination performed by a gynaecologist 
and the right moment of education were mentioned as facilitators in both focus groups. 
domain 3: determinants at organisational leVel
Three main barriers were identified in this domain: the inflexibility of the calling system at the 
GP practice, limited communication between GP and the hospital, and lack of initiative of the 
professional to remind the female RTR to undergo gynaecological examination. The nephrologists 
feel that the organisation at the GP’s office is inflexible. The nephrologists feel that examination 
performed by the GP’s assistant is not reliable, because of lack of attention for the anogenital 
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area and lack of knowledge to recognize abnormalities. The results of the cervical smears taken 
by the GP are not accessible for the nephrologists and not communicated to the nephrologists 
either. Another barrier was the transmission of care from the transplantation centre back to the 
referring hospitals: especially the indistinctness of the responsibility for the participation in annual 
gynaecological screening. Furthermore, the lack of initiative of the professional (both nephrologist 
and GP) to remind the female RTRs to undergo gynaecological examination was mentioned as 
barrier.
Sending an annual reminder to the patients is suggested as main facilitator. Ideally, gynaecological 
screening should be implemented in the annual outpatient visit to the nephrologist (university or 
referring hospital). Patients need to undergo blood- and urine testing during this appointment and 
offering simultaneous gynaecological screening may increase the participation rate significantly. 
domain 4: determinants at financial leVel
The only barrier mentioned in this domain was that health care could become more expensive if all 
female RTRs will go to the gynaecologist for screening. In one of the focus groups it was suggested 
that self-sampling might be cheaper than conventional cervical smear.
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Figure 1. Illustrative quotations from female renal transplant recipients and nephrologists 
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Professional determinant facilitator 
“ Nowadays the assistant of the GP 
performs the examination and I was a 
little startled, because there is trust 
between me and my GP. And the 
assistant, well, she answers the 
phone”
“After six months you are a little 
back on track...”. “It is indeed an 
idea to plan an education after six 
months on ‘We are transplanted 
and what is next’”
“When a patient is in a calling 
system, she does not have to think 
about it. In this way, a part of the 
slackness can be obviated.”
“At the end of the first year after 
transplantation, before patients are 
referred back to their referring 
nephrologist, patients are doing 
well and do not have renal 
problems. This might be the right 
time for me to be more proactive in 
information supply”
“You need to divide your attention 
among different things. The thing 
that is important at this time has 
more priority than the thing you 
might suffer from in the future”
“I do not have any reason for not 
undergoing a gynaecological 
examination...”. “Except for not 
knowing...”,”Exactly”
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DISCUSSION
Our study provides unique perspectives on the barriers and facilitators in gynaecological screening 
by both female RTRs and nephrologists working in the field of transplantation. Thereby, the barriers 
and facilitators in this study are applicable in other developed countries as well. We found that the 
main barriers mentioned by female RTRs as well as nephrologists lay in the patient, professional and 
organisational domain. For female RTRs the main barriers were: unpleasantness of gynaecological 
examination especially when it is performed by GP, lack of knowledge and priority, and limited 
information supply by the professional. For the professionals, main barriers included: inadequate 
examination performed by GP, patients’ lack of time, priority or laziness/slackness/negligence and 
limited information supply by the professional due to limited knowledge. The main difference in 
barriers lay in the patient domain. The female RTRs mentioned the unpleasant gynaecological 
examination itself as a main barrier just as a lack of reminder, while professionals mentioned the lack 
of priority for the female RTR as main barrier. Total agreement was established on the facilitators, 
particularly reminder for the patient to undergo the examination, checklist of all examinations/
visits, integration of gynaecological examination in annual check-up, self-sampling and better timed 
information supply.
Until now, little research has been done on the barriers for gynaecological screening in female RTRs. 
Most studies investigated the barriers for gynaecological screening in the general population only. 
The examination performed by the GP or assistant is one of the main barriers mentioned. In the 
general population only 2% of the women not attending regular cervical screening, did not want their 
own GP to perform the examination. Their main barrier was organisational; women had difficulties 
to schedule an appointment (27, 28). These practical barriers were found more predictable than 
emotional factors. However emotional barriers and a previous negative experience were also 
mentioned (28, 29).  Female RTRs also mentioned that they forgot to make an appointment or 
were not aware of the risks. Furthermore, they did not receive a reminder for the gynaecological 
examination. In the general population research has shown that screening compliance is associated 
with women’s knowledge of cervical cancer and their attitudes toward screening (30). Moreover, 
knowledge of HPV in the general population is limited (31-34). A Swedish study showed that women 
aged 29 years or younger were better informed than older women (30-49 years) (35). Female RTRs 
have a median age of 40-50 years. 
The nephrologists believe that the female RTRs have other priorities than undergoing a 
gynaecological examination. In contrast with the general population, inspection of the vulvar area 
is very important in the gynaecological screening of female RTRs, because of the increased risk 
of vulvar (pre)malignancies. The nephrologists believe that a GP is not educated to screen for 
vulvar (pre)malignancies, because they diagnose 1-2 vulvar malignancies in his/her entire career 
due to the low incidence of vulvar cancer (36, 37). In this case, it would be more useful to inform 
the patients on the risks and the most common symptoms of vulvar (pre)malignancies. It also 
might be helpful to provide more clear information to the GPs on gynaecological screening after 
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renal transplantation. Female RTRs mentioned that their GPs do not know they need to undergo 
gynaecological examination more frequently. The nephrologists mentioned it is very difficult to 
change the calling system by the GP from every 5 years to every year. 
Several studies have investigated the influence of a reminder letter on the participation rate in 
cervical cancer screening programmes in the general population. Women who are personally 
reminded by their GP or received a general reminder letter had the greatest likelihood of attending 
screening (21, 38). A pre-assigned date for screening and a personalized letter increased the 
coverage with 25% in women between 60-70 years in Spain (20). The influence of a reminder letter 
in a younger population (18-35 years) is less effective, with an increase in attendance of only 7.9% 
to 12.2% (39, 40). The female RTRs and nephrologists pointed out that a reminder would encourage 
the attendance of gynaecological screening. Nephrologists in referring hospitals might have a role 
in reminding their patients, since they see them regularly. 
Furthermore, female RTRs pointed out that a checklist would be very helpful. This would provide 
an overview of all the necessary examinations they have to undergo after transplantation. Gill et al. 
(41) showed in a pilot study that the use of a checklist by professionals before transplantation was 
useful. The same checklist for both nephrologist and patient might improve the communication.
In many hospitals, patients are informed about the increased risks of HPV related genital 
abnormalities before  the transplantation. In this period, patients may experience anxiety or distress 
because of their health issues. This information is briefly repeated when the patients are discharged 
from the hospital after the transplantation. RTRs as well as nephrologists mention that this might be 
the wrong moment for this information. They both suggest that when the renal function is stable 
and the patient is referred back to their own referring nephrologist, would be a good moment for 
education on the post transplantation period, including reasons for gynaecological screening. 
In the Netherlands, the participation rate of the general population in cervical cancer screening 
programme is not at its optimum. Women who do not attend cervical screening within two 
reminders, are called ‘non-responders’. Research showed that this group of women has a higher 
incidence of cervical (pre)malignancies compared to ‘responders’. To reach these ’non-responders’, 
a cervico-vaginal self-sampling method to detect HPV may be an alternative. Self-sampling is highly 
accepted and even preferred over physician taken sample in 95% of cases by women and the 
sensitivity of high risk HPV testing on self-sampling material equals sampling materials obtained 
by physicians (42). The implementation of self-sampling in the Netherlands showed a response 
rate of approximately 30% in the non-responders of the population-based screening (43, 44). 
Self-sampling will therefore be implemented to be available to the non-responder group of the 
new Dutch national screening program. Self-sampling was preferred over physician taken sample 
because it was easy to use with simple instructions and less painful, which was confirmed by the 
female RTRs in our focus groups. The nephrologists mentioned all of the above arguments as well 
and pointed out that self-sampling is easy to implement in the annual check up of female RTRs.
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CONCLUSION
Based on the findings of this study, we suggest every female RTR should receive a small checklist 
one year after transplantation (or when referred back to their own nephrologist), with the 
examinations they need to undergo at different time intervals. Furthermore, HPV self-sampling in 
the annual check-up by the nephrologist (with referral to the gynaecologist in case of HPV-positivity) 
would obviate a lot of barriers and meets the main facilitators. Implementing these changes might 
improve the participation rate of female RTRs in gynaecological screening.
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AbSTRACT
Objectives: Female renal transplant recipients (RTRs) have increased risk for developing human 
papillomavirus (HPV)-related (pre)malignancies of the lower genital tract. Annual cervical screening 
is advised for RTRs, but the participation rate is low. The aim of this study is to investigate whether 
HPV self-sampling is suitable for gynaecological screening of RTRs to increase participation rate. 
Methods: A large cohort of 253 RTRs was investigated for the prevalence of HPV. All participants 
received a device for a cervico-vaginal self-sample. Questionnaires were sent to assess the 
experience with this device. High- risk (hrHPV) presence was determined with the SPF10-LiPA25 
system and GP5+/6+ PCR. HrHPV positive patients underwent gynaecologic examination. 
Results: More than 90% of the patients rated their experience with the self-sample device as good 
to excellent, and 77% preferred self-sampling over a physician taken sample. Approximately 35 
of 217 women tested hrHPV positive with SPF10-LiPA25, and 22 tested positive with the GP5+/6+ 
PCR. Eleven hrHPV-positive patients had clinically relevant gynecological abnormalities, and they all 
tested positive with GP5+/6+ PCR.
Conclusions: Self-sampling is clinically applicable in a gynaecological screening and is preferred 
by female RTRs. Therefore, self-sampling could be implemented with the aim to increase the 
participation rate of female RTRs in yearly gynaecological screening.
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INTRODUCTION
Female renal transplant recipients (RTRs) have a markedly increased risk of developing human 
papillomavirus (HPV)-related (pre)malignancies of the female lower genital tract (1-5). They have a 
14-fold increased risk of cervical cancer and up to 50-fold increased risk of vulvar cancer because 
of the lifelong use of immunosuppressive drugs. Human papillomavirus plays a key role in the 
oncogenesis of these malignancies in RTRs. This is in contrast with the general population in which 
HPV, although causing nearly 100% of the cervical cancers, causes only 20% of the vulvar (pre)
malignancies (6).
Because of the higher risk of (pre)malignant cervical lesions and the need for early detection, 
because of the limited treatment options due to the kidney transplant in the pelvis, guidelines 
and publications advise annual cervical screening for female RTRs (7-9). However, evidence on the 
optimal frequency of cervical screening is scarce. In daily practice, we found the average screening 
interval in female RTRs of 5 years (10, 11). A possible explanation for this long-interval screening 
in RTRs could be that the female RTRs and/or the nephrologists focus more on the preservation 
of renal function than on long-term complications. Other possible reasons for non-attending 
screening could be embarrassment and fear of the gynaecological examination or lack of time to 
schedule an appointment.
The participation rate of women in the Dutch well-organized national screening program, which is 
currently based on cervical cytology, is only approximately 65% (12). Women not participating after 
invitation (“nonparticipants”) have a higher risk of developing cervical (pre)malignancies (13, 14).
High-risk (hr)HPV tests have a higher sensitivity in detecting cervical intraepithelial neoplasia (CIN) 
2/3  than cervical screening by PAP smear  (~90% versus ~60%)  and screening based on hrHPV tests 
affords better protection against cervical cancer (15-17). Therefore, it was decided to introduce the 
hrHPV test as primary screening tool in the general population in The Netherlands in 2017 (18). 
Human papillomavirus testing can be adequately and reliably performed on a cervicovaginal sample 
taken by women themselves (self-sampling) (19, 20). Self-sampling is highly accepted by women and 
the sensitivity of hrHPV testing on self-sampling material equals that obtained with sampling by 
physicians (21). The implementation of self-sampling in The Netherlands showed a response rate of 
approximately 30% in the nonparticipants of the population-based screening (22, 23). Self-sampling 
will therefore be available  to the nonparticipant group of the Dutch national screening program.
Because the female RTRs who do not participate in yearly gynaecological screening can be 
considered as “nonparticipant”, self-sampling might be a promising option to increase the yearly 
screening rate in female RTRs. 
The aim of this study is to investigate whether HPV self-sampling is suitable to implement in 
gynaecological screening of RTRs and can ultimately increase the participation rate.
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METHODS 
Female RTRs were invited to participate in a study to investigate the prevalence of HPV in female 
RTRs. 24 Female RTRs who fulfilled the following criteria were invited to participate: (1) renal 
transplantation at the Radboud University Medical Center (Radboudumc), Nijmegen, or the 
Maastricht University Medical Center (MUMC), Maastricht, The Netherlands, in the period 1968-
2008; (2) a functioning donor kidney as of February 2012; (3) living in The Netherlands; and (4) older 
than 18 years. Of the 626 invited participants, 253 RTRs (40%) gave their written informed consent 
for this study. 
All 253 participants from the cohort study were asked to self-collect a cervicovaginal sample in 
the privacy of their own home with the dry Evalyn Brush® system (Rovers Medical Devices B.V., 
Oss, The Netherlands), which was proven to provide similar results as a physician-taken sample 
for hrHPV detection (20, 25, 26). Patients received the collection device and written instructions 
with illustrations and returned the package comprising a leak proof seal bag, absorption sheet, 
and a plastic return envelope complying with the packing instruction for the sending of biological 
substances (category B) per mail. All samples were stored dry and certified the unique study code.
Each recipient received a questionnaire, which assessed the experience of the RTRs regarding self-
sampling with the dry Evalyn Brush® system. The questionnaire also contained items to assess 
socio-demographic characteristics, medical data, and sexual behaviour. Questionnaires could be 
filled out using a digital (secured) system or via a paper version. All questionnaires were provided 
and saved with a unique study code.
The self-sampling device was resuspended in 1·5 ml ThinPrep medium at the laboratory of the 
Department of Medical Microbiology at the Radboudumc. The vials were vortexed for 3x15s, stored 
overnight at 4°C, and again vortexed for 2x15s. From each resuspended dry specimen, 200 μl was 
used for DNA extraction with the MagNaPure 96 (Roche Molecular Diagnostics). The purified DNA was 
eluated in 50μl TE-buffer. For detection and genotyping of HPV, broad spectrum HPV amplification 
was performed using the short-PCR-fragment assay (SPF10-LiPA25; Labo Bio-medical Products B.V., 
Rijswijk, The Netherlands). This assay amplifies a small fragment of 65-bp from the L1 open reading 
frame and allows detection of a broad range of HPV genotypes and has a high analytical sensitivity. 
The SPF10-LiPA25 system will detect a relatively high amount of HPV not associated with genital (pre)
malignancies. On the other hand, the GP5+/6+ PCR enzyme immunoassay (EIA)  is less sensitive, but 
is more specific in detecting (pre)malignancies. Patients who tested hrHPV positive with the SPF10-
LiPA25 system were invited for gynaecological examination. Gynaecological examination comprised 
an extensive inspection of the genital area and a smear of the cervix or vaginal vault in case of 
hysterectomy in the past. In case of any abnormal finding during this visit, patients were referred 
for additional  tests (i.e., vulvar biopsy, colposcopy) and treatment according national guidelines. 
To assess the clinical applicability of HPV testing on self-sampling material in the gynaecological 
screening of female RTRs, any samples that were hrHPV positive with the highly sensitive SPF10-
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LiPA25 were retested with a clinically validated HPV test, the GP5+/6+ PCR EIA (EIA HPV GP HR 
kit, Diassay, Voorburg, The Netherlands). Women with  SPF10-LiPA25 HPV-negative samples were 
not retested with the GP5+/6+ PCR. As a quality control for the presence of DNA and absence of 
PCR inhibitors in the isolated material, a PCR for β-globin was performed. The HPV results of the 
GP5+/6+ PCR EIA were related to the cytological and/or histological outcome of the gynaecological 
examination.
RESULTS
Of the 253 patients who signed the informed consent form, 217 (86%) returned the sample, and 
212 (84%) patients filled out the questionnaire; 157 patients returned the sample and filled out the 
questionnaire completely. These 157 patients who completed questionnaires were used to assess 
the opinion of the RTRs on the self-collected cervicovaginal sample with the dry Evalyn Brush® 
system. The included patients had a median age of 56 years (range 23-79) and the interval after 
their first transplantation was 10 years (range 3-37). One hundred thirty-five (86%) of 157 patients 
used the self-sampling device without any problems. Problems that did occur include pain with 
insertion and unpleasant feeling when turning the brush or blood on the device. From the total 
group, 144 (92%) patients rated their experience with and convenience of using the self-sampling 
device as good to excellent. The instructions for using the brush were considered good to excellent 
by 153 (97%) of the 157 female RTRs. The feelings that patients experienced during self-sampling 
are summarized in Figure 1. Overall, self-sampling did not raise feelings of shame and was not 
referred to as scary or unpleasant. Most patients were confident that they performed the self-
sampling correctly, and 68% rated the sampling as not difficult at all. Cervical screening using the 
self-sampling method was preferred above sampling by a physician by 119 (76%) of the 157 female 
RTRs, and 3 female RTRs had no preference for either.
Most patients used a calcineurine inhibitor (tacrolimus/cyclosporine A), in most cases with 
corticosteroids and in some cases with a proliferation inhibitor (azathioprine/mycophenolate 
mofetil). Time on immunosuppressive medication and the type of immunosuppressive treatment 
were not related to HPV prevalence (24).
Of the 217 completed self-samples, 35 samples (16%; 95% confidence interval [CI], 11%-21%) were 
positive for hrHPV by the sensitive SPF10 test. These RTRs were invited to the outpatient clinic of the 
Department of Obstetrics and Gynaecology for gynaecological examination. Of these 35 samples, 
20 (57%; 95% CI, 41%-73%) samples tested hrHPV positive with the clinically validated GP5+/6+ 
PCR, and  the overall hrHPV positivity was 9% (95% CI, 5%-13%) with GP5+/6+ PCR. The 20 samples 
that were hrHPV positive with the GP5+/6+ PCR included all 11 samples of patients with clinically 
relevant cervical/vaginal and/or vulvar abnormalities (table 1). In the remaining 9 cases that were 
hrHPV positive with the GP5+/6+ PCR, there were no abnormal cytology results. Two of the 11 
patients had HPV-related vulvar abnormalities, consisting of usual vulvar intraepithelial neoplasia 
(uVIN) and condylomata
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Figure 1. Feelings of 157 female RTRs experienced during self-sampling. 
table 1. Details of clinically relevant genital abnormalities found in female RTRs, who tested 
hrHPV positive on self-sampling material.
n=35
no relevant abnormalities 24
Clinically relevant abnormalities 11
Cervical
      - Moderate dysplasia 5
      - Severe dysplasia 2
Vulvar/vaginal
      - Condylomata  1
      - uVIN 2-3 1
Combined cervical/vaginal and vulvar
      - Moderate vaginal dysplasia and uVIN 3 1
      - Moderate dysplasia cervix and condylomata 1
uVIN indicates usual vulvar intraepithelial neoplasia, + 1 patient also had moderate dysplasia of the cervix.
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DISCUSSION
Our study showed that 75% of the included female RTRs preferred self-sampling to a physician 
taken sample. Furthermore, hrHPV testing on self-sampling material with a clinically validated HPV 
test seems a reliable tool in detecting clinically relevant gynaecological abnormalities in female RTRs.
The question whether HPV testing on self-sampling material is equivalent to HPV testing on 
clinician- collected samples was addressed in a recent meta-analysis by Arbyn et al. (21). It was 
concluded that PCR with the GP5+/6+ primers have a similar sensitivity and specificity (91-95% 
and 51-54% respectively) on self-samples versus clinician-taken samples for detecting cervical 
abnormalities. Our study confirms the clinical applicability of the PCR on self-sampling material 
in female RTRs, which is an important finding, even in a small study population. Implementation 
of this self-sampling strategy offers the potential to increase the participation rate in the yearly 
gynaecological screening of female RTRs. Yearly HPV self-sampling as a routine at the outpatient 
clinic nephrology with referral to the gynaecologist in case of an HPV positive test could comprise 
the gynaecological screening of female RTRs.
Interestingly, a secondary finding in our study was that also vulvar abnormalities may be detected 
by self-sampling using HPV PCR, even in the absence of cervical/vaginal abnormalities. Although 
there were only 2 patients with vulvar abnormalities in this small population, it is of the utmost 
importance that vulvar abnormalities in female RTRs are detected in an early stage, as the vulvar 
(pre)malignancies tend to develop more rapidly in female RTRs (27). In the general population, 
a majority of vulvar squamous cell carcinomas (SCCs) consists of non HPV-related SCCs in a 
background of lichen sclerosus and/or differentiated VIN (28). However, in women treated with 
immunosuppressive drugs, almost 100% of SCCs are HPV-related vulvar (pre)malignancies and/
or usual VIN (29). We did not find any publications on the use of cervicovaginal self-sampling in 
relation to the presence of vulvar (pre)malignancies. The RTRs that were hrHPV negative did not 
undergo gynaecological examination, so the prevalence of vulvar abnormalities in this group is 
not entirely clear. Our findings emphasize the importance of inspection of the total genital area in 
hrHPV-positive female RTRs. 
The participation rate of female RTRs in annual cervical screening is low, despite their increased risk 
of developing genital abnormalities. The reasons for not participating in screening are not entirely 
clear. Most likely, the main focus of the female RTRs is on the preservation of the renal transplant 
and less on the prevention of long-term complications. Another explanation of the low participation 
rate may be the age of the RTR population. In the general population, age has an influence on 
cervical screening uptake, and the uptake is worse in women over 55 years (30). Participants in our 
study had a median age of 56 years. The influence of educational level was also investigated, but 
yielded no significant effect on screening participation (30). A study among RTRs in Sydney showed 
that awareness of increased cancer risk was present, but patients were primarily focused on skin 
cancer (31). It also may be hypothesized that patients do not receive or do not recall information on 
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the need for gynaecological screening. More insight in the reasons for non-attending might help us 
to improve the gynaecological screening in female RTRs.
strengths and limitations
This study is the first to assess the experiences of female RTRs with an HPV self-sampling device. 
Furthermore, we compared the results of the analytical sensitive SPF10-LiPA25 test with the clinically 
sensitive GP5+/6+ PCR and related the outcome with clinically relevant gynaecological abnormalities, 
which is of great importance for possible implementation of HPV testing in the gynaecological 
screening. A limitation of the study is the composition of the study population. There could be 
population bias because the female RTRs who participated already have a positive opinion on HPV 
self-sampling at study entry. We have no information on the opinion of the female RTRs who did not 
participate. Most RTRs are focused on the preservation of the renal transplant and already need to 
go to the hospital regularly. Furthermore, the self-sampling technique is new and not yet introduced 
in the general population, and nephrologists are not yet informed about HPV self-sampling. This 
could be explanations for the participation rate of 40%.
CONCLUSIONS
In conclusion, HPV testing on cervicovaginal self-sampling material could be a reliable tool for 
gynaecological screening in female RTRs. The experiences of the female RTRs in this study with 
the self-sampling device were quite favourable. Human papillomavirus self-sampling could be 
implemented in the follow up of female RTRs, mainly to ensure and improve the yearly gynaecological 
screening in these women. 
In future research, it would be interesting to assess the barriers and facilitators in gynaecological 
screening of female RTRs. The results might present suggestions for further improvement of 
gynaecological screening.
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GENERAL DISCUSSION
In this thesis, different studies on vulvar- and cervical (pre)malignancies in either the general 
population and renal transplant recipients were described. This chapter will focus on two important 
issues in more extent; tumour localization in vulvar squamous cell carcinoma (SCC) and screening 
of HPV-related genital (pre)malignancies in renal transplant recipients (RTRs). These topics are 
highly relevant because of their influence on (future) clinical practice.
1. VUlVAr CAnCer: role oF tUMoUr loCAliZAtion?
ClitorAl tUMoUr: WorSt ProGnoSiS
In Chapter 2 we have shown that vulvar SCC with clitoral involvement has a worse prognosis 
compared to other localizations on the vulva. The localization itself appeared not to be an 
independent risk factor, but several tumour characteristics that were in itself independent risk 
factors were more often present in tumours with clitoral involvement. The characteristics larger 
tumour diameter, deeper tumour invasion, more lymphovascular space invasion (LVSI), positive 
surgical margins, and the presence of lymph node metastases were independently related to 
prognosis. 
Patients’ and doctors’ delay in the diagnostic process may be an explanation for the larger and 
deeper invading tumours around the clitoris. Patients may fear the implications of the lesion to the 
clitoral function which could lead to reluctance to visit a doctor combined with uncertainty, fear and 
shame. Diagnostic delay by doctors in clitoral SCC might be enhanced by the hesitation to biopsy 
the lesion at the outpatient clinic, because of fear damaging the clitoris. 
Another hypothesis for the increased depth of invasion and more LVSI in clitoral SCC could be that 
clitoral tissue is more prone for tumour invasion due to higher blood circulation and a large number 
of (lymph) vessels and nerves. This might stimulate faster and deeper tumour growth. In general, 
the prognosis of vulvar SCC is mainly based on the presence and number of inguinofemoral lymph 
node metastases which are representative for unfavourable histopathological factors such as larger 
and deeper invading tumours (1).
The shorter distance from tumour to the inguinofemoral lymph nodes may also play a role in higher 
rate of lymph node metastases compared to tumours that are located further from the groins. 
Metastases to the groins develop via embolization; one could imagine that a larger distance to the 
groins may lead to a longer interval for groin nodes to become positive. Furthermore, tumours 
with clitoral involvement had more often positive or surgical margins <8mm. These factors might 
increase the local recurrence rate, however it is still a debate whether close surgical margins truly 
influence recurrence rates (2). 
Anatomic localization and histopathological characteristics of a tumour cannot be changed. More 
direct lymphatic drainage from the clitoris does not totally explain the higher rate of positive lymph 
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nodes, since Iversen et al. (3) assessed lymph drainage from different vulvar areas and found no 
difference in uptake of 99mTc-colloid between different injection sites (including clitoris) (3). However, 
the particles of 99mTc-colloid are extremely small and may pass through the lymphatic system more 
easily than tumour cells. In vulvar SCC the perineum is further from to the groin nodes than the 
clitoris and tumour cells may cluster together and may not reach the groin nodes in contrast to 
the tumour cells from the primary vulvar SCC located on the clitoris. The only factors that may be 
influenced are either the patient/doctors delay and the treatment. Earlier detection of tumour might 
minimize tumour invasion. This could be established by better education of general practitioners 
and gynaecologists. Patient education is also very important, especially to diminish the feelings of 
shame concerning vulvar complaints. 
Prognosis of vulvar SCC is worse in case of more local recurrences. The question rises whether 
primary treatment can be improved to decrease the number of local recurrences resulting in a 
better prognosis. There is no clear definition of local vulvar SCC recurrence in the current literature. 
There is no consensus on the minimum or maximum time span between the primary tumour 
and the recurrence. Some authors define local recurrence as the new appearance of a tumour 
after therapy with radical intent and a disease-free period of at least 6 months (4). Most real local 
recurrences occur within 2 years after primary treatment, so recurrences after 2–3 years might be 
considered de novo tumours based on the adjacent premalignancy (5, 6). The incidence of isolated 
local recurrences is 20–23% (4, 7, 8). More than 50% of all recurrences are local. So, how can we 
minimize local recurrences in vulvar SCC with clitoral involvement and try to improve survival in 
these patients? Is more radical surgery necessary? Are all the local recurrences diagnosed until now 
true recurrences or de novo tumours? 
The width of the tumour-free margin is one of the most clinically important and controversial topics 
in treatment of vulvar SCC. Although it is obvious that a tumour positive margin is associated with 
an increased local recurrence rate, the association between the width of the tumour-free margin 
and local recurrence rate is less clear (6, 9-13). Studies yielded varying results with regard to the 
tumour-free margin and the risk of local recurrence (6, 9, 10, 12, 13). A recent study by Nooij et al. 
(2) showed no clear difference in the risk of local recurrence in the <8 versus ≥8 mm group and 
showed positive surgical margins the only independent risk factor for local recurrences. Based on 
these study results more extensive surgery does not seem to be the solution in the prevention 
of local recurrences. Does this also mean that re-excision in case of a surgical margin <8 mm is 
not necessary based on these results? Apparently, only positive margins give a proven higher risk 
of local recurrence. More research on this topic is certainly needed but adapting this conclusion 
would lead to a substantial decrease in the number of repeat surgical procedures significantly 
decreasing patient morbidity.
It seems that more information on the localization of the primary tumour could give more 
information on the approach of an alleged recurrence. Nowadays the time span between primary 
treatment and the occurrence of a new tumour is leading in the determination of recurrence or de 
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novo tumour. Because documentation of the exact location of the primary tumour is often absent, 
the distance to the primary site to define recurrence is difficult to assess. In ongoing and future 
prospective studies, introduction of digital cameras may be helpful in reporting the exact location 
of the primary tumour. Digital documentation of the localization of the primary tumour will provide 
better demarcation of the tumour site and be used in defining recurrence. Recurrent tumours 
located >1cm from the primary tumour site could be considered de novo also when the tumour 
develops within 2 years after primary treatment. The underlying premalignancy (lichen sclerosus 
(LS), differentiated vulvar intraepithelial neoplasia or high-grade squamous intraepithelial lesion 
(HSIL) of the vulva) is probably more important for developing local recurrences (de novo?) than 
the tumour free margins but good clinical studies are lacking. Currently, the standard treatment of 
vulvar SCC is local excision and sentinel lymph node (SLN) procedure of the groins (14). In case of 
a local recurrence the treatment is re-excision and inguinofemoral lymphadenectomy with all the 
associated morbidity; the indication for lymphadenectomy results in losing the advantages of only 
a SLN procedure in case of a negative SLN. Prevention of local recurrences is of utmost importance 
for either mortality and morbidity in patients with vulvar SCC. Besides the use of digital cameras, 
genetic profiling of primary vulvar SCCs and the local recurrences may be helpful in distinguishing 
between real local recurrences and de novo vulvar SCC. Furthermore, in case of HPV-related vulvar 
SCC, HPV genotyping could also help in defining between recurrence and de novo tumour. When 
another HPV genotype is found in the recurrent SCC it is more likely a de novo tumour. These 
tools should be part of future studies on the role of tumour free margins and the underlying 
premalignancy with respect to local recurrences and prognosis. 
PerineUM: BeSt ProGnoSiS
In contrast to the bad prognosis for patients with vulvar SCC located on the clitoris, patients with 
vulvar SCC on the perineum have a better prognosis. We showed in Chapter 3 that HPV-related 
vulvar SCCs are more often located on the perineum. It seems that HPV-associated vulvar SCC has a 
better prognosis.  Another explanation for the favourable prognosis could be the early detection of 
vulvar SCC on the perineum, as a tumour on the perineum could give more and earlier discomfort 
for the patient. This might result in an earlier presentation to the general practitioner. Furthermore, 
the perineum is a relative safe place to take a biopsy. All these factors might  contribute to more 
early stage vulvar SCC on the perineum.
Patients with vulvar SCC on the perineum have a relatively good prognosis. Chapter 3 showed that 
HPV-relation has a positive influence on the prognosis. The question rises whether the localization 
or the HPV relation are explanations for the better prognosis? Nowadays, the HPV status of vulvar 
SCC is not assessed in the diagnostic process because lack of consequences for the treatment. 
Vulvar cancer is primarily surgically treated with wide local excision and SLN procedure of the 
groin nodes independent of the oncogenesis (HPV-related or LS-related). What is known about 
the role of HPV in other malignancies? Cancer of the cervix and vagina are almost always HPV-
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related and treatment consists of surgery and/or radiotherapy dependent on the stage of disease. 
Head- and neck tumours comprise tumours of the mouth, oropharynx, hypopharynx, and larynx. 
The oropharyngeal SCCs are partly HPV-related and treated with (chemo)radiation therapy. The 
last decade, head- and neck tumours (especially oropharyngeal tumours) have been extensively 
reviewed since a rise in incidence has been observed in the past years. The increasing incidence 
correlates with the increase of HPV infections associated with alterations in sexual behaviour with 
a trend toward increased number of sexual partners and increased number of orogenital partners 
(15). HPV-related head- and neck tumours differ from the traditional tumours in the region and 
are associated with improved response to therapy and longer life-span. The HPV-positive tumours 
are more sensitive for radiotherapy than the HPV-negative tumours, probably based on intact p53 
protein (16). Despite the numerous differences in HPV-related and non HPV-related head- and neck 
tumours, currently there is no specific algorithm to treat HPV-related head- and neck tumours. 
However, it has been suggested to minimize the intensity of the radiotherapy treatment due to the 
better response to radiotherapy. In head- and neck cancer hypoxia seems to play an important 
role. Hypoxia is the result of an imbalance between oxygen delivery and oxygen consumption, 
and hypoxic areas are a common feature in solid tumours. Hypoxia activates various signalling 
pathways that enhance the survival of tumour cells (e.g., HIF-1 and AKT) and is, therefore, an 
inherent negative factor for outcome. Hypoxia induces stabilization of the transcription factor HIF-
1alpha (HIF-1α), associated with (chemo)radiotherapy resistance in oropharyngeal SCC. HIF-1α 
protein overexpression is associated with worse overall survival in oropharyngeal SCC, especially in 
the HPV-related tumours (17). 
Radiotherapy in vulvar cancer is used adjuvant in case of positive groin nodes, in case of close/
positive surgical margins, and in combination with chemotherapy in locally advanced vulvar SCC. In 
line with HPV-related head- and neck tumours, HPV-related vulvar SCC may benefit from treatment 
with radiotherapy. We need to investigate the effect of radiotherapy in vulvar SCC further. Recently, 
the worldwide multicenter study (Groningen International Study on Sentinel nodes in Vulvar 
cancer (GROINSS-V) II) has been closed awaiting for final results; the effect of only radiotherapy 
after positive sentinel lymph nodes in patients with early stage vulvar SCC is the main aim of the 
study. Furthermore, a study on chemoradiation in vulvar SCC is ongoing in patients with primary 
or recurrent vulvar SCC with locally advanced disease not curable with surgery unless extensive 
reconstructive surgery. We suggest to investigate the role of HPV status of all primary and recurrent 
vulvar SCCs of these two studies in relation to the efficacy of radiotherapy between non HPV-related 
and HPV-related vulvar SCC. Assessing the role of hypoxia in vulvar SCC could give more insight 
in the difference in prognosis between HPV-related and non HPV-related vulvar SCC. This may 
ultimately contribute to better personalized cancer care.
Furthermore, is surgery of inguinofemoral lymph nodes always necessary in case of a small vulvar 
SCC located on the perineum? What do we know about small anal tumours, which are often located 
close to the perineum? In other words, are there similarities between these two tumours? It might 
be argued that the lymph drainage from the perineum differs from the other tumour localizations 
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of the vulva and is more comparable to anal cancer? There are no studies on this topic.
Anal cancer can be divided into anal canal cancer and anal margin cancer, where anal margin cancer 
is often SCC of the skin around the anus and represents one-fourth to one-third of all SCC of the 
anus. Tumours are HPV-related in 70-80% of the cases. The incidence of metastatic lymph nodes 
is related to tumour size with 0% in tumours less than 2 cm, 23% of tumours 2 to 5 cm and 67% of 
tumours greater than 5 cm (18). Tumours that are limited to the anal margin are treated similar to 
cutaneous SCC elsewhere on the body with wide local excision (WLE). Only for patients with larger 
tumours, nodal involvement, or invasion of the sphincter muscle, treatment with chemoradiation 
is the appropriate treatment. In these cases inguinofemoral nodes should always be part of the 
irradiation field (19). As in vulvar SCC, inguinofemoral groin node status is an important prognostic 
factor in anal cancer (20). Small anal margin SCC is treated like cutaneous SCC, so what is the 
reason to treat all vulvar SCC with >1 mm invasion depth with WLE and SLN procedure? In vulvar 
cancer untreated positive groin nodes/groin recurrences decreases the prognosis significantly. 
Since the perineum is so close to the anal margin it could be hypothesized that  lymph drainage is 
comparable. Before we can change the surgical treatment of perineal SCC, we should assess the 
percentage of groin node metastases in all perineal SCCs < 2 cm, between 2-5 cm, and larger than 
5 cm. In vulvar SCC invasion depth of the tumour plays an important role in treatment decision, so 
this tumour characteristic should definitely be measured next to tumour diameter. Based on these 
results, small perineal vulvar SCCs could possibly be treated with only WLE like cutaneous SCC and 
anal margin SCC and diminish disease burden and treatment morbidity. 
2. HPV in renAl trAnSPlAnt reCiPientS: HoW to oPtiMiZe SCreeninG  
AnD VACCinAtion
In this thesis we demonstrated an increased cervical HPV prevalence in patients before and after 
renal transplantation (Chapter 5). All these patients use immunosuppressants: drugs that lower the 
body’s ability to reject a transplanted organ. We suggested that the start of immunosuppressants 
after renal transplantation results in re-activation of latent HPV infection and not by acquiring 
new infections. Remarkably, there was also a higher cervical HPV prevalence found in female 
patients with end stage renal disease before transplantation compared to women in the general 
population in the same age group. A likely explanation is that (some) patients with end stage renal 
disease are already immunocompromised based on either their underlying kidney disease and/
or immunosuppressive medication. Due to short follow-up time, the persistence of the hrHPV 
infections after transplantation could not be established, nor could an increase in incidence of 
genital (pre)malignancies be observed. However, the results explain the increased risk of HPV-
related cervical- and vulvar (pre)malignancies in women after renal transplantation.
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SCreeninG
Knowing that HPV infections may contribute to the increased incidence of HPV-related (pre)
malignancies in RTRs, the question arises how cervical screening could help to reduce the incidence 
of HPV-related genital malignancies.
International guidelines suggest cervical screening after renal transplantation (21-23) to be 
performed annually. However, the level of evidence for this high frequency of screening is low. 
Patients with HIV are screened annually and twice in the first year after diagnosis (24), but they differ 
from transplant patients with respect to the degree of immunosuppression and the risk of acquiring 
genital HPV infections. Does the literature provide us with information on cervical screening in 
immunocompromised patients, other than HIV patients? Patients with systemic inflammatory 
disease, such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE), who are also treated with immunosuppressive drugs, have an increased risk 
of cervical dysplasia as well (25-30). Of these patient groups, especially patients with SLE are at 
higher risk. A meta-analysis by Zard et al. (31) showed an increased risk of high grade cervical 
squamous intraepithelial lesions for patients with SLE with a cumulative odds ratio of 8.6. There is 
currently no international consensus on the frequency of screening in these patient groups.
Even in the general population there is no international consensus on frequency and target age 
group in cervical screening (table 1) (32).
table 1. International differences in design of cervical cancer screening in the general 
population
Country target range 
(in years)
Screening interval 
in years
Smears per women 
lifelong
Belgium 25-64 3 14
Denmark 23-59 3 13
Finland 30-60 5 7
France 25-65 3 14
Germany ≥ 20 1 50+
Italy 25-64 3 14
Netherlands 30-60 5 7
Sweden 20-59 5 14
UK (England) 20-65 3 or 5 16-10
Australia 18-70 2 43
USA 21-65 3 16
Canada 30-69 3 14
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During recent years, the Dutch well-organized screening programme invited women between 30-
60 years every 5 years and screening was based on cytological examination of PAP smears. The 
choices for this target range and screening interval were based on cost-effectiveness analyses. 
High-risk (hr)HPV tests have a higher sensitivity in detecting CIN 2/3 than cervical screening by PAP 
smear (~90% versus ~60%) and screening based on hrHPV tests affords better protection against 
cervical cancer (32-34). Therefore, it was decided to introduce the hrHPV test as primary screening 
tool in the general population in the Netherlands from 2017 (35). This means that the primary triage 
is an hrHPV test; only in case of positive hrHPV test, cytologic examination of the smear will be 
performed. The changes in the Dutch screening programme are displayed in table 2.
table 2. Changes in the Dutch screening programme
old screening programme new screening programme 
(start 2017)
Invitation by General practitioner/screening 
organization 
screening organization 
Screening test Cytology hrHPV-test 
Target range 30 – 60 years 30 – 60 years 
Age at invitation (years) 30, 35, 40, 45, 50, 55, 60 30, 35, 40, 50, 60
(45, 55, 65 in case hrHPV 
positive in previous round)
Number of screening rounds 7 min. 5 - max. 8 
Like for the cytological screening, it is challenging to give an evidence based advise on the optimal 
strategy for screening of female RTRs with the hrHPV-test. The Dutch guideline cervical intraepithelial 
neoplasia (CIN), which includes screening based on hrHPV testing, does not recommend more 
frequent screening in female RTRs, but is this justified? In our view, the following aspects of 
screening should be considered in more detail based on the results presented in this thesis: pre-
transplantation screening, the target age range of screening, and the optimal screening interval.
PretransPlantation screening
Meeuwis et al. (36) showed that there are two peaks in the incidence of genital (pre)malignancies 
after transplantation: either shortly (<three years) or >8-10 years after transplantation. It is likely 
that the first peak is explained by abnormalities already present at the time of transplantation 
since a large number of the female RTRS in this study never participated in cervical screening. 
Fairley et al. (37) showed an overall HPV prevalence of 20% in dialysis patients. Next to a higher 
HPV prevalence, it has been shown that dialysis patients have an increased risk of cancer, including 
cervical- and vulvovaginal cancer (38). In our study, 10% of the female renal transplant candidates 
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had an abnormal cervical smear which in half of the cases was a HSIL, and two patients newly 
developed HSIL within two years after transplantation. In addition, the risk of HPV reactivation due 
to immunosuppressive therapy will be highest during the first year after transplantation because 
of more intense immunosuppression. We therefore think a recent screening test (participation 
in national screening programme is sufficient) should be hrHPV negative or hrHPV positive with 
normal cytology before patients can be listed for a cadaveric donor transplantation, or be planned 
for a living donor transplantation. 
age range of screening
In the national programme screening starts at the age of 30 years and continues until the age of 
60 years. In the general population cervical cytological abnormalities are common at young age, 
but regress in almost all cases. Therefore and to prevent overtreatment, screening is not indicated 
before the age of 30 years in the general population. However, in female RTRs <30 years of age 
the chance of progression of cytological abnormalities is higher and the rate of spontaneous 
regression of CIN lesions is lower than in the general population (39). Therefore, we suggest to start 
the screening of female RTRs at 25 years of age, provided that women are sexually active. We chose 
25 years, because in the general population the incidence rates of cervical cancer start around 
the early twenties. Below the age of 25 years, cervical cancer is hardly diagnosed. The national 
screening programme screens females until the age of 60 years. Our studies did not provide 
information on the behaviour of HPV infections or the development of genital (pre)malignancies 
in female RTRs >60 years of age. Furthermore, no other studies investigated this specific group 
of patients in extent. These advises only comprise screening, but in case of complaints (abnormal 
vaginal bleeding) gynaecological examination should be performed despite the age of the woman. 
freQuency of screening
It is known that female RTRs have an increased risk of developing HPV-related malignancies 
(increased standardized incidence ratios between 1.0-2.5 for cervical cancer and 7.3-23.9 for 
vulvar/vaginal cancer), but we do not know how long it takes for a (pre)malignancy to develop in 
female RTRs. The data in Chapter 5 of this thesis show that latent HPV infections are re-activated 
after transplantation, but do not provide information on the persistence of these infections nor on 
the time course of developing genital (pre)malignancies.
To properly advise on the frequency of screening, more research into these issues needs to be 
done. A first step would be to extend the follow up of the study population from Chapter 5. We 
could assess HPV status, genotype, and the presence of cytological abnormalities 5 years after 
renal transplantation (RT). This would give us information on the persistence of the HPV infection 
and if persistence is established, the effect on developing genital (pre)malignancies. Nevertheless, 
due to the fact that female RTRs are lifelong treated with immunosuppressive drugs we should 
consider a more aggressive course of (pre) malignant HPV-induced malignancies. Moreover, the 
mere presence of a renal graft in the pelvic region may hamper adequate treatment of different 
stages of cervical cancer: full pelvic lymphadenectomy is technically impossible while radiotherapy 
of the pelvis will result in dysfunction of the transplanted kidney. Based on these considerations we 
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propose to limit the maximum time interval between two screening tests to 5 years, which deviates 
from the national programme for women above 40 years of age (table 2). 
Taken together, there are no solid data to support annual cervical screening of female RTRs. On the 
other hand, the screening programme for the general population does not take into account some 
issues that are specific for this population. Until we have the results of our follow up studies, we 
would like to give the following recommendations concerning the cervical screening in female RTRs:
- All female RTRs should be strongly advised to take part in the national screening programme. 
Any abnormal test result should be evaluated according to the guidelines in this programme;
- A screening test should be performed before transplantation in all women between 30 and 60 
years of age according to national screening programme; 
- The starting age of screening after transplantation should be lowered from 30 to 25 years in 
case of sexual activity;
-  The interval between screenings test should be maximized to 5 years (no 10 year intervals in 
female RTRs in case of hrHPV negativity and normal cytology).
The Dutch society for Organ Transplantation and the Dutch society for Obstetrics and Gynaecology 
should cooperate on potential amendments to the Dutch CIN guideline for organ transplant 
recipients. Ideally, a national consensus should be reached on gynaecological screening in all 
immunocomprised patients.
iMPleMentAtion oF SCreeninG – PAtientS AS PArtnerS
Meeuwis et al. (40) showed that the actual screening frequency in female RTRs was 0.2 cervical 
smears per year, while 30% never got a cervical smear after RT at all. A major step forward would 
be to reach the female RTRs that do not participate in screening at all (35% of all invited women), 
because we know that 50% of all women with cervical cancer (in the whole Dutch population) never 
participated in screening (41). An HPV self-test, which provided an increase in participation of 10% in 
the general population and is now offered to non-responders in the national screening programme, 
might strongly improve the participation rate of non-participating female RTRs. Furthermore, 
screening participation can be increased by educating the female RTRs on the risks and symptoms 
of genital (pre)malignancies. Renal transplant patients receive a lot of information at once when 
they are discharged after their renal transplant surgery. The female RTRs in the focus groups of 
Chapter 6 suggested to repeat the information on gynaecological screening approximately 6-12 
months after transplantation and to develop a checklist with all the necessary examinations during 
follow-up after transplantation. Female RTRs stated that the repetition of the information is more 
important than the manner of information supply. The following patient factors are known to be 
associated with a lower participation rate in cervical screening programmes: higher age, associated 
morbidity, lower income, and long-term care residence (42). Efforts to increase the participation 
rate should therefore be targeted on patients with these characteristics. The general practitioner 
should be notified that participation to the screening programme is mandatory in these patients 
and an extra reminder might be necessary. Several different decision aids, for example paper-
186  Chapter 8
8
based information booklets, audio books, videodiscs, CD-ROM programmes, and internet sites, 
are developed to enable patients to make an informed decision about diagnostic and therapeutic 
procedures. A successful decision-making procedure will enhance patient autonomy (43, 44). 
Optimizing the contents and timing of education on the risks of HPV-related genital abnormalities 
could increase the participation in gynecological screening. In the upcoming years, the development 
of an app or roadmap with all the recommended post-transplantation check-ups could enhance 
patient autonomy and participation rate.
VACCinAtion
Trial results showed high efficacy in the general population of the quadrivalent (HPV genotypes 16, 
18, 6, and 11) and bivalent (HPV genotypes 16 and 18) prophylactic HPV vaccines (>90%) against 
the targeted HPV infection, CIN and vulvar HSIL lesions, and genital warts (in case of quadrivalent 
vaccine) (45). Since 2015, a third, nonavalent HPV vaccine has been developed to protect against 
an additional five oncogenic types (HPV genotypes 31, 33, 45, 52, and 58) and showed an overall 
vaccine efficacy of 96.7% in women aged 16-29 years in the general population (46). This vaccine 
also gives more protection against other anogenital HPV-related (pre)malignancies such as 
vaginal-, vulvar-, and anal (pre)malignancies. To date, there are only a few studies conducted with 
the quadrivalent HPV vaccine in immunocompromised patients. Nelson et al. (47) showed a good 
response to the quadrivalent HPV vaccine in a group of girls and young women (9-21 years of 
age) with chronic kidney disease. Similar responses were observed in adults on dialysis and with 
late-stage chronic kidney disease (48). No serious vaccine-related adverse events were observed. 
However, Nelson et al. (47) also showed a less robust response to the vaccine among those girls 
and women with a kidney transplant with only about 50-75% of patients achieving seropositivity. On 
the contrary, two other studies on HPV vaccination in immunocompromised adolescents (after solid 
organ transplantation, stem cell transplantation, and auto-immune disorders) showed an adequate 
immune response to the quadrivalent HPV vaccine with seroconversion to all four HPV genotypes 
(49, 50). In adult transplant recipients, however, suboptimal immunogenicity of the quadrivalent 
HPV vaccine was observed (51). Vaccinating female patients with end-stage renal disease (ESRD) 
before they undergo transplantation might diminish the prevalence of hrHPV infections and 
prevent development of genital (pre)malignancies after transplantation. Meeuwis et al. (52) as well 
as Chapter 5 of this thesis, showed a broad spectrum of HPV genotypes in female RTRs, which 
would not be covered by the existing quadrivalent HPV vaccine. Consequently, patients with ESRD 
should be vaccinated with the nonavalent vaccine to optimize the coverage. There is a need to 
investigate the efficacy of the nonavalent vaccine in female patients with ESRD and in female RTRs. 
The design of such a study should include serological and cervical monitoring of HPV infection 
before and after RT. Moreover the influence of various immunosuppressive drugs on the efficacy 
of vaccination should be addressed. Introduction of HPV vaccination in female patients with ESRD 
does not imply that cervical screening becomes unnecessary. These women need to be screened, 
as do the women in the general population.
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3. FinAl ConSiDerAtionS
A new entity in vulvar SCC could be diagnosed based on localization of the tumour and HPV-
relationship. Further research should bring us more insight in the influence of these two features 
of the tumours on the current treatment guidelines in vulvar SCC. In the management of HPV-
related genital (pre)malignancies in RTRs the main focus should be on encouraging patients to 
participate in the national cervical screening programme. Further research on persistence of HPV 
infections, incidence of genital (pre)malignancies, and the role of vaccination in female RTRs and 
other immunocomprised patients should be conducted to develop a well designed screening 
programme for all immunocomprised patients.
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CHAPter 1
Most common lower genital (pre)malignancies arise from the cervix and the vulva. The oncogenesis 
of cervical (pre)malignancies is extensively researched and an infection with high-risk Human 
Papillomavirus (hrHPV) is an essential step in the development of cervical cancer. Vulvar cancer arises 
from two different pathways: a non HPV-related (70%) and an HPV-related pathway (30%). In vulvar 
cancer the exact role of HPV in the oncogenesis is unclear. Patients who use immunosuppressants 
have an increased risk for HPV infections. The largest immunocomprised patient groups are HIV-
infected patients and organ transplant recipients. The renal transplant recipients (RTRs) are the 
subject of this thesis. Studies have shown that RTRs have an increased risk of cervical- and vulvar 
(pre)malignancies due to an increased prevalence of HPV.
To be able to get more insight in the oncogenesis of vulvar cancer in the general population and to 
explore the behaviour of HPV and the screening possibilities in female RTRs, the following aims are 
composed in this thesis:
1. To assess the influence of tumour localization in vulvar cancer on the prognosis (Chapter 2).
2. To define the predilection site and prognosis of HPV-related vulvar cancer on the vulva 
compared to non HPV-related vulvar cancer (Chapter 3).
3. To establish the HPV prevalence before and after renal transplantation in females with an end-
stage renal disease (Chapter 5).
4. To determine the barriers and facilitators for annual gynaecological screening in female RTRs 
from patients’ and professionals’ perspective (Chapter 6).
5. To assess the experience of female RTRs with and the clinical applicability of HPV self-sampling 
in gynaecological screening (Chapter 7).
CHAPter 2
The overall 5-year survival of vulvar squamous cell carcinoma (SCC) is 70%. The aim of this study 
was to investigate if clitoral involvement of the tumour led to a worse prognosis. We performed a 
retrospective study with all consecutive patients with primary vulvar SCC treated with surgery. In 
total 347 patients were included in the analysis: 72 patients had a tumour with clitoral involvement 
and 275 patients had a tumour without clitoral involvement. We found that patients with a clitoral 
SCC more often had larger and deeper invaded tumours, lymphovascular space involvement (LVSI), 
positive surgical margins and a higher percentage of positive lymph nodes. The 5- and 10- year 
DSS rates of the clitoral involvement group were lower than in the non clitoral involvement group. 
We could not confirm clitoral involvement as an independent risk factor, however, the clinical- and 
histopathological characteristics of the tumours with clitoral involvement were independent risk 
factors for a worse prognosis. It is important to recognize and quickly refer patients with vulvar 
tumours with clitoral involvement to prevent diagnostic delay. The next chapter describes the role 
of tumour localization of vulvar SCC in more extent.
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CHAPter 3
There are two etiologic pathways for vulvar SCC. The first occurs most frequently and presents 
mainly in elderly women, often in a background of lichen sclerosus and/or differentiated vulvar 
intraepithelial neoplasia (dVIN). The second is related to hrHPV infection with its precursor lesion 
high grade squamous intraepithelial lesion (HSIL) of the vulva, formerly usual vulvar intraepithelial 
neoplasia. Although a clear relation is established, the precise role of HPV in the oncogenesis of 
vulvar SCC remains unknown. Our hypothesis is that micro-traumata on the perineum facilitate 
access of HPV to the cell as a first step in the oncogenesis of HPV-related vulvar SCC. The aim of 
this study was to assess the predilection site and survival of HPV-related vulvar SCCs compared to 
non HPV-related vulvar SCCs. All consecutive patients with primary vulvar SCC between March 1988 
and January 2015 were analyzed.  All available histological specimen were tested on HPV with the 
SPF10-LiPA25 system assay and p16
INK4a staining was performed using CINtec® histology kit. Vulvar 
SCCs were considered HPV-related in case of either >25% p16INK4a expression and HPV positive 
or >25% p16INK4a expression, HPV negative, and HSIL next to the tumour. The tumour localization, 
disease specific survival (DSS), disease free survival (DFS) and overall survival (OS) of patients with 
HPV-related and non HPV-related vulvar SCC were compared. In total 318 patients were included: 
55 (17%) patients had an HPV-related vulvar SCC with 93% hrHPV positive tumours (Group 1) and 
263 (83%) patients had a non HPV-related vulvar SCC with 92% hrHPV negative tumours (Group 2). 
The tumours in Group 1 were significantly more often located at the perineum compared to Group 
2, respectively 30% compared to 14%. Furthermore, there was significantly better DSS, DFS and OS 
in the HPV-related vulvar SCC patients.  All patients with tumours with perineal involvement had 
better survival compared to the patients with tumours without perineal involvement. Comparing 
the HPV-related with perineal involvement (N = 20) to the non HPV-related vulvar SCCs with perineal 
involvement (N = 35) showed significantly better survival rates for the HPV-related vulvar SCCs. HPV-
related vulvar SCCs are more frequently located at the perineum and have a favourable prognosis 
compared to non HPV-related vulvar SCCs. Both localization of the tumour and the HPV-related 
pathway could explain the favourable prognosis. HPV-related vulvar malignancies seem to be a 
separate entity within vulvar SCC.
CHAPter 4
Chapter 4 is a review about HPV-related (pre)malignancies of the female anogenital tract in 
RTRs. Renal transplantation and the risk for developing malignancies in general are discussed. 
Furthermore, HPV, cervical-, vulvar-, and anal (pre)malignancies in general and specified in female 
RTRs are extensively described.
CHAPter 5
We designed a prospective study to assess the HPV prevalence before and after renal 
transplantation. Female patients with end-stage renal disease (ESRD), who were judged whether 
they were appropriate candidates for renal transplantation (RT), were invited to participate in 
this study. In total 123 patients participated in the study. All patients underwent gynaecological 
examination, including cervical /vaginal cytology and HPV test, at first contact, after 1- and 2 years. 
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The patient was asked to self collect a cervico-vaginal sample with a collection device at the first 
visit and at home every three months. Furthermore, patients filled out questionnaires on relations/
sexual behaviour at start of the study and with every self-sample moment. HPV detection was 
performed by a sensitive test, the SPF10-LiPA25 system, optimally assessing genital prevalence and 
a clinically validated test, COBAS 4800, assessing the relevant infections at that time point. In total 
65 patients were transplanted. hrHPV prevalence assessed with the sensitive test significantly 
increased from 19% before to 31% after RT. Using the clinically validated test, hrHPV prevalence 
increased from 10% before to 14% after. Eight patients (12.3%) had cytological abnormalities: five 
high-grade lesions. No relevant changes in sexual behaviour were reported. Thirty-three patients, 
not undergoing RT, showed a hrHPV prevalence of 21% at study entry and 27% after 12 months 
with the sensitive test. With the clinically validated test this value remained stable at 16%. In this 
cohort of patients with end-stage renal disease, the hrHPV prevalence was higher than the age-
specific hrHPV prevalence in the general population, before as well as after the transplantation. 
The increase in hrHPV prevalence after transplantation, without any change in sexual behaviour, 
suggests activation of latent HPV infections during immunosuppression. The activation of latent 
HPV infections could contribute to the increased risk of HPV-related cervical- and vulvar (pre)
malignancies in female RTRs.
CHAPter 6
Several national and international guidelines recommend annual cervical screening in female RTRs. 
Gynaecological examination should definitely also include inspection of the vulvar area, but no 
recommendations are specified. The participation rate in screening is low in female RTRs. The 
reasons for not participating in screening are unclear. In this chapter the barriers and facilitators for 
gynaecological screening were assessed both from a female RTRs’ as a nephrologists’ perspective. 
We conducted focus group interviews and divided the mentioned barriers and facilitators according 
to four influencing factors: patient, professional, organisation, and finance. Both nephrologists and 
female RTRs mentioned similar barriers: uncomfortable and less reliable examination by a general 
practitioner (GP) compared to examination by a gynaecologist, limited knowledge of professionals, 
and limited information supply to patients on increased risk for developing HPV-related genital 
(pre)malignancies. However, female RTRs focused more on unpleasantness of the examination 
itself. Total agreement between female RTRs and nephrologists was found on the facilitators: a 
reminder for annual gynaecological screening, a checklist for all the examinations the female RTRs 
should undergo in which timeframe, integration of gynaecological examination in annual check-
up, HPV self-sampling and information supply at the right moment. We recommended that every 
female RTR should receive a small checklist one year after transplantation. Furthermore, HPV self-
sampling in the annual check-up by the nephrologist (with referral to the gynaecologist in case of 
HPV positivity) would obviate a lot of barriers and meets the main facilitators. Implementing these 
changes might improve the participation rate of female RTRs in gynaecological screening. 
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CHAPter 7
In this chapter we explore the role of HPV self-sampling in gynaecological screening. HPV self-
sampling has shown to reach non-participants in cervical screening in the general population. 
However, no research has been done to assess the clinical applicability of HPV testing on self-
sampling material in female RTRs. The aim of this study is to investigate whether HPV self-sampling 
is suitable for gynaecological screening of RTRs. A large cohort of 253 RTRs was investigated for the 
prevalence of HPV. All  participants received a device for a cervico-vaginal self-sample. Furthermore, 
questionnaires were sent to assess the experience with this device. High risk (hr)HPV presence was 
determined with the SPF10-LiPA25 system and when patients tested hrHPV positive, gynaecological 
examination was performed. The hrHPV positive samples were retested with the GP5+/6+ PCR to 
assess the clinical applicability of HPV self-sampling in female RTRs. More than 90% of the patients 
rated their experience with self-sampling device as good to excellent and 77% preferred self-
sampling over a physician taken sample. Thirty-five of 217 women (16%)  tested hrHPV positive with 
SPF10- LiPA25, and 22 tested positive with the GP5+/6+ PCR. Eleven of the 35 hrHPV-positive patients 
(31%) had clinically relevant gynecological abnormalities, and they all tested positive with GP5+/6+ 
PCR. Eleven hrHPV positive patients had clinically relevant gynaecological abnormalities and they 
all tested positive with GP5+/6+ PCR. Self-sampling could be applicable in gynaecological screening 
and is preferred by female RTRs. Therefore, self-sampling could be implemented with the aim to 
increase the participation rate of female RTRs in yearly gynaecological screening.
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SAMENVATTING
HooFDStUk 1
De meest voorkomende genitale (pre)maligniteiten bij vrouwen ontstaan in het gebied van de cervix 
en de vulva. De oncogenese van cervicale (pre)maligniteiten is al uitgebreid onderzocht: een infectie 
met het hoog risico Humaan Papillomavirus (hrHPV) is een essentiële stap in de ontwikkeling tot 
een cervix carcinoom. Bij het plaveiselcel carcinoom (PCC) van de vulva zijn twee verschillende 
ontstaanswijzen beschreven: een niet HPV-gerelateerde (70%) en een HPV-gerelateerde (30%) 
ontstaanswijze, waarbij deze laatste gelijkenissen vertoont met het ontstaan van cervixcarcinoom. 
Patiënten die immuunsuppressiva gebruiken hebben een verhoogd risico op het krijgen 
van een HPV infectie. Patiënten met HIV en ontvangers van een orgaantransplantaat zijn de 
grootste groepen immuungecompromiteerde patiënten. Verschillende studies tonen aan dat 
niertransplantatiepatiënten een groter risico hebben op het ontwikkelen van cervicale – en vulvaire 
(pre)maligniteiten als gevolg van een verhoogde prevalentie van HPV infecties. Het huidige proefschrift 
gaat met name over de vrouwelijke niertransplantatiepatiënten omdat deze patiëntengroep steeds 
frequenter met HPV-gerelateerde problematiek gezien wordt op de polikliniek Gynaecologie. Om 
meer inzicht te krijgen in de oncogenese van het vulvacarcinoom in de algemene populatie en 
om het biologisch gedrag van HPV en screeningsmogelijkheden bij niertransplantatiepatiënten te 
onderzoeken, zijn de volgende onderzoeksvragen geformuleerd:
1. Wat is de invloed van tumorlokalisatie op de prognose van het vulvacarcinoom? (Hoofdstuk 2)
2. Wat is de voorkeurslokalisatie en prognose van het HPV gerelateerde vulvacarcinoom 
vergeleken met het niet HPV gerelateerde vulvacarcinoom? (Hoofdstuk 3)
3. Hoe verhoudt de HPV prevalentie zich voor en na niertransplantatie bij vrouwen met eind 
stadium nierziekte? (Hoofdstuk 5)
4. Welke factoren beïnvloeden de deelname aan gynaecologische screening van vrouwelijke nier-
transplantatiepatiënten vanuit het perspectief van patiënten en professionals? (Hoofdstuk 6)
5. Wat is de ervaring van vrouwelijke niertransplantatiepatiënten met en de klinische 
toepasbaarheid van de HPV zelftest bij gynaecologische screening? (Hoofdstuk 7)
HooFDStUk 2
De 5-jaarsoverleving van het PCC van de vulva is 70%. Vanuit de kliniek bestond het gevoel dat de 
tumoren in het clitorisgebied een slechtere prognose hebben. Het doel van de studie in Hoofdstuk 
2 was om te onderzoeken of de lokalisatie van een tumor bij de clitoris inderdaad leidt tot een 
slechtere prognose. We hebben de data van alle chirurgisch behandelde patiënten met een primair 
PCC van de vulva retrospectief geanalyseerd. In totaal hebben we 347 patiënten geïncludeerd in 
de analyse: 72 patiënten hadden een clitoris tumor en 275 patiënten hadden een tumor zonder 
betrokkenheid van de clitoris. De resultaten lieten zien dat de clitoris tumoren vaak groter en 
dieper geïnvadeerd waren, lymfvatinvasie lieten zien, positieve snijranden en een hoger percentage 
positieve lymfklieren hadden. De 5- en 10-jaars overleving van de patiënten met clitoris tumoren 
was slechter dan in de groep zonder clitoris betrokkenheid. We konden de lokalisatie bij/op de 
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clitoris niet als een onafhankelijke risicofactor bevestigen, maar de klinische en histopathologische 
eigenschappen van deze tumoren waren wel onafhankelijke risicofactoren voor een slechtere 
prognose. Het is dus belangrijk om patiënten met een vulvacarcinoom met clitorisbetrokkenheid 
te herkennen en snel te verwijzen om vertraging in het diagnostische proces te voorkomen. In het 
volgende hoofdstuk komt de rol van tumor lokalisatie van het vulvacarcinoom uitgebreider aan bod.
HooFDStUk 3
Er zijn twee ontstaanswijzen beschreven voor het PCC van de vulva. De eerste komt het meeste 
voor en voornamelijk bij oudere vrouwen tegen een achtergrond van lichen sclerosus en / 
of gedifferentieerde vulvaire intraepitheliale neoplasie (dVIN). De tweede ontstaanswijze is 
gerelateerd aan een hoog risico (hr) HPV infectie met hoog-gradige squameuze intraepitheliale 
neoplasie (HSIL) van de vulva, voorheen usual VIN, als premaligne afwijking. Het is duidelijk dat HPV 
een rol speelt in de oncogenese van het vulvacarcinoom, maar de precieze rol blijft onduidelijk. 
Onze hypothese is dat microtraumata op het perineum de toegang van HPV tot de cel faciliteren 
en fungeren als eerste stap in de oncogenese van het HPV-gerelateerde vulvacarcinoom. Het 
doel van deze studie was om de voorkeurslokalisatie van de HPV-gerelateerde tumor te bepalen 
in vergelijking met de niet HPV-gerelateerde tumoren. Daarnaast werd de prognose vergeleken 
tussen patiënten met een HPV-gerelateerd en een niet HPV-gerelateerd vulvacarcinoom. Alle 
patiënten, die chirurgisch behandeld werden voor een primair PCC van de vulva in de periode 
maart 1988 en januari 2015 werden geanalyseerd. Al het beschikbare histologische materiaal werd 
getest op HPV, zowel hoog als laag risico typen, met de SPF10-LiPA25-systeem assay en er werd 
een p16INK4a-kleuring uitgevoerd met behulp van CINtec® histologie kit. Vulvaire tumoren werden 
beschouwd als HPV- gerelateerd in het geval van >25% p16INK4a expressie en hrHPV positiviteit 
of in het geval van >25% p16INK4a expressie, afwezigheid van hrHPV en HSIL naast de tumor. De 
tumor lokalisatie bij en de prognose van patiënten met HPV-gerelateerde en niet HPV-gerelateerde 
PCC van de vulva werden vergeleken. Er werden in totaal 318 patiënten geanalyseerd: 55 (17%) 
patiënten hadden een HPV- gerelateerd vulvacarcinoom (Groep 1) en 263 (83%) patiënten hadden 
een niet HPV- gerelateerd vulvacarcinoom (Groep 2). De tumoren in Groep 1 waren significant 
vaker op het perineum gelokaliseerd in vergelijking met Groep 2, respectievelijk 30% ten opzichte 
van 14%. Bovendien hadden patiënten met een HPV- gerelateerd vulvacarcinoom een aanzienlijk 
betere overleving. Alle patiënten met tumoren op het perineum hadden een betere overleving ten 
opzichte van de patiënten met tumoren zonder perineale betrokkenheid. Het vergelijken van de 
HPV–gerelateerde tumoren met perineale betrokkenheid (N = 20) met de niet HPV-gerelateerde 
tumoren met perineale betrokkenheid (N = 35) toonde significant betere overlevingscijfers in de 
HPV-gerelateerde groep. HPV-gerelateerde PCC van de vulva komen vaker voor op het perineum 
en hebben een gunstigere prognose in vergelijking met niet HPV-gerelateerde PCC van de vulva. 
Zowel de lokalisatie van de tumor als de HPV-gerelateerde ontstaanswijze kan de gunstige 
prognose verklaren. HPV-gerelateerde vulva tumoren lijken een aparte entiteit te zijn binnen 
het vulvacarcinoom. Verder onderzoek zal moeten uitwijzen of er plaats is voor alternatieve 
behandelingsopties voor HPV-gerelateerde vulvacarcinomen. 
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HooFDStUk 4
Hoofdstuk 4 is een review welke een duidelijk overzicht van HPV-gerelateerde (pre)maligniteiten 
van het anogenitale gebied bij vrouwelijke niertransplantatiepatiënten weergeeft. In dit hoofdstuk 
worden niertransplantatie en het risico op het ontwikkelen van maligniteiten besproken. Daarnaast 
komen HPV-gerelateerde cervicale -, vulvaire - en anale (pre)maligniteiten in de normale populatie 
en bij vrouwelijke niertransplantatiepatiënten uitgebreid aan bod. 
HooFDStUk 5
Om de HPV prevalentie vóór en na niertransplantatie te bepalen, hebben we een prospectieve 
studie opgezet die in Hoofdstuk 5 worden weergegeven. Vrouwelijke patiënten met eindstadium 
nierziekte, die op de polikliniek Nefrologie onderzocht werden op geschiktheid voor een 
niertransplantatie, werden uitgenodigd om deel te nemen aan onze studie. In totaal zijn er 123 
patiënten geïncludeerd in de studie. Alle patiënten ondergingen gynaecologisch onderzoek, 
inclusief cervicale / vaginale cytologie en een HPV test, die 1 en 2 jaar na het eerste contact werden 
herhaald. De patiënt werd gevraagd om zowel bij het eerste bezoek als thuis om de drie maanden, 
een cervico-vaginaal uitstrijkje af te nemen met een zelftest. Bij de start van de studie en bij elk 
zelfafname moment hebben patiënten vragenlijsten over hun relaties / seksueel gedrag ingevuld. 
De aanwezigheid van HPV werd bepaald door enerzijds een gevoelige test, het SPF10-LiPA25-
systeem, waarbij hele kleine hoeveelheden van zowel laag risico als hoog risico HPV typen ontdekt 
konden worden en anderzijds een klinisch gevalideerde test, COBAS 4800, waarbij alleen de klinisch 
relevante hrHPV infecties op dat moment werden beoordeeld. In totaal ondergingen 65 patiënten 
een niertransplantatie. De hrHPV prevalentie bepaald met de gevoelige test was aanzienlijk gestegen 
van 19% vóór tot 31% na de niertransplantatie. De hrHPV prevalentie bepaald met de klinisch 
gevalideerde test was gestegen van 10% naar 14%. Acht patiënten (12,3%) hadden cytologische 
afwijkingen waarvan vijf hoog-gradige afwijkingen. Er werden geen relevante veranderingen in 
seksueel gedrag gemeld. Drieëndertig patiënten, die geen niertransplantatie ondergingen, hadden 
een hrHPV prevalentie van 21% bij de start van de studie en van 27% na 12 maanden (gemeten met 
de gevoelige test). Met de klinisch gevalideerde test bleef deze waarde stabiel op 16%. Opvallend 
is dat in dit cohort van patiënten met eindstadium nierziekte de prevalentie van de hrHPV infecties 
hoger was dan de leeftijdsspecifieke hrHPV prevalentie in de algemene populatie, zowel vóór als 
ook na de transplantatie. De stijging van de hrHPV prevalentie na transplantatie, zonder enige 
verandering in seksueel gedrag, suggereert reactivatie van latente hrHPV infecties tijdens gebruik 
van immunosuppressieve medicatie. De activering van latente hrHPV infecties kan bijdragen aan 
het verhoogde risico op HPV-gerelateerde cervicale- en vulvaire (pre)maligniteiten bij vrouwelijke 
niertransplantatiepatiënten.
HooFDStUk 6
Vanwege het verhoogde risico op het ontwikkelen van HPV-gerelateerde genitale (pre)
maligniteiten adviseren verschillende nationale en internationale richtlijnen vrouwelijke 
niertransplantatiepatiënten om jaarlijks cervicale screening te laten verrichten. Het percentage 
vrouwelijke niertransplantatiepatiënten dat deelneemt aan de screening is relatief laag; slechts 
204  Chapter 9
9
70% van de vrouwen laat screening uitvoeren na niertransplantatie. De redenen om niet aan deze 
screening deel te nemen zijn onduidelijk. In Hoofdstuk 6 werden de factoren die de deelname 
aan gynaecologische screening beïnvloeden vanuit het perspectief van zowel vrouwelijke 
niertransplantatiepatiënten als nefrologen belicht. We organiseerden focusgroep interviews en 
deelden de factoren van invloed in vier categorieën: patiëntgebonden, professional, organisatie 
en financieel. Zowel nefrologen als vrouwelijke niertransplantatiepatiënten noemden dezelfde 
factoren die de deelname aan screening negatief beïnvloeden: het gynaecologisch onderzoek 
wordt pijnlijker ervaren wanneer uitgevoerd door een huisarts en minder betrouwbaar beschouwd 
dan wanneer het uitgevoerd wordt door een gynaecoloog, de beperkte kennis van professionals 
over en beperkte informatievoorziening aan patiënten met een verhoogd risico op het ontwikkelen 
van HPV-gerelateerde (pre)maligniteiten. Echter, vrouwelijke niertransplantatiepatiënten gaven 
aan dat het ongemak van het onderzoek zelf de grootste belemmerende factor is. De vrouwelijke 
niertransplantatiepatiënten en nefrologen waren het eens wat betreft de bevorderende factoren 
voor deelname aan screening: een jaarlijkse oproep, een checklist voor alle onderzoeken die de 
vrouwelijke niertransplantatiepatiënten zouden moeten ondergaan, integratie van gynaecologisch 
onderzoek bij de jaarlijkse controle van de nefroloog, het gebruik van de HPV zelftest en het geven 
van informatie over gynaecologische screening op het juiste moment na de niertransplantatie. 
Op basis van deze uitkomsten adviseerden wij het meegeven van een kleine checklist aan iedere 
vrouwelijke niertransplantatiepatiënt een jaar na de transplantatie. Het gebruik van de HPV 
zelftest bij de jaarlijkse controle door de nefroloog (met verwijzing naar de gynaecoloog bij hrHPV 
positiviteit) zou veel belemmering wegnemen en zelfs kunnen stimuleren om deel te nemen aan 
de gynaecologische screening. Het toepassen van deze twee veranderingen zou in onze ogen de 
deelname van vrouwelijke niertransplantatiepatiënten aan gynaecologische screening substantieel 
kunnen verbeteren.
HooFDStUk 7
In dit hoofdstuk wordt de rol van de HPV zelftest bij gynaecologische screening onderzocht. In de 
algemene populatie heeft het aanbieden van de HPV zelftest gezorgd voor een stijging in deelname 
aan het bevolkingsonderzoek baarmoederhalskanker en is aangetoond dat de HPV test op 
zelfafname materiaal even betrouwbaar is als op materiaal afgenomen door een arts. Er is echter 
nog geen onderzoek gedaan naar de klinische toepasbaarheid van het testen van HPV op zelfafname 
materiaal bij vrouwelijke niertransplantatiepatiënten. Het doel van deze studie was om te testen of 
de HPV zelftest geschikt is voor gynaecologische screening van niertransplantatiepatiënten. Een 
eerder onderzoek uitgevoerd door onze onderzoeksgroep heeft de prevalentie van HPV van een 
cohort van 253 niertransplantatiepatiënten bepaald. Alle deelnemers ontvingen een brush voor het 
afnemen van cervico-vaginaal materiaal en een vragenlijst waarin gevraagd werd naar de ervaringen 
met deze HPV zelftest. Het zelfafname materiaal werd getest op de aanwezigheid van hrHPV 
met behulp van het SPF10-LiPA25-systeem, een zeer gevoelige assay. De patiënten ondergingen 
een gynaecologisch onderzoek wanneer zij positief testten voor HPV. Er werden 35 van de 217 
patiënten (16%), die zelfafname materiaal hadden ingestuurd, hrHPV positief bevonden met het 
SPF10-LiPA25-systeem. Elf hrHPV positieve patiënten (31%) hadden een gynaecologische afwijking. 
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Wij hebben het HPV positieve materiaal opnieuw getest met de klinisch gevalideerde GP5+/6+ PCR 
om de klinische toepasbaarheid van de HPV zelftest bij vrouwelijke niertransplantatiepatiënten te 
beoordelen. De resultaten van de vragenlijsten lieten zien dat meer dan 90% van de patiënten de 
zelftest als goed tot uitstekend beoordeelden en 77% gaf zelfs de voorkeur aan de HPV zelftest 
in plaats van een uitstrijkje afgenomen door een arts. Alle 11 hrHPV positieve patiënten met een 
afwijking werden ook hrHPV positief bevonden met de GP5+/6+ PCR. Wij concludeerden hieruit dat 
de HPV zelftest betrouwbaar is en de voorkeur heeft van de vrouwelijke niertransplantatiepatiënten 
bij gynaecologische screening. De HPV zelftest zou geïmplementeerd kunnen worden om de 
deelname van vrouwelijke niertransplantatiepatiënten aan de gynaecologische screening te 
verhogen. 
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je hulp en belangstelling voor de voortgang gedurende mijn promotietraject.
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van Remko, Pleun en Renee. Remko ‘de professor’, erg fijn om af en toe met je te sparren over 
het onderzoek. Daarnaast ga ik denk ik nooit iemand anders een frikadel XXL zien eten. Pleuntje, 
jouw organisatorische talent is bewonderenswaardig en jouw humor verfrissend. Succes met het 
afronden van jouw proefschrift. Lieve Renee, je was mijn reddende engel aan het einde van mijn 
onderzoekstijd. Zonder jou zat ik denk ik nu nog te pipetteren en was de afdeling Pathologie zeker 
overstroomd (oeps). 
Financiële ondersteuning is onmisbaar voor het doen van onderzoek. De Nierstichting heeft ons 
project gesteund en mede daardoor is dit proefschrift tot stand gekomen.
Secretariaat Verloskunde&Gynaecologie, wat zijn jullie een gezellige club en een mooi visitekaartje 
voor de afdeling. Bedankt voor al jullie hulp.
Medewerkers polikliniek Verloskunde&Gynaecologie, ik voelde met meteen op mijn gemak op de 
polikliniek. Eerst alleen met mijn studiepatiënten, maar later ook als arts op de Vulvapoli. Bedankt 
voor jullie ondersteuning, verwerken van de foto’s, maken van afspraken en het kletsen tussen de 
afspraken door.
Polikliniek Nefrologie, post Geel, ik was toch een beetje een vreemde eend in de bijt met mijn grijze 
‘steriele bak’ op de vrijdagmiddag. Bedankt voor de gastvrijheid en behulpzaamheid.
Alle gynaecologisch oncologen, bedankt voor jullie input tijdens de onco-avonden en voor de gezel-
ligheid tijdens de verschillende congressen.
Studenten en arts-assistenten, bedankt voor jullie hulp bij de verschillende projecten en voor het 
draaiende houden van de studies tijdens mijn zwangerschapsverlof.
Beste Lenno, ik wist niet dat je met de trein kon reizen met een glas bubbels in plaats van op een 
stapelbed. Bedankt voor je begeleiding op de vulvapoli. Ik heb erg veel van je geleerd. 
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